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ABSTRACT 
 
Pain is a leading cause of morbidity in neuro-orthopaedic conditions, and remains an 
unmet clinical need.  In this study, I aimed to advance the assessment of the pain 
states using novel objective methods in patients with neuro-orthopaedic disorders, and 
to develop biomarkers that could be useful in clinical trials of new therapies.  
Quantitative sensory testing, the current method of assessment of small fibre 
(nociceptor) function, was compared to novel objective methods including skin 
biopsy, contact heat evoked potentials (CHEPS) and functional magnetic resonance 
imaging (fMRI), in human volunteer models and patients.  The clinical conditions 
studied were congenital insensitivity to pain presenting as orthopaedic disorders, 
complex regional pain syndrome, osteoarthritis, small-fibre pain syndromes, nerve 
and spinal root injuries. 
 
Cutaneous sensitisation biomarkers and mechanisms were identified in topical 
capsaicin pain models in human volunteers with study of skin biopsies, contact heat 
and laser evoked cerebral potentials, and fMRI.  The models showed features 
observed in patients with neurogenic hypersensitivity, including hypersensitivity 
associated with regenerating nerve fibres.  In patient groups, congenital insensitivity 
of pain patients showed absent CHEPS and lack of intra-epidermal nerve fibres, a 
novel finding.  In patient groups with pain / hypersensitivity, CHEPS distinguished 
neuropathic from inflammatory mechanisms, while skin biopsies showed changes in 
nerve fibre density, particularly of nerve fibres positive for GAP43, a marker of 
regenerating nerve fibres, and of TRPV1, the heat and capsaicin receptor.  As these 
changes require p38 MAP kinase activation in neurons, an inhibitor of p38MAP 
5 
kinase was studied in a neuropathic pain clinical trial, which showed efficacy and 
support of the biomarkers.  fMRI studies showed increased activation in regions of the 
brain associated with pain processing in the capsaicin model and painful osteoarthritis 
affecting the hand.   
 
These findings advance the assessment and understanding of pain disorders, and 
provide biomarkers for the development of new analgesics. 
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Chapter 1 Introduction 
 
 
1.1 AIMS AND OBJECTIVES 
 
Pain is a prominent symptom requiring treatment following injury and inflammation.  
Recent research has focussed on the types of stimuli resulting in pain, nerve fibre 
subsets and their receptors triggered by such stimuli, and mechanisms of transmission 
to higher centres in the central nervous system.  Progress has been made in identifying 
molecules integral to the process of signal transduction in nociception.  By developing 
clinical models which reflect pathological changes underlying nociceptive disorders, 
and identifying and validating novel biomarkers of pain, the underlying pathology can 
be explored, and novel analgesics can be developed which target these mechanisms. 
 
The aim of these studies was to develop mechanism-related biomarkers to enable 
objective assessment of clinical pain states, which could also be useful in novel drug 
development.  The objective biomarkers included nociceptor receptors such as 
TRPV1, the heat and capsaicin receptor, growth associated protein 43 (GAP43), 
which is a marker of regenerating nerve fibres, contact heat evoked potentials 
(CHEPS) and functional magnetic resonance imaging.  Quantitative sensory testing 
(QST) was used alongside these objective measures in human volunteer pain models 
and in clinical pain disorders - complex regional pain syndrome, osteoarthritis and 
congenital insensitivity to pain.  As inhibitors of p38 mitogen-activated protein kinase 
(MAPK)  have shown to be involved in the regulation of TRPV1 and  may reduce 
neuronal sensitisation and pain in animal models , a clinical trial was conducted in 
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patients with pain following peripheral nerve trauma or radiculopathy, to study the 
effects on symptoms and biomarkers. 
 
1.2 NOCICEPTIVE MECHANISMS AND MANAGEMENT 
 
1.2.1 The Pain Pathway 
 
Much of the anatomical work on sensory and nociceptive mechanisms was conducted 
in the nineteenth century.  In 1811, Bell, a Scottish physician and an anatomist, 
proposed that the dorsal and ventral roots of the spinal cord differ in function with the 
ventral roots responsible for muscle contraction (Pearce 1993), while Magendie, in 
1822, demonstrated the sensory function of the dorsal roots.  In 1840 Muller proposed 
that different somatic sensations are served by different and distinctive nerve fibres 
(Perl 2007).  Anatomists noted that the dorsal roots on joining the spinal cord separate 
into a medial division, consisting of large diameter nerve fibres and a lateral division 
consisting of small diameter nerve fibres(Sindou et al. 1974).  Head and colleagues in 
1905 postulated two different classes of somatic sensory innervation; epicritic 
(discriminative) and protopathic (crude).  Diffuse, aching pain was of the protopathic 
genre.  A decade later Ranson proposed that fine unmyelinated fibres of the lateral 
dorsal root division are protopathic and in part represent an afferent limb for pain 
(Perl 2007). 
 
Peripheral nerves consist of fibres of different calibre and conduction velocities.  The 
first association of the calibre of the nerve fibre with its conduction velocity was made 
by Gőthlin in 1907 (Gasser 1941).  Further research on the relationship between nerve 
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calibre and conduction velocity was carried out by Lapicque and Legendre four years 
later and subsequently by Blair and Erlanger (Blair 1933).  Erlanger and Gasser 
developed a classification system for peripheral nerve fibres based on axonal size, 
myelination and conduction velocity (Manzano et al. 2008).  Lloyd and Hunt 
developed another system of classification of afferent nerve fibres based on their 
diameters (Hunt 1954). 
 
Sherrington distinguished four types of sensory receptors (Sherrington 1907).  
Teleceptors provide information about the distant environment (hearing and sight), 
whilst exteroceptors provide information about the immediate surrounding (cutaneous 
sensation and taste).  Interoceptors give information about bodily functions and, 
proprioceptors, information about body position.  The sensations of pain and 
temperature are detected by exteroceptors.  The unpleasant sensation of pain is a 
result of interactions between complex mechanisms extending from the receptors 
encoding the painful stimulus to the higher cortico-limbic structures.  Along this 
pathway of transmission lie structures responsible for modulating the noxious 
stimulus, while it is progressively transmitted to higher centres.  
 
1.2.1.1 The sensory afferents 
 
Two systems are commonly used to classify peripheral nerve fibres.  These include 
the Erlanger and Gasser system, used to classify both afferents and efferents, and the 
Lloyd and Hunt system, used exclusively to define afferents (Tables 1.1 and 1.2).   
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Table 1.1 Erlanger and Gasser classification of nerve fibres  
Type of fibre 
Diameter, 
μm 
Conduction 
velocity, m/sec 
General Function 
A-alpha 12-22 70-120 
alpha-motoneurons, muscle spindle 
primary endings, Golgi tendon 
organs, touch 
A-beta 5-12 30-70 
touch, nociception, muscle spindle 
secondary endings 
A-gamma 2-8 15-30 
touch, pressure, gamma-
motoneurons 
A-delta 1-5 5-30 
pain, crude touch, pressure, 
temperature 
B 1-3 3-15 preganglionic autonomic 
C 0.1-1.3 0.6-2 
pain, touch, pressure, temperature, 
postganglionic autonomic 
 
 
Table 1.2 Lloyd and Hunt classification of nerve fibres 
Type of fibre Diameter, 
μm 
Conduction 
velocity, m/sec 
General Function 
Ia 12-20 70-120 muscle spindle primary endings 
Ib 11-19 66-114 Golgi tendon organs 
II 6-12 20-50 touch, nociception, muscle spindle 
secondary endings 
III 3-4 4-20 pain, crude touch, pressure, 
temperature 
IV 0.1-2 0.2-3 pain, touch, pressure, temperature 
 
The primary afferent fibres which transmit the initial stimulus from the periphery and 
classified based on their size, myelination and conduction velocity into C, Aδ and Aβ 
fibres are present in skin roughly in the proportion of 70, 10 and 20% respectively 
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(Millan 1999).  Under normal conditions only C and Aδ fibres mediate pain 
perception.  
 
C-fibres 
These are thin unmyelinated nerve fibres with a slow conduction velocity of 0.6 to 2.0 
m/sec.  They transmit the second, dull, burning pain following application of a 
nociceptive stimulus (Craig 2003).  Among C-fibres, thermoreceptors responsive to 
warming and cooling, chemo specific nociceptors and low threshold mechanoceptors 
responsive to pressure have been described (Schmidt et al. 1995; Meyer 2006).  There 
are also high threshold receptors localised on C-fibres which encode responses to 
noxious thermal and/or mechanical stimuli.  Some C-fibres respond to mechanical, 
heat and irritant chemical stimuli and are referred to as polymodal C-fibres.  A class 
of C-fibres responding primarily to noxious heat stimuli has been reported in primates 
including man and these may play a role in the axonal flare response along with the 
polymodal C-fibres (Lynn et al. 1996).  Microneurography in the human skin has 
identified another class of very thin slowly conducting histamine responsive mechano 
insensitive C-fibres which are thought to mediate itch (Meyer 2006). 
 
Aδ fibres 
These medium diameter, myelinated fibres of intermediate conduction velocity (5- 30 
m/sec) elicit the rapid first phase of pain which is sharp in nature.  Two classes of Aδ 
nerve fibres have been described.  Type I fibres are high threshold, rapidly-conducting 
mechanoceptors that are weakly responsive to high intensity heat (52- 56°C), cold and 
chemical stimuli.  They are activated by high intensity mechanical stimuli in the 
noxious range (for example, pinch) and are capsaicin insensitive.  Following repetitive 
thermal stimulation these fibres can become sensitised and following tissue damage 
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they can become more heat responsive showing sustained responses to thermal stimuli 
of long duration and slow latency.  Polymodal C-fibres on the other hand in glabarous 
skin showed decreased responsiveness following repetitive heat stimulation or injury.  
Type II fibres have a lower threshold to noxious heat stimuli (40- 45° C) and are 
sensitive to capsaicin.  Response increases with temperature elevation, with 
asymptomatic response at 53°C.  Aδ fibres more responsive to cooling than 
mechanical stimuli and capable of encoding stimulus intensity also exist.  The 
responses of these heat sensitive Aδ fibres sub serve the rapid painful reaction to first 
exposure of noxious heat and the ability to discriminate thermal (nociceptive) 
sensation according to intensity (Meyer 2006). 
 
Aβ fibres 
These fibres, have a larger diameter, are myelinated, fast conducting (30- 70 m/sec) 
and normally respond only to touch, vibration, pressure and other modes of non- 
noxious low intensity mechanical stimuli.  Following injury they have been shown to 
respond to mechanical stimuli and contribute to mechanical allodynia (Treede and 
Cole 1993; Wasner et al. 1999)  
 
Silent nociceptors 
A subset of unmyelinated C fibres (approximately 10- 20%) in the skin joints and 
viscera are normally unresponsive to acute noxious stimuli but under conditions of 
injury and tissue inflammation become sensitised and are activated by a variety of 
chemical mediators (Koltzenburg and Torebjork 1995; Dmitrieva and McMahon 
1996).  This subset of fibres is termed „silent nociceptors‟.  Similarly, there are some 
high threshold mechano-sensitive Aδ fibres that only respond to thermal stimuli 
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following their sensitisation.  These silent nociceptors are likely to be responsible for 
the prolonged inflammatory pain and contribute to the sensitisation and central 
adaptive changes that underlie primary hyperalgesia following tissue inflammation. 
 
1.2.1.2  Anatomy of cutaneous nociceptors 
 
Immunostaining for protein gene product (PGP) 9.5, a carboxy-terminal ubiquitin 
hydrolase, a pan-neuronal marker, has proved sensitive in identifying small diameter 
afferents in the skin (Dalsgaard et al. 1989) where unmyelinated fibres can be traced 
far into the epidermal layer.  The parent axons of these fibres are sensory and mediate 
sensations of pain and temperature; they can be both myelinated or unmyelinated, and 
contain neuropeptides such as substance P (SP) or calcitonin gene related peptide 
(CGRP) (Gibbins et al. 1987).  Immunodetection of epidermal fibres in vertical 
sections through the epidermis reveal that they emerge from the subepidermal nerve 
plexus and lose their Schwann cells before entering the epidermis to penetrate as 
„naked fibres‟ as far as the stratum corneum (Kruger et al. 1981). 
 
1.2.1.3 Transmission of impulses to the spinal cord - role of sodium channels 
 
Nociceptive signals from the periphery are transmitted by primary afferent fibres via 
Na
+
- dependent depolarisation.  The voltage gated sodium channels (Nav)  involved in 
transmitting the electrical impulse are complex trans-membrane proteins whose initial 
classification into two classes was based on their sensitivity (TTX-S) or resistance 
(TTX-R) to tetrodotoxin, a toxin found in the liver of puffer fish (Fukuda and 
Kameyama 1980).  Following advances in molecular biology in the 1980s individual 
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sodium channel isoforms were identified and cloned.  Nine distinct voltage-gated 
sodium channel α-subunits (Nav1.1–1.9) have been cloned from mammals (Goldin et 
al. 2000).  Adult central nervous system (CNS) neurons may express combinations of 
Nav1.1, Nav1.2 and Nav1.6 (Trimmer and Rhodes 2004), whilst adult dorsal root 
ganglion (DRG) sensory neurons can express combinations of Nav1.1, Nav1.6, Nav1.7, 
Nav1.8 and Nav1.9 sodium channels (Black et al. 1996; Dib-Hajj et al. 1998; Amaya 
et al. 2000).  Nav1.3 is predominantly expressed in immature neurons and normally 
found at very low levels in adult neurons (Beckh et al. 1989).  However, under certain 
conditions Nav1.3 expression is up regulated in adult neurons and may play a role in 
altered pain states.  Although the messenger ribonucleic acid (mRNA) encoding for 
Nav1.2, one of the predominant CNS isoforms, is detectable in adult DRG neurons, 
expression is considered to be low in these cells under most conditions (Black et al. 
1996).  Nociceptive afferents express TTX-S as well as TTX-R sodium channels.  
While TTX-S current is important for conduction of nociceptive signals, it has been 
postulated that the TTX-R current may play a modulatory role on peripheral 
nociceptors and in the generation of ectopic activity (Woolf and Costigan 1999).  Two 
tetrodotoxin-resistant sodium channel proteins (SNS/PN3 or Nav1.8 and NaN/SNS2 
or Nav1 .9) have been localised in peripheral nerve fibres and axon terminals (Fjell et 
al. 2000).  Both, nerve growth factor (NGF) and glial cell line-derived neurotrophic 
factor (GDNF) are able to up-regulate TTX-R sodium channels after peripheral 
axotomy. 
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1.2.1.4  Classification of cell bodies in the dorsal root ganglia 
 
Cell bodies of nociceptive somatic and visceral afferents are located in the dorsal root 
ganglia.  Nociceptors including slowly conducting Aδ and C fibres have small cell 
bodies (Lawson and Waddell 1991).  The distribution of the soma size for C-fibre 
afferents matches that of the so-called small dark cell population of group-B neurons.  
The large light cells (group – A neurons) can be labelled with RT97, an antibody 
directed against phosphorylated heavy chain neurofilament protein (NF200).  But only 
a minority of the small dark neurons bind RT97 and are thought to represent small 
myelinated Aδ afferents (Meyer 2006).  Small dorsal root ganglion cells can be 
further divided into peptidergic neurons (containing peptides like SP, CGRP, and 
somatostatin) and non-peptidergic neurons.  Almost all of visceral afferents are 
peptidergic but only about half of the afferents projecting to the skin are peptidergic 
(Perry and Lawson 1998).  Non peptidergic neurons contain fluoride-resistant acid 
phosphatase (FRAP) and also bind to the plant lectin IB4 (Silverman and Kruger 
1988b; Silverman and Kruger 1988a).  Peptidergic fibres mainly project to lamina I 
and lamina II outer while IB4- binding fibres project preferably to lamina II inner of 
the spinal cord (Hunt and Rossi 1985; Silverman and Kruger 1988b).  Most 
peptidergic neurons express the tyrosine kinase receptor A (TrkA), suggesting that 
they depend on nerve NGF for survival (Averill et al. 1995).  IB4 positive dorsal root 
ganglion cells do not express TrkA but express one of the GDNF family receptors 
(GFRα1-4) together with receptor tyrosine kinase Ret (Bennett et al. 1998; Orozco et 
al. 2001).  
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1.2.1.5 CNS transmission 
 
Dorsal horn of spinal cord 
Studies in humans and monkeys have shown a segregation of fibres as they enter the 
dorsal root entry zone.  Fine fibres run along the ventrolateral zone compared with 
large fibres which are found in a dorsomedial position (Sindou et al. 1974; Snyder 
1977).  Electron microscopy and autoradiography has revealed that at least half of the 
fibres which run in the Lissauer‟s tract situated on the top edge of the dorsal horn 
come from the dorsal root, particularly the ventrolateral fibres (Light and Perl 1979).  
These afferent fibres run in this tract for one or two segments before terminating in 
the spinal grey mater.   
 
By studying the spinal cord of cats on a cytoarchitectonic basis the grey mater has 
been divided into 10 laminae (Rexed 1952).  Of these the two most superficial 
laminae (I and II0) along with the deeper laminae V, VI and X are predominantly 
involved in nociception.  Nociceptive C-fibres from skin project heavily to II0 and, 
less intensely, to lamina I: they also provide a comparatively weak input to lamina V 
and, probably, lamina X.  High threshold, Aδ fibres terminate predominantly in 
lamina I, and to a sparse extent in II0: they also provide an input to laminae X.  
Laminae I and V/VI receive unmyelinated nociceptive fibres from viscera, joints and 
muscle.  Some unmyelinated, visceral fibres also innervate lamina X (Millan 1999).  
There is a significant degree of convergence of impulses from skin, joint and viscera 
at the dorsal horn (DH).  This could result in „referred pain‟.  Larger, low threshold 
Aβ fibres mediating non-nociceptive have been shown to terminate mainly in laminae 
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III – IV, less markedly in laminae V/VI, and possibly in laminae IIi I. They do not 
innervate lamina II0 (Millan 1999) 
 
Based on the response to nociceptive input, DH neurons can be classified into three 
types (Dubner and Bennett 1983; Cervero 1995).  The nociceptive-specific neurons 
are typically silent and are only activated by high intensity noxious stimuli mediated 
by C and Aδ fibres.  The wide-dynamic range (WDR) neurons have considerable 
convergence from cutaneous, muscle and visceral input.  They are activated by 
thermal, mechanical and chemical stimuli mediated via both C and Aδ and also Aβ 
fibres (Dubner et al. 1989).  The non-nociceptive neurons do not transmit impulses 
related to nociception.  The nociceptive specific neurons are most concentrated in 
laminae I (and II0) and to some extent in laminae V and VI.  They have limited ability 
to encode stimulus intensity.  The WDR neurons produce a dynamic response over for 
stimuli ranging from non painful to painful ones.  They are found mostly in laminae V 
and some are also found in laminae IV, VI, I and II0, X and the ventral horn.  The 
non-nociceptive neurons are located in laminae II, III and IV and to a lesser extent in 
lamina I (Millan 1999). 
 
DH neurons can be classified based on output destinations as projection neurons (PN), 
which transmit impulse supraspinally, and interneurons (INs) which can be inter or 
intra laminar and intra or intersegmental.  The INs which are either excitatory 
(EXINs) or inhibitory (ININs) (Willis and Coggeshall 1991) can modulate impulse 
and influence pain perception.  
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The EXINs and ININs along with the Aβ fibres and descending pathways originating 
in the brain stem inhibit or facilitate nociceptive signals in dorsal horn neurons.  This 
can be by their actions pre or postsynaptically or by interactions with interneurons 
(Millan 1999). 
 
Transmission to supraspinal centres 
Ascending pathways transmitting impulse to higher centres can be monosynaptic or 
polysynaptic.  The spinothalamic tract, spinomesencephalic tract, spinoparabrachial 
tract, spinohypothalamic tract and the spinoreticular tract are monosynaptic and 
project directly to contralateral cerebral structures.  The spinomesencephalic tract is 
thought to include the spinoannular tract which projects to the periaqueductal grey 
matter and a spinotectal tract projecting to the deep superior colliculus.  The 
polysynaptic pathway involves relay of impulses in the cervical cord through a spino 
cervical pathway or in the gracile and cuneate nucleus in the brainstem through the 
dorsal column lemniscal system.  Impulses are then projected into the various nuclei 
of the thalamus.  At the spinal cord level the polysynaptic pathways carry ipsilateral 
impulses.  The second order neurons cross over to the contralateral side and project to 
higher centres.  Complex interactions exist between the thalamus, midbrain, limbic 
system, cortex, reticular formation and many other cerebral structures (Willis and 
Coggeshall 1991; Millan 1999). 
 
Supraspinal centres 
The thalamus is the most important point for the reception and processing of sensory 
signals on its way to the cortex.  The thalamus encodes information concerning the 
type, temporal pattern, intensity and localisation.  Through its connections with 
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cortical and limbic structures it is responsible for the sensory-discriminative and 
emotional dimension of pain.  It is thought that nociceptive information from the 
thalamus is directed to the first somatosensory area (S I) of the post central cortical 
gyrus.  Recent neurophysiological and imaging studies have identified other areas that 
are consistently activated by noxious stimuli applied to cutaneous and other tissue 
regions.  The somatosensory area II (S II) which occupies the parietal operculum in 
the sylvian sulcus of the lateral parietal cortex, several regions of the inferior and the 
anterior parietal cortex, the insular cortex, the anterior cingulate cortex and medial 
prefrontal cortex is involved in pain perception.  These structures are linked to each 
other and the thalamus and with the limbic system.  Imaging studies suggest 
contralateral activation of the SI region upon noxious stimulation.  This supports the 
pain-localizing, discriminative–sensory function of this region.  The medial pain 
system which processes the affective component of pain consists of the prefrontal 
cortex, anterior cingulate cortex, and the thalamus.  This pattern of activation is 
secondary to complex connections involved in emotional and affective response and 
sensitisation (Casey et al. 1996; Svensson et al. 1997). 
 
1.2.2 The Molecular Basis of Pain 
 
An understanding of the molecular basis of processing pain signals has been 
revolutionised following the discovery and cloning of the super family of TRP ion 
channels.  Apart from the structures involved in transmitting pain signals to the higher 
centres where pain is perceived, intricate mechanisms exist to convert nociceptive 
stimuli into impulses which are then transmitted to the cortical centres.  Following the 
observation of a spontaneous mutant of Drosophilia melanogaster where the response 
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to steady light appeared to be transient in contrast to the sustained response in wild-
type flies, the term transient receptor potential was coined to name the mutant (Cosens 
and Manning 1969).  The responsible gene was subsequently cloned and the structural 
resemblance of the gene product to ion channels was noted (Montell and Rubin 1989).  
Since then, extensive research has been carried out to identify homologous channels 
and seven sub families of TRP channel genes have been identified encoding stimuli 
including pain and temperature.  Excitatory and inhibitory neurochemicals add to our 
knowledge of such receptors and include substances which serve to modify the 
impulses generated by the nociceptors as they are transmitted along the neuronal 
pathway.   
 
1.2.2.1 Receptor channels 
 
TRPV family 
Cesare and McNaughton discovered a heat-activated cationic current in a 
subpopulation of nociceptors (Cesare and McNaughton 1996).  Plant derived agents 
such as capsaicin and resiniferatoxin were known to induce a burning type of pain.  
These vanilloid compounds selectively depolarised nociceptors by mimicking the 
action of an endogenous ligand or physiological stimulus.  The receptor involved was 
termed vanilloid receptor 1 (VR1).  This capsaicin activated channel behaved as a non 
selective cation channel permeable to various cations including calcium (Oh et al. 
1996).  The gene coding for the capsaicin receptor was identified and cloned in 1997 
in rat sensory DRG (Caterina et al. 1997).  This receptor was structurally related to the 
TRP family of ion channels and was labelled TRPV1.  This channel is also stimulated 
by protons, noxious heat and some lipids.  The activation temperature threshold for 
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this cation channel was around 43
o
C.  This was shown to be primarily expressed in 
small size, unmyelinated neurons responsible for nociception.  TRPV1 can be 
activated by temperature, extracellular protons, endogenously occurring lipid 
molecules , monovalent and divalent cations (Caterina 2007).  TRPV1 was proposed 
as the molecular substrate for polymodality in these neurons providing them the 
ability to respond to heat and injurious chemical stimuli (Caterina et al. 1997; 
Tominaga et al. 1998).  Warming to 37°C potentiates the responsiveness of TRPV1 to 
chemical agonists.  Heating to a temperature >42
o
C can activate the TRPV1 channel 
in the absence of chemical ligands.  This is close to the psychophysical perception of 
pain in the human skin and threshold of activation of C-fibre nociceptors (Bessou and 
Perl 1969; LaMotte and Campbell 1978).  Following the discovery of TRPV1, three 
other channels of the TRPV family were cloned, TRPV2 (known as VRL-1), TRPV3 
and TRPV4 (known as VROAC or OTRPC4).  TRPV2 is activated by very hot 
stimuli with a threshold of about 52°C, while TRPV3 and TRPV4 are activated by 
relatively warm stimuli at 34° to 39°C and 25° to 34°C respectively (Caterina 2007).  
 
Other TRP channels  
Menthol induces a sensation of cooling when applied to skin and mucous membranes 
(Hensel and Zotterman 1951).  This response was found to be due to a specific 
interaction with calcium channels rather than a non specific, alcohol related effect and 
subsequently a cold and menthol sensitive receptor (CMR1) was cloned in 2002 
(McKemy et al. 2002; Peier et al. 2002).  CMR1 was shown to be a member of the 
family of TRP channels and named TRPM8.  This channel has an activation 
temperature of 25- 28°C and is also activated by menthol, eucalyptol and icilin.  
TRPM8 was shown to be expressed in a subset of DRG and trigeminal ganglia 
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neurons that can be classified as neurons giving rise to small- diameter C-fibres, but 
TRPM8 is not co expressed with TRPV1.  Subsequently another channel TRPA1 
(ANKTM1) was described as a cold sensitive channel but with an activation 
temperature of 17° C, suggesting that this channel was involved in cold nociception 
(Story et al. 2003).  TRPA1 is co expressed with TRPV1 in a subset of sensory 
neurons that also produce neuropeptides CGRP and SP.  The presence of these 
chemicals may explain the paradoxical hot sensation felt when one is stimulated by a 
very cold stimulus.  However, the role of TRPA1 in mediating cold sensation is 
disputed (Jordt et al. 2004).  
 
Mechanosensation and pain 
Despite advances in understanding the molecular basis of thermal sensation and pain, 
the identity of channels involved in mechanosensation and pain is uncertain (Lewin 
and Moshourab 2004).  The channels that have a mechanosensory role include the 
TRP channels TRPA1, TRPC1, TRPV4; the acid- sensing ion channels (ASIC); the 
two pore domain K
+ 
channels and the P2X purinergic receptors (Cockayne et al. 2000; 
Lesage and Lazdunski 2000; Lin and Corey 2005; Belmonte and Viana 2008).  
 
TRPV4 is reproducibly gated by extracellular hypotonic solution and is possibly a 
high threshold mechanosensor whilst TRPC1 is a candidate stretch activated channel 
(Liedtke et al. 2000; Vriens et al. 2004; Maroto et al. 2005).  ASIC are activated by a 
relatively modest drop in pH (6.5- 6.9).  Six ASIC subtypes have been isolated in 
rodents; ASIC1a, ASIC1b, ASIC2a, ASIC2b ASIC3 and ASIC4 (Garcia-Anoveros 
and Corey 1997; Waldmann et al. 1997; Deval et al. 2010).  In humans ASIC1b 
mRNA has not been described so far.  Among these ASIC3 is found mainly in C-fibre 
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nociceptors and is thought to participate in ischemia- induced nociception such as 
chest pain or muscle hyperalgesia (Immke and McCleskey 2001; Sluka et al. 2003). 
P2X purinoceptors are expressed in sensory neurons and detect extracellular ATP 
(Khakh and North 2006).  The P2X3 homomer and P2X2/3 heteromer are mainly 
expressed in sensory neurons.  ATP released from mechanically stimulated cells 
elicits current responses in sensory neurons (Cook and McCleskey 2002).  P2X3 
expression is found to be regulated in acute and chronic inflammation models (Xu and 
Huang 2002; Inoue 2006).  P2X4, though not found in nociceptors is up regulated in 
microglia in neuropathy and has a role in the development of neuropathic pain and 
mechanical allodynia (Tsuda et al. 2003).  
 
Potassium channels, though not primary sensors for external stimuli, have the 
potential to control excitability of sensory neurons.  The two-pore domain potassium 
channels (K2Ps) are involved in maintaining resting membrane potentials in sensory 
neurons.  Many subgroups of K2P channels have been cloned (Lesage et al. 1996).  
Electrophysiological studies have identified TREK-1, TREK-2 and TRAAK in 
sensory neurons with temperature sensitivity in the range 25- 30°C (Maingret et al. 
2000; Kang et al. 2005).  Channel opening of the K2Ps by a warm temperature should 
lead to hyperpolarization or stabilization of the membrane potential with negative 
modification of warm sensation mediated by other heat-gated channels.  Mechanical 
stretch and osmotic shock also activate TREKs and TRAAK (Lesage et al. 2000; 
Honore et al. 2006).   
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1.2.2.2 Neurotransmitters and Neuromodulators 
 
Neurotransmitters 
Nociceptive peripheral afferent fibres synthesise a variety of chemicals involved in 
the transmission and modulation of pain impulses and may be classified accordingly.  
The chemicals found include glutamate (GLU) and other excitatory amino acids 
(EAA), neuropeptides such as SP and CGRP; adenosine tri phosphate (ATP), nitric 
oxide (NO), prostaglandins and neurotrophins.  This has been extensively reviewed 
(Millan 1999).   
 
A substantial proportion of C-fibre nociceptors are sensitive to capsaicin.  Of these, 
one group contain CGRP and SP and are developmentally dependent on the 
neurotrophin NGF (Donnerer et al. 1996; Molliver and Snider 1997).  A second group 
of these fibres is dependent on the neurotrophin GDNF, binds isolectin B4 (IB4) and 
possesses a subclass of excitatory receptor for ATP on their peripheral terminals 
(Zwick et al. 2002).  Neurotransmitters released by the peripheral afferents while 
transmitting nociceptive information, in addition to influencing ionic fluxes, are 
coupled to intracelluar transduction mechanisms and modulate neuronal excitability.  
The opening of cation-ion permeable channels depolarizes neurones.  There follows a 
cascade of intracellular signals with activation of phospholipase C (PLC) and 
adenylcyclase (AC) triggering mechanisms leading to an increase in neuronal 
excitability and sensitivity.  By negative or positive coupling with cation influx , PLC 
and AC, neurotransmitters released from PAF exert pronociceptive or antinociceptive 
effects. 
 
36 
The pronociceptive tachykinins, SP and neurokinin A act on the receptors, NK1 and 
NK2.  These receptors are positively coupled to PLC (Bentley and Gent 1995; Traub 
1996).  CGRP, another pronociceptive neuropeptide act on the receptors CGRP1 and 
CGRP2, both of which are positively coupled to AC (van Rossum et al. 1997).  EAA 
such as GLU and aspartate act on metabotropic (mGlu) receptors (coupled via G- 
proteins to soluble second messengers) and inotropic receptors (coupled directly to 
cation-permeable ion channels).  Major receptors in DH involved in transmitting 
nociceptive signals include the DL-α-NH2-2,3-dihydro-5-methyl-3- oxo-4-
isoxazolepropanoic acid (AMPA receptor) and N- methyl-D-aspartate (NMDA 
receptor) (Leem et al. 2010).  
 
The EAAs, tachykinins and CGRP elicit excitatory post synaptic potentials (EPSP) in 
the dorsal horn neurons.  AMPA receptors mediate a rapid depolarization (inward 
current) over a few msec.  The subsequent engagement of NMDA, group I mGlu, 
NK1, NK2 and CGRP receptors is associated with slower and more sustained EPSPs.  
Repetitive stimulation can result in temporal summation and amplification of 
responses in the DH.  Impulse transmission to the DH can be blocked by inhibiting 
presynaptic release of these neurotransmitters or blocking their action post- 
synaptically (Millan 1999).  
 
Neuropeptide Y, somatostatin, corticotrophin releasing factor and vasoactive 
intestinal peptide are some of the other modulators of nociceptive impulse found in 
peripheral afferent fibres, the levels of which change during injured states.  The 
interactions between various neurotransmitters determine the intensity of pain felt by 
the individual.  Neurotransmitters including EAA, cholecystokinin (CCK) and gamma 
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amino butyric acid (GABA) are present in the CNS and are involved in the 
transmission of nociceptive impulses to the thalamus and cortical structures (Millan 
1999).  
 
Neuromodulin (GAP43) 
A clamodulin-binding phosphoprotein, termed GAP43, is found almost exclusively in 
presynaptic terminals.  It is a principal component of the growth cones of developing 
neurones, sprouting, and intact neurones and injured, regenerating C-fibres (Benowitz 
and Routtenberg 1997; Buffo et al. 1997).  Following nerve injury GAP43 is activated 
by a protein kinase C mechanism.  GAP43 modulates neurotransmitter release and 
plays a role in modification and re establishment of synaptic connectivity.  By altering 
the release of SP and other pronociceptive neurotransmitters it plays a role in 
nociception.  It has a broader role in neuroplasticity underlying prolonged and rapid 
alteration in synaptic transmission (Kapfhammer 1997). 
 
1.2.2.3 Sensitisation of peripheral afferent fibres during injury and inflammation 
 
Pain and hyperalgesia following inflammation, tissue injury or prolonged nociceptive 
stimulation can be the result of sensitisation of primary afferent fibres (PAFs) (Dray 
and Bevan 1993; Dray and Urban 1996).  Substances such as bradykinin and 
prostaglandins excite sensory terminals and can potentiate the action of each other.  
Aspirin and other inhibitor of cyclooxygenase enzyme block the synthesis of 
prostaglandins and reduce pain and hyperalgesia.  Sensitisation is achieved via the 
activation of intracellular transduction mechanisms which either directly modulate 
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activity at specific ion channels or exert long-term modifications by altering gene 
transcription (Millan 1999). 
 
Levels of cAMP in the PAF may play a role in mediating the sensitization of PAFs in 
response to heat, PG, adenosine, CGRP, histamine or 5-hydroxy tryptamine (5-HT) 
(Ferreira 1993; Kress et al. 1996).  Other substances such as PGE2, 5HT and 
adenosine may facilitate a tetrodotoxin resistant voltage gated Na
+ 
current which is 
specific to small calibre nociceptive neurons.  The activation threshold of these 
neurons is decreased while the magnitude and rate of activation are enhanced (Gold et 
al. 1996).  Other mechanisms of sensitisation of PAFs include increased NO 
following up regulation of NO synthase in DRG and immune–competent cells 
following inflammation and increased NGF.  This increase modifies the activity of 
sensory neurons by modulating gene expression with corresponding changes in 
phenotype, synaptic transmission, cellular excitation and neurotransmitter release 
(Rukwied et al. 2010).  Interactions between bradykinins and prostaglandins also lead 
to and increase in the pain response by sensitisation and recruitment of silent 
nociceptors and (Stucky et al. 1996).   
 
While all these mechanisms increase the orthodromic input from the PAFs to the DH 
neurons, antidromic responses from the PAFs propagated via collateral fibres and a 
limited degree of C-fibre terminal coupling leads to an increased release of EAAs, 
CGRP and SP peripherally.  This release, which is further amplified by a local, 
positive feedback action on PAF terminals, underlies the phenomenon of neurogenic 
inflammation.  This mechanisms further enhances the sensitisation and responsiveness 
of PAFs (Woolf 1996; White 1997).  
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1.2.2.4 Central mechanisms of sensitisation 
 
Adaptive events in the CNS, which amplify the abnormal and/or excessive PAF input, 
also play an important role in altering pain sensation.  Mechanical allodynia in 
surrounding normal tissue, secondary hyperalgesia and spatially-referred pain are 
likely secondary to central sensitisation triggered by peripheral events and involving 
both C and Aβ fibres (Woolf 2010).  The release of EAAs, tachykinins and CGRP 
from a subset of nocisponsive C fibres innervating the skin and other organs mediate 
DH sensitization.  Multiple mechanisms are involved which include direct alteration 
of the ion flux at the cation permeable channels, interaction with intracellular 
transduction mechanisms leading to secondary modification of ionic currents and long 
term effects involving gene transcription of receptors and neurotransmitters (Lin et al. 
1997; Sluka 1997; Sluka et al. 1997).  These mechanisms by converging reinforce 
transmission at NMDA receptors and result in a pronounced and sustained release of 
Ca
2+
 triggering and maintaining neuronal sensitization in the DH neurons.  Other 
receptors involved in central sensitisation include the AMPA, NK1/2, mGlu and CGRP 
receptors.  This is mediated by increases in Ca
2+
 influx and Ca
2+
 levels in dorsal horn 
neurons, enhancement of activities of PKs, induction of NO synthesis, generation of 
prostaglandins and gene transcription in the DH neurons (Sluka 1996; Rustioni 2005; 
Tao 2010).  
 
Prolonged stimulation of nociceptors following inflammatory tissue damage and PAF 
injury also leads to a degeneration or reduced activity of GABAergic and glycinergic 
inhibitory ININs.  Activation of NMDA receptors by C-fibres following injury leads 
to release of EAAs on to vulnerable ININs leading to an increase of Ca
2+
 and NO and 
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degeneration of ININs.  The alteration of ININs can disrupt the feedback received by 
the higher centres leading to changes in descending facilitation and inhibition.  Other 
dopaminergic and serotonergic mechanisms are also involved in long term modulation 
of CNS sensitivity (Millan 1999).  Adaptive changes also occur at the thalamic and 
cortical levels consistent with a role of EAAs/NMDA receptors as 
transmitters/receptors in ascending projections to the CNS centres as well as with a 
modulatory influence of GABAergic mechanisms upon thalamic and cortical sensory 
processing.  NMDA and mGlu receptors are involved in modulating CNS synaptic 
plasticity (Latremoliere and Woolf 2009). 
 
1.2.2.5 Role of neurotrophins in the modulation of nociception 
 
Neurotrophins are a family of related proteins which include NGF, brain derived 
neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and neurotrophic 4/5 (NT-4/5).  
They support the survival and influence the phenotype of several neuronal sub-
populations during development and their maintenance in adults.  All neurotrophins 
bind to a low affinity transmembrane receptor p75
NTR
.  Each of these also binds to a 
high affinity receptor viz. NGF to trkA, BDNF and NT-4/5 to trkB, NT-3 to trkC (and 
to trkA with a lower affinity).  The neurotrophins 3 and 4/5 play a relatively modest 
role in pain processing in most circumstances (Pezet and McMahon 2006). 
 
NGF 
The majority of primary sensory neurons of dorsal root ganglia in mice at birth are 
sensitive to NGF, which supports their survival and, through an independent 
mechanism, promotes neurite outgrowth (Patel et al. 2000).  The NGF dependent 
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sensory neurons are of small and medium diameter and comprise of 70 – 75% of the 
total number.  Administration of NGF to terminals or cell bodies of sensory neurons 
in vivo up regulates neuropeptides and neuromodulaters such as CGRP, SP, and 
BDNF; receptors such as TRPV1 and P2X3; and ion channels including those with 
TTXs or TTXr sodium currents.  Sympathetic, postganglionic neurones express trkA, 
and NGF induces sprouting of these fibres so that they wrap around primary sensory 
neurones in basket-like structures (Ramer et al. 1999).  NGF also promotes hyper 
innervation of the epidermis and other targets treated with NGF (Albers et al. 1994; 
Christianson et al. 2007).   
 
Pain perception and pain related behaviour in humans is altered following NGF 
treatment.  In human volunteers, small subcutaneous or intramuscular injections of 
NGF give rise to pain and tenderness (hyperalgesia) at the injection site, starting 
within minutes and persisting for several hours.  Small intravenous doses result in 
widespread deep pain and tenderness lasting for days (Petty et al. 1994).  In normal 
animals, a limited amount of NGF is produced in the peripheral tissues such as basal 
keratinocytes in the skin and epithelial cells of the hollow viscera.  In the presence of 
inflammation, various inflammatory factors including interleukin 1β, TNFα, platelet 
derived growth factor, IL-4 and transforming growth factor β induce expression of 
NGF by many other cells such as mast cells, macrophages and Schwann cells (Pezet 
and McMahon 2006).  While NGF, by its neuroprotective effect, can prevent 
secondary hyperalgesia following nerve damage, an increased availability of NGF can 
lead to increase in nerve sensitivity and pain in damaged nerve tissue such as 
neuromas (Atherton et al. 2006).  Anti NGF drugs could hence play a role in 
neuropathic pain. 
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BDNF 
BDNF is synthesised by a sub population of, small to medium sized DRG neurons 
representing about 10- 40% of the population of neurons.  Through anterograde 
transport BDNF is transported to the central terminals of these neurons mainly in 
lamina I and II of the spinal dorsal horn.  By an NGF dependent mechanism in trkA 
expressing neurons, BDNF is up regulated during inflammation (Pezet et al. 2002; 
Merighi et al. 2004).  The mitogen activated protein kinases (MAP), ERK 
(extracellular signal regulated kinase) and p38 are important mediators of BDNF up 
regulation and pain related behaviour in inflammatory and neuropathic pain (Obata 
and Noguchi 2004).  BDNF levels are also altered in spinal and supraspinal levels 
following injury (Pezet and McMahon 2006).  Estrogens are reported to potentiate the 
up regulation of BDNF in the spinal cord (Zhao et al. 2003).  
 
The mechanism by which BDNF can contribute to pain include activation of trkB, 
intracellular signalling cascades, gene and protein synthesis, modulation of NMDA 
receptor activity and modulation of chloride influx (Pezet and McMahon 2006).  trkB 
is expressed in many cells (both neurons and glial) throughout the whole spinal cord 
(Zhou et al. 1993), including neurons of the spinothalamic tract (Slack et al. 2005), 
and is up regulated following both increased neuronal activity and peripheral 
inflammation (Mannion et al. 1999).  
 
1.2.3 Neuropathic Pain 
 
Pain has traditionally been classified as nociceptive pain that arises following tissue 
injury in the presence of normal pain pathways, inflammatory pain, and neuropathic 
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pain where there is damage or dysfunction of pain pathways.  A further type of pain, 
psychological pain, has sometimes been described.  However in many cases this 
classification can be over simplistic since multiple mechanisms co-exist leading to the 
transition of pain from one type to another.  Presence of a neuropathic component can 
modulate the perception of nociceptive pain.  Identification of the type of pain, and 
detection of the components involved in its causation and persistence will help 
development of novel therapies targeting specific pathologies.  Assessment of a pain 
pathway should involve analysis of both the structures involved and the physiology of 
pain transmission.  Altered perception of a nociceptive stimulus in affected 
individuals could be due to structural pathology or a disorder in transmission and 
processing of signals.  Congenital and acquired conditions can alter these by 
mutations in channels, or by inflammatory mediator which can secondarily alter gene 
expression.  Hence various neuropathic pain syndromes can result due to changes in 
the peripheral and central nociceptive pathways. 
 
1.2.3.1 Definition of neuropathic pain 
 
Neuropathic pain is termed “pain initiated or caused by a primary lesion or 
dysfunction of the nervous system” as defined by the International Association for the 
Study of Pain (Merskey and Bogduk 1994).  It can be the result of conditions ranging 
from neoplasms compressing nerves, surgical damage, immunological or 
endocrinological disturbance or ischemic damage to the nervous system.  Diagnostic 
features include pain out of proportion to the severity of injury, dysaesthesia and signs 
of nerve injury detected on neurological examination.  Neuropathic pain can be 
peripheral or central depending upon the location of the pathology. 
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Peripheral neuropathic pain can result following involvement of single nerves as in 
mononeuropathies (e.g. carpal tunnel syndrome) or plexopathies (e.g. following 
compression of plexus by tumours) or multiple nerves as in polyneuropathies (e.g. 
diabetic peripheral neuropathy).  Pain can follow deafferentation or be sympathetic 
mediated, examples of which include complex regional pain syndromes and phantom 
limb pain.  A lesion or dysfunction in the central nervous system can lead to central 
neuropathic pain.  Neuropathic pain can be acute or chronic; the latter defined as pain 
that has persisted beyond the normal time of healing or for more than three months. 
 
1.2.3.2 Symptoms and signs 
 
Unlike nociceptive pain, neuropathic pain tends to be deep, aching and often 
associated with numbness and tingling.  These symptoms may be constant or may be 
associated with triggering factors such as temperature or local stimulation.  Various 
terms have been used to describe these altered pain symptoms.  It is important to 
distinguish between pain that is evoked by a stimulus and stimulus independent pain.  
Spontaneously occurring, stimulus independent pain typically is present all the time 
but can vary in intensity and be described with more than one feature including, 
shooting, stabbing, burning or electric shock like.  Stimulus dependent pain can have 
variable clinical features.  Different terminologies have been used to describe such 
states of altered sensation (Table 1.3). 
 
 
 
 
45 
Table 1.3 Pain terminologies 
Pain term Definition 
Allodynia Pain due to a stimulus that does not normally provoke pain 
Analgesia 
Absence of pain in response to stimulation that would normally be 
painful 
Hyperalgesia An increased response to a stimulus that is normally painful 
Hyperaesthesia Increased sensitivity to stimulation, excluding the special senses 
Hyperpathia 
A painful syndrome characterized by an abnormally painful reaction 
to a stimulus, especially a repetitive stimulus, as well as an increased 
threshold 
Hypoalgesia Diminished pain in response to a normally painful stimulus 
Hypoaesthesia Decreased sensitivity to stimulation, excluding the special senses. 
 
In affected patients, dynamic allodynia can be elicited by lightly moving a paint brush 
or a cotton swab across the skin and static allodynia can be elicited by light blunt 
pressure with a finger or light pressure with a von Frey filament.  Thermal allodynia 
can be assessed by applying a warm or cool tuning fork over the affected area or by 
brief application of ice.  Patients also often describe sensations including itching, 
tingling and pins and needles.  These abnormal sensations are termed dysaesthesia 
when unpleasant and paraesthesia when not unpleasant.  Spontaneous activity in 
nociceptor C- fibres is thought to be responsible for persistent burning pain following 
sensitisation of dorsal horn neurons.  Spontaneous activity in the large myelinated Aδ 
fibres results in paraesthesiae. Central sensitisation leads to dysaesthesae and pain.  
Neuropathic pain can be present in various clinical conditions (Table 1.4) 
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Table 1.4 Commonly seen neuropathic pain syndromes  
Peripheral neuropathic pain syndromes Central neuropathic pain syndromes 
Chemotherapy-induced neuropathy Central post- stroke pain 
Complex regional pain syndrome Multiple sclerosis pain 
HIV sensory neuropathy Parkinson‟s disease pain 
Neuropathy secondary to tumour infiltration Spinal cord injury pain 
Painful diabetic neuropathy  
Phantom limb pain  
Post herpetic neuralgia  
Post mastectomy pain  
Trigeminal neuralgia  
 
The McGill Pain Questionnaire (MPQ), its short version, Short Form –MPQ and the 
Neuropathic Pain Scale (NPS), are useful in describing the different types of 
symptoms and assessing neuropathic pain.  Quantitative sensory testing nerve fibres 
serving different types of sensations help identify the pain mechanisms involved, and 
can be useful in monitoring progress and response to treatment. 
 
1.2.3.3 Mechanisms of neuropathic pain  
 
Stimulus independent pain 
Accumulation of tetrodotoxin sensitive and resistant sodium channels along the length 
of the axon and neuroma site following nerve injury results in hyper excitability and 
spontaneous ectopic discharge in the axon and cell body of injured sensory neurons 
(Woolf and Mannion 1999).  Tetradotoxin resistant sodium channels are implicated in 
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the causation of ectopic discharges (Novakovic et al. 1998).  Neuropathic pain can 
hence be treated using sodium channel blockers such as local anaesthetics, tricyclic 
antidepressants and antiarrhythmic and antiepileptic agents.  Unfortunately side 
effects can occur due to the action of these drugs on sodium channels in the central 
nervous system and cardiovascular system. 
 
Stimulus independent pain is maintained in some patients sympathetically by 
expression of α-adrenoceptors by the injured and uninjured axons.  This renders them 
sensitive to circulating catecholamines and noradrenaline released from the post 
ganglionic sympathetic terminals.  Following nerve injury, there is an induction of 
sprouting of sympathetic axons into the dorsal root ganglion where they form baskets 
around the cell bodies of sensory neurons.  This can result in activation of sensory 
fibres following sympathetic activity (McLachlan et al. 1993).  Sympathetic blocks 
using guanethidine or α1 antagonists may be useful to treat such patients although the 
outcome using these methods is doubtful (Kingery 1997). 
 
A decrease in the inhibitory control over the dorsal horn neurons (disinhibition) can 
reduce the effect of the spinal gate and result in stimulus independent pain.  Following 
peripheral nerve injury there can be a reduction of GABA with subsequent down 
regulation of GABA receptors, or a reduction of spinal inhibitory interneurons in 
lamina II following their death through and excitotoxic mechanism (Sugimoto et al. 
1990).  Gabapentin has been used to mimic the action of GABA and is useful in 
neuropathic pain (Rosenberg et al. 1997), although this drug does not act on GABA 
receptors.  Other drugs such as clonidine to mimic descending inhibition may be 
useful. 
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Stimulus dependent pain 
Sensitization of the dorsal horn neurons following continuous input from 
spontaneously firing nociceptors C-fibres can make them respond to normal stimulus 
in an exaggerated manner.  This can result in hyperalgesia to normally non- painful 
stimulus.  SP which is co localized with glutamate, an excitatory neurotransmitter, 
phosphorylates the glutamate receptor NMDA by its action on neurokinin 1 receptor 
through the process of extending depolarisation, increasing intracellular concentration 
of calcium and activating PKC (Woolf 1983; Chen and Huang 1992).  This increases 
the excitability of the NMDA receptor and results in sensitization of the DH neurons.  
Central sensitization can manifest by spreading of the painful area beyond the 
territory of the injured nerve, increased response to supra threshold stimulus or painful 
response to sub threshold stimulus including stimulation of tactile Aβ fibres.  NMDA 
antagonists, blockage of Aβ fibre conduction by ischemia or pressure and blocking 
constant activity of nociceptors using local anaesthetics can abolish features of 
allodynia (Woolf and Mannion 1999).  
 
Other mechanisms of allodynia and hyperalgesia without a sensory input include 
disinhibition, A- fibres sprouting in the spinal cord, and A- fibre phenotypic switching 
after peripheral nerve injury.  A-fibres sprouting into lamina II which normally 
receives nociceptor input can result in misinterpretation of non painful stimulus as 
painful (Woolf et al. 1992; Woolf and Doubell 1994).  The neurotransmitters SP and 
CGRP normally produced by C and Aδ fibres are down regulated after nerve injury.  
However a phenotypic switch can occur and large myelinated Aβ fibres can begin 
expressing these and result in an altered pain state (Miki et al. 1998).  A change in the 
function, chemistry and structure (neuronal plasticity) can also occur in the central 
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nervous system.  Dramatic changes in cortical maps seen after amputation and nerve 
injury may contribute to phantom pains (Flor et al. 1995).  
 
1.2.4 Assessment of Nociception 
 
Pain is considered the primary symptom that instigates people to seek medical 
attention (Turk and Melzack 2001).  Assessment of pain is important not only to 
evaluate the severity of an underlying condition, but also to monitor response to 
therapy.  For the normal clinician managing the patient‟s pain the tools available to 
assess pain must include a description and severity of the pain, a record of the 
responses of the patient to pain and a gauge of the impact the pain has had on the 
patient‟s life (Strong 1999).  Unfortunately a major obstacle in the assessment of pain 
is its inherent subjectivity.  A clinical researcher is interested not only in the recording 
the same measures, but also in understanding pain in a more objective fashion and its 
pathophysiology so as to be able to devise newer methods to treat patients comparing 
it with existing methods between patients and in the same patient.  Questionnaires 
have been formulated to help the patient describe the nature, severity and effects of 
pain.  Some of the symptoms and disabilities experienced by the patient can be due to 
the secondary effects on other modalities of sensation following sensitisation.  
Quantitative methods are available to assess the function of different classes of nerve 
fibres involved in sensory perception.  This could help in studying the relative 
contribution of these fibres in neuropathic pain syndromes.  Neurophysiological 
methods such as nerve conduction studies assess the conduction of impulses to the 
central nervous system.  Additional information on disorders of pain perception can 
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be gained by studying small nerve fibres from the skin using biopsies stained for 
neuronal, ion channel and inflammation/ regeneration related biomarkers. 
 
1.2.4.1 Bedside examination 
 
Examination of a patient in pain begins with eliciting a history.  Knowledge of the 
negative (sensory loss) and positive (pain and paraesthesia) signs and symptoms is 
essential.  The nature of pain, whether spontaneous, or stimulus dependent, is noted.  
The pain provoking stimulus, mechanical, thermal or chemical and the type of 
abnormal sensation elicited, allodynia or hyperalgesia is recorded.  
 
A full neurological examination is performed.  A body sensory map may be used to 
help identify the involved nerves.  Assessment of touch sensation can be performed 
using cotton wool or a brush.  Pin prick sensations can be elicited using sharp pins.  
Quantitative sensory testing is performed for a more detailed examination. 
 
1.2.4.2 Questionnaires for pain 
 
One of the simplest methods to understand pain as felt by the patient is by the use of 
questionnaires.  Simple questionnaires such as the category rating scale in which the 
patient describes the severity of pain as mild, moderate, severe or unbearable are a 
quick way of measuring pain.  This can be elaborated on a numeric rating scale of 0- 
10.  A more sensitive scale is the visual analogue scale where a person marks the 
severity of pain on a straight line, 10 cm long with anchor points on either end 
measuring no pain on one end to most severe pain on the other.  In children or 
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situations where it is difficult to communicate the details of a numeric or visual 
analogue scale, a Wong-Baker FACES pain rating scale can be used (Hockenberry 
2009).  For use in research settings multidimensional pain questionnaires have been 
devised including the Mc Gill Pain Questionnaire (Melzack 1987), Brief Pain 
Inventory (Cleeland and Ryan 1994), and Gracely Pain Scale (Gracely et al. 1978).   
 
Detailed questionnaires have been devised to enable distinguish neuropathic pain 
from nociceptive pain.  The Neuropathic Pain Questionnaire (NPQ) (Krause and 
Backonja 2003), ID Pain (Portenoy 2006) and Pain DETECT (Freynhagen et al. 2006) 
use interviews to diagnose neuropathic pain.  The Leeds Assessment of Neuropathic 
Symptoms and Signs (LANSS) scale (Bennett 2001) and Douleur Neuropathique en 4 
Questions (DN4) questionnaire (Bouhassira et al. 2005) use both interview questions 
and physical tests (pinprick and tactile hypoesthesia, pain to light touch), and achieve 
higher sensitivity and specificity than the screening tools that use only interview 
questions.   
 
1.2.4.3 Quantitative sensory testing (QST) 
 
Cutaneous touch thresholds 
Maximilian von Frey in 1896 described using hairs of different sizes to determine 
touch thresholds.  To expand the range of sizes  and standardize the pressure applied 
during touch test J. Semmes and S. Weinstein (1960) designed and developed nylon 
monofilaments of increasing diameter for peripheral nerve testing with such filaments 
set at right angles to the end of acrylic (Lucite) rods.  The filament is pressed against 
the skin of the patient perpendicularly until it bows.  A series of nylon monofilaments 
52 
are sized and numbered to correspond to Log (10×force in mg) of force.  The lowest 
force in the series is 4.5 mg and the highest force is 447 grams.  The monofilaments 
(of constant length but of increasing diameters) are designed to bend when a specific 
value of force is reached and such design provides unique control of, and credibility 
to, the Semmes-Weinstein sensory test method.  These are usually provided as a set of 
five units having selected sensory level designations of 2.83, 3.61, 4.31, 4.56 and 6.65 
to measure five levels of sensation viz. normal, diminished light touch, diminished 
protective sensation, loss of protective sensation and deep pressure sensation 
respectively. 
 
Tactile pain thresholds 
Painful sensations can result following application of tactile stimuli (allodynia and 
hyperalgesia).  If the pain occurs in response to light touch or pressure it is termed 
static mechanical allodynia.  This can be identified by the Semmes-Weinstein 
monofilament with a high target force.  Pain in response to brushing the skin in 
termed dynamic mechanical allodynia.  This can be detected by brushing the skin 
slowly with a cotton wool or a foam brush. 
 
Weighted needles are used to detect hyperalgesia over the skin.  By recording the 
intensity of pain over different areas of the skin, areas with an abnormal sensation are 
identified.  An increase in pain felt on pin prick is termed pin prick hyperalgesia and 
indicates a dysfunction of Aδ fibres. 
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Vibration threshold 
Deformation of tissue resulting from a vibrating stimulus is believed to excite the 
Pacinian corpuscle (Scott 1949) which subsequently transmits the impulse via Aβ 
fibres to the spinal cord.  Pacinian corpuscles are concentrated in finger tips, palms, 
soles, toes, bony periosteum, fascial tissue planes, muscles, around blood vessels, 
nerve trunks and joint ligaments(Aro et al. 1982; Macefield 2005).  Vibrations from 
suitably energised tuning forks displace subcutaneous tissues and periosteum exciting 
the pacinian corpuscles.  These corpuscles respond to a vibration frequency ranging 
from 120 to 250 cycles/ second (Hz). Tuning forks although can be used as a valuable 
tool for quick bedside examination, for a more accurate examination in a research 
setting it is necessary to use a tool through which a controlled frequency and energy 
can be applied.  This can be done using electromechanical devices such as the 
biothesiometer. 
 
Neurogenic flare reaction 
Pioneering studies by Sir Thomas Lewis in the 1920‟s led to the discovery of 
histamine (substance H) (Lewis 1927).  He described the triple response of red line, 
flare and wheal following trauma to skin.  This response follows post traumatic 
degranulation of mast cells in the dermis which spills histamine.  The flare reaction 
was described as being secondary to antidromic conduction along the axons, and was 
termed, the axon reflex.  This reaction can be elicited by other stimuli such as insect 
bites, intradermal injection of histamine, substance P and bradykinin.  Neural 
mediators of the axon flare are suggested to be C-fibre nociceptors which through 
antidromic conduction stimulate vasodilatation via release of SP and CGRP 
(Wallengren and Hakanson 1987; Magerl and Treede 1996; Sann and Pierau 1998; 
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Schmelz et al. 2000).  The flare reaction induced by intradermal injection of histamine 
can be used to assess the function of C-fibres. 
 
Thermal thresholds 
Temperature sensation, a function of C and Aδ fibres can be quantitatively assessed 
by measuring the temperature change required for an individual to perceive a sense of 
warmth or cold (warm or cold threshold) and temperature at which heat or cold 
evokes a painful sensation (heat or cold pain).  The neural apparatus known to 
underlie the sensation of cold in man is served at the primary afferent level by small 
calibre myelinated fibres.  Indirect measurement of conduction velocity of afferent 
input related to cold sensation and other human experimental studies support the 
notion that Aδ fibres convey the primary neural message that is perceived as cold 
sensation (Fowler et al. 1988; Yarnitsky and Ochoa 1991).  Small unmyelinated C-
fibres carry the afferent signal evoked by non noxious elevation of temperature 
perceived as warmth (Hallin et al. 1982; Yarnitsky and Ochoa 1991).  Unmyelinated 
fibres also carry the afferent input induced by noxious heat perceived as heat evoked 
pain (Yarnitsky and Ochoa 1990; Yarnitsky and Ochoa 1991).  Although Aδ fibres 
can also contribute to heat pain sensation, their involvement is considered to be 
limited in comparison to the unmyelinated C-fibres (Verdugo and Ochoa 1992).  Both 
Aδ and C-fibres are suggested to play a role in cold evoked pain.  This sensation 
evoked by low thermal stimulation is a blend of cold sensation contributed by input 
along cold specific thermoceptors (Aδ) and pain sensation contributed by nociceptors 
(C-fibres).  It has been shown that upon abolition of Aδ cold specific component of 
cold pain, the magnitude of painful component becomes disinhibited and its quality 
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shifts to a strikingly burning nature in keeping with its C-nociceptor basis (Wahren et 
al. 1989; Yarnitsky and Ochoa 1990). 
 
Systems that deliver thermal stimuli commonly use Peltier contact thermodes with a 
surface area ranging from 3 to 13 cm2.  The thermode is set at a baseline or holding 
temperature of 30- 34°C (usually 32°C) and placed against the skin.  The temperature 
may be increased or decreased to measure warm and cold sensation, or, upon further 
termperature change, heat and cold pain thresholds (Verdugo and Ochoa 1992; 
Gruener and Dyck 1994; Dotson 1997; Yarnitsky 1997). 
 
Testing can be performed either by using the „method of limits‟ or „method of levels‟ 
(forced choice method).  In the „method of limits‟, which is the most common method 
used, the intensity of stimulus is gradually decreased or increased until the subject 
perceives the sensation (Verdugo and Ochoa 1992).  This method is affected by the 
rate of change  and also the subject‟s reaction time (Chong and Cros 2004).  It is 
quick to perform.  In the „method of levels‟, stimulus is applied either in an increasing 
or decreasing manner.  At each intensity, the subject is asked if the stimulus is felt (or 
if pain is felt), thereby forcing the patient to indicate make a choice (Yarnitsky 1997).  
This method is less dependent on the subject‟s reaction time or rate of change, but is 
very time consuming.  Threshold values obtained vary depending on the apparatus 
used, age of the subject, region of body tested, rate of change of stimulus intensity, 
room temperature and size of the thermode used.  Hence it is essential to have a set of 
normative values against which comparisons can be made. 
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1.2.4.4 Other tests  
 
Electrodiagnostic tests 
Tests using applied electrical impulses are an important tool in assessment of function 
of nerves (Dotson 1997).  Following nerve injury or neuropathy there are changes in 
transmission of electrical impulses along the nerves which can be measured using 
nerve conduction tests.  Integrity of both, sensory and motor components of a 
peripheral nerve can be evaluated.  Electromyograpy (EMG) which records electrical 
activity in a muscle by inserting fine needle electrodes can detect denervation and 
signs of re innervation of muscles.  Nerve conduction tests (NCS) assess mainly two 
aspects of a nerve; axonal disruption and axonal demyelination.  Both these conditions 
can cause weakness, pain and other sensory abnormalities.  The types of tests 
performed during a nerve conduction study include sensory NCS, motor NCS, H-
reflex and F-wave study.   
 
During a sensory NCS the stimulating electrode is applied distally on the skin 
overlying the nerve and the recording electrode, a short distance proximally.  Lesions 
of the nerve proximal to the dorsal root ganglion such as radiculopathy and traumatic 
avulsion of spinal nerve roots do not alter the NCS where as lesion distally such as 
compression neuropathy and nerve transaction result in a reduced conduction velocity 
(in demyelination) or reduced/absent amplitude in axonal injury.  A motor NCS 
measures the velocity and amplitude of motor conduction by stimulating a motor 
nerve proximally with electrodes placed on the skin overlying the nerve and recording 
contraction of the supplied nerve.  A F-wave study uses supramaximal stimulation of 
a motor nerve to transmit impulses from the peripheral nerve to the anterior horn of 
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the cell and back along the same nerve.  This helps study the segment of the nerve 
from the periphery to the spine.  The H-reflex is similar but a mixed nerve is 
stimulated to deliver impulses along the sensory fibres to the spine which are then 
transmitted back along a motor nerve. 
 
Neurophysiological tests have been used in the diagnosis and monitoring of painful 
conditions such as radiculopathy, carpal tunnel syndrome brachial plexopathy and 
other forms of neuropathy.  In most cases however, NCS measures the function of 
large diameter nerve fibres.  Conventional NCS are less useful in the management of 
small fibre pathology which are implicated in the causation of pain.   
 
Skin biopsy 
Paul Langerhans first described nerve fibres in the human epidermis in 1868 (Sommer 
and Lauria 2007).  Discovery of the protein gene product 9.5 (PGP9.5) in neural tissue 
and development of antibodies to it led to studies on nerve fibres in the skin by 
staining them with PGP9.5 antibodies (Dalsgaard et al. 1989).  Painful stimuli are 
transmitted by unmyelinated C fibres and thinly myelinated Aδ fibres.  These fibres 
are involved in neuropathies with altered pain states and their quantification by 
measuring their density in the epidermis and dermis can provide information on 
pathophysiology.  Detailed studies on epidermal nerves can be performed by staining 
them with antibodies to PGP9.5 and is now recommended in the assessment of small 
fibre neuropathy (Lauria et al. 2010).  Intraepidermal nerve fibre (IENF) density has 
been shown to vary during states of inflammation, degeneration and regeneration.  
Normative values have been reported for different age groups and different body 
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regions along with description of changes in pathological states (McArthur et al. 
1998; Lauria et al. 1999; Goransson et al. 2004). 
 
1.2.5 Treatment of pain 
 
One of most important factors affecting the quality of life is pain.  Conditions such as 
arthritis, trauma, nerve compression primarily present with pain.  In other conditions 
such as neuropathic pain in complex regional pain syndromes, the cause is less clear.  
Successful treatment of pain in such conditions is vital to prevent secondary effects 
such as disability, depression, addiction to drugs and in some cases death.  Treatment 
strategies have continued to evolve reflecting our improved understanding of the 
mechanisms of nociception.  Methods such as prayers, sacrifices, alcohol and opium 
during the early part of civilisation have been abandoned, refined or radically changed 
during the last two centuries.  Current strategies to treat pain include physical therapy, 
drugs to alter transmission of neural impulses such as anaesthetics, general sedative 
and surgical procedures such as dorsal column stimulation, thalamic stimulation and 
neurotomy/ neurectomy.  It has become clear that management must involve a 
multidisciplinary approach targeting not just the treatment of pain, but also the 
causative pathology and the secondary effects resulting from pain.  While acute pain, 
which serves a protective function, is generally self limiting, and stops when the tissue 
damage heals, it needs treatment to reduce its severity and provide comfort.  Chronic 
pain, such as neuropathic pain on the other hand has no protective function, results in 
suffering and disability and needs treatment in the form of measures to rehabilitate the 
individual apart from using pain relieving therapies. 
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1.2.5.1 Planning treatment 
 
The first step in the treatment of pain is to identify the site, cause and nature of pain.  
Other secondary effects like disturbance of sleep, health-related quality of life, 
including social and emotional functioning, should be assessed.  Presence of 
depression or anxiety needs to be recorded as they can influence the outcome of 
management.  A realistic goal needs to be agreed upon with the patient to avoid false 
expectations and side effects of treatment.  An interdisciplinary treatment approach is 
adopted including pharmacological and non pharmacological treatment regimens, 
such as cognitive behaviour, physical and occupational therapy.  Several guidelines 
and meta analysis have been published reviewing and providing a framework for 
treatment of neuropathic pain (Dworkin et al. 2007).  The various treatment options in 
patients with neuropathic pain have been reviewed and are summarized below
1
 . 
 
1.2.5.2 Pharmacological treatment 
 
Current pharmacological treatment regimens for pain in neuropathy mainly include 
antidepressant or anticonvulsant drugs.  Important drugs and their mechanisms of 
action in described in Table 1.5 (Shenoy 2008). 
 
 
 
 
                                                 
1
 Shenoy R; Roberts K; Anand P. Peripheral Neuropathies. In Clinical Pain Management 4 Volume Set. . Rice A (ed). 
Oxford University Press, USA (29 Nov 2008).  
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Table 1.5 Commonly used drugs to treat pain and their mechanisms of action 
Drug Mechanism 
Amitriptyline/Imipramine NE/5-HT re-uptake inhibition 
Sodium channel blockade 
Duloxetine 5- HT and NE re- uptake inhibition 
Carbamazepine Sodium channel blocker 
Gabapentin Calcium channel blockade? 
GABA-ergic mechanism? 
Pregabalin Calcium channel blockade? 
GABA-ergic mechanism? 
Clonazepam GABA-ergic mechanism 
Mexiletine Sodium channel blocker 
Phenytoin Sodium channel blocker 
Clonidine á2-Adrenoreceptor agonist 
Tramadol Centrally acting opioid 
Nonopioid analgesic 
Dextromethorphan NMDA receptor antagonist 
 
Topical agents 
Capsaicin, the active constituent of „hot‟ chilli peppers, responsible for eliciting the 
symptoms of heat, burning, and erythema, has been advocated as a topical agent for 
the therapy of postherpetic neuralgia and painful diabetic peripheral neuropathy 
.(Watson et al. 1988; Westerman et al. 1988; Lynn 1990; Rains and Bryson 1995)  
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The underlying mechanism is not yet clear, but may rely on the depletion of substance 
P via activation of the TRPV1 receptor or an effect on nerve terminals.  The 
degeneration of epidermal nerve fibers, which is reversible on discontinuing 
capsaicin, is also postulated to contribute to analgesia (Nolano et al. 1999).  High 
concentrations of capsaicin (8%) applied as a patch for 60 minutes has been shown to 
mimic the degeneration of epidermal nerve fibers seen with prolonged exposure to 
low dose capsaicin and the pain relief produced can last up to 3 months (Malmberg et 
al. 2004). 
 
EMLA (eutectic mixture of local anaesthetics) and topical aspirin/diethyl ether 
mixture have been shown to be useful in painful conditions like herpes zoster and post 
herpetic neuralgia (De Benedittis and Lorenzetti 1996; Litman et al. 1996). 
 
1.2.5.3 Surgical and other non-pharmacological treatment 
 
Anatomical studies detailing pathways of transmission of nociceptive signals led to 
the development of surgical and non-surgical methods of interrupting or modulating 
transmission to the cranial pain centers.  In the presence of a causative pathology as in 
carpal tunnel syndrome or intervertebral disc decompressing the involved peripheral 
nerve or nerve root is sufficient to provide relief if the damage inflicted on the nerve 
is reversible.  Neuropathic pain, where there is no identifiable area of compression or 
constriction poses a challenge.  In these conditions techniques to prevent this pain 
being appreciated at the higher centres are followed.  The surgical options can be 
classified as neuromodulatory or ablative surgery.  While neuromodulatory methods 
are safer and reversible, they require long term continuity.  Ablative options generally 
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are more convenient long term options, but carries risks of operative complications 
and potential risk of worsening pain. 
 
Peripheral nerve stimulation 
Following early experiments by Wall in the 1960s different techniques of peripheral 
nerve stimulation have been developed.  The principle behind these procedures 
involves stimulating large diameter nerve fibres to produce overall nerve inhibition 
following gate control hypothesis as proposed by Melzack and Wall.  Techniques 
used include: 
1. Large surface metal electrodes placed over peripheral nerves associated with 
painful areas to stimulate the large Aβ afferents.  This technique known as 
transcutaneous electrical nerve stimulation (TENS) may be helpful, if correctly 
administered, in some patients with neuropathic pain and needs persistence to find the 
optimum conditions of stimulation (Meyer and Fields 1972; Kumar and Marshall 
1997) 
2. Percutaneous temporary electrodes placed in the vicinity of the affected nerves 
producing a strong but not unpleasant tingling sensation in the distribution of the 
nerve. 
3. The third method involves silicon cuff electrodes places around affected 
nerves and attached to a subcutaneously placed radiofrequency receiver. 
 
Spinal cord stimulation 
Flexible electrodes are introduced through a lumbar puncture to stimulate the cauda 
equina.  Other regions of the spinal cord can be stimulated similarly.  It is thought to 
activate spinal inhibitory circuits, mainly those concerned with GABAergic 
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mechanisms (Cui et al. 1997; Stanton-Hicks and Salamon 1997), and may have a 
suppressive action on dorsal horn neuronal hyperexcitability (Yakhnitsa et al. 1999).  
Prior to permanent implantation of a stimulation device, a trial period with temporary 
external stimulation is strongly recommended.  Spinal cord stimulation has been 
shown to have long-term benefit in various conditions associated with neuropathic 
pain including diabetic painful neuropathy (Tesfaye et al. 1996), complex regional 
pain syndromes, and failed back syndrome (Kumar et al. 1996; Lang 1997; Kumar et 
al. 1998; Murphy et al. 1998; Segal et al. 1998; Kemler et al. 1999).  Postherpetic pain 
and trigeminal neuralgia seem to respond less favorably over the long term, as do pain 
due to cauda equina injury and phantom limb pain.  Strict criteria need to be applied 
to the selection of a patient, and all therapeutic modalities should be exhausted before 
the decision to implant a stimulator is made. 
 
Deep brain and cortical stimulation 
Based on the rationale that deafferentiation central pain arises because of an absence 
of sensory input into the somatosensory thalamic relay nucleus or the sensory cortex, 
Mazars et al  in 1960 stimulated the ventralis posterolateralis of the thalamus (Mazars 
et al. 1960).  Following recent advances in stereotactic surgical techniques, deep brain 
stimulation has gained popularity in movement disorder surgery (Broggi et al. 2007; 
Capelle et al. 2011).  Their mechanism of action in pain relief surgery is proposed to 
be due to blocking or jamming of neuronal signals and an activation of axonal tracts.  
These techniques are generally reserved for only those who have incapacitating pain 
not relieved by other measures.  A similar technique of stimulating the motor cortex 
has been described.  Surgical procedures using open or stereotactic methods have 
been described to stimulate the motor cortex in treating central de afferentation pain. 
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Acupuncture 
Acupuncture, a traditional method to induce analgesia, relies on the placement of 
needles at specific acupuncture spots, where stimulation of afferents presumably 
activates endogenous inhibitory systems (Sweet 1981; Lewith and Machin 1983; Ng 
1992) . 
 
Ablative surgery 
Creating a physical disruption of the pain pathway is the principle used in ablative 
surgery.  This could be by excision of neuroma and peripheral neurectomy for 
peripheral nerves; sympathectomy for complex regional pain syndromes (Straube et 
al. 2010) and visceral pain; spinal dorsal rhizotomy and ganglionectomy for 
neuropathic pain syndromes (Wilkinson and Chan 2001) including cancer pain; 
anterolateral cordotomy and spinothalamic tractotomy for cancer pain; dorsal root 
entry zone procedures (DREZ) at spinal and medullary level for plexus avulsion 
injuries, post herpetic neuralgia, spinal cord and cauda equina injuries and 
commissural myelotomy for midline cancer pain in the pelvic area; facet rhizolysis for 
facet joint pain (Meyerson 2001; Whitworth and Feler 2002). Other ablative 
procedures carried out on the cranial nerves for indications such as tic douloureux 
include percutaneous radiofrequency rhizolysis, percutaneous glycerol injection and 
open rhizotomy (Charlton 2005).  Destructive procedures in the brain and brain stem 
have been described. These are mainly done steriotactically and include 
mesencephalic tractotomy, medial thalamotomy, central lateral thalamotomy and 
cingulumotomy (Charlton 2005).  Such procedures are generally reserved only for 
selective cases in specialist treatment centres. 
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1.3 SUMMARY 
 
Pain perception is a complex process involving interactions between receptors and 
pathways.  A `pain centre‟ or `pain centres‟ may not, as such, exist.  Rather, a matrix 
of cerebral structures and multiple, parallel thalamocorticolimbic networks 
synergistically contribute to the experience of pain.  Mechanisms exist between 
receptors and higher centres that enable characterisation of properties of the stimuli 
such as intensity, localisation and physical nature.  Higher centres including the 
cerebral cortex, thalamus, insula and limbic structures process the signals relayed to 
them and recognise the characteristics of pain and bring about an emotional response 
to pain.  Pathways within the spinal cord and descending from higher centres 
modulate the signals, thus bringing about facilitation or inhibition.  Integral to the pain 
pathway are key molecules which help generate and transmit nociceptive impulses. 
 
Neuropathic pain caused by pathology affecting the nervous system can result in 
positive sensory symptoms such as hyperalgesia and allodynia and negative 
symptoms such as numbness.  The pain experienced by the patient could be stimulus 
dependent or due to spontaneous activity in the damaged nerves.  Specific assessment 
tools including biomarkers are needed to identify the processes underlying 
pathological pain which would enable development of targeted therapy. 
 
Acute and injury related pain generally needs short term treatment with a combination 
of physical intervention and analgesics.  Neuropathic pain on the other hand is more 
challenging.  A multidisciplinary approach needs to be initiated to tackle the physical 
and functional effects of such pain.  Central and peripheral mechanisms leading to 
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such pain will need to be managed pharmacologically or surgically.  All oral drugs, 
topical agents, neurostimulation techniques and ablative surgery have risks and 
limitations.  No single method is equally effective in all patients as the pathology 
leading to pain can be variable.  The subjective nature of pain makes it more 
challenging to compare treatment.  Hence better techniques are needed to assess pain 
and the pain pathway to enable tailoring treatment to the individual.  There also is the 
need to discover treatment methods which selectively block nociception.  
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Chapter 2 Volunteer models of pain 
 
 
2.1 HUMAN PAIN MODELS 
 
Introduction 
With the development of innovative investigative tools, research has focussed on 
developing methods for non-invasive assessment of pain, and the study of pain 
processing at an integrative level in the central nervous system (CNS).  Improved 
knowledge of receptors and structures in the pain pathway has enabled refinement of 
techniques to assess and modulate the relative contribution of peripheral and central 
structures processing pain.  Cloning of receptor molecules and a study into their 
structure and activation characteristics has enabled development of chemicals which 
can influence them.  These agonists and antagonists can be used in experimental 
studies into nociception by the development of experimental models.   
 
Pain induced modulation of neuronal activity can be investigated in animal and 
human models.  While microelectroneurography enables recording of activity in 
peripheral nociceptive afferents following stimulation of receptors with painful 
stimuli, withdrawal reflexes and vegetative reactions in response to experimental 
induced pain have been used to quantify pain states and their experimentally-induced 
attenuation.  These methods help study stimulus evoked nociceptive activity in the 
spinal and supraspinal structures independent of conscious pain experience.  At a 
peripheral level studying patterns of altered expression of receptor proteins and 
68 
channels have enabled identification of the processes leading to sensitisation and 
spontaneous pain.   
 
Electrophysiological methods which could relate more closely to conscious perception 
of pain include recording of pain-evoked brain potentials.  A stimulus evoked 
potential on a background spontaneous electroencephalogram indicates that there is 
activation of a specific sensory system and transmission of the impulse pattern to the 
brain.   
 
Another method of confirming activation of brain structures is by imaging techniques, 
to capture changes in these centres following activation of peripheral receptors.   
 
These techniques need to be validated as biomarkers for clinical pain states.  To 
enable this, as a first step, clinically relevant experimental volunteer models and 
methods to activate the nociceptors need to be developed.  The results from such 
experimental techniques then need to be applied to subgroups of patients suffering 
from pain disorders. 
 
2.1.1 Methods to Activate Nociceptors in Humans 
 
The electrical stimulation models, although relatively easy and safe to perform, 
exhibit poor nociceptive specificity.  Mechanical pressure produces pain but co-
activates mechanoreceptors.  Ultrasound stimulation of the knee has been shown to 
produce evoked potentials but this method is not adequate for a broader field 
application (Wright and Davies 1989).  Other methods explored include chemical 
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activation of nociceptors such as capsaicin and mustard oil.  By themselves these 
topical chemical methods produce very slow onset and disappearance of an evoked 
response, and are not adequate (Bromm and Lorenz 1998). 
 
2.1.1.1 Laser evoked potentials (LEPs) 
 
Since the first report of delivering a brief radiant heat pulse by lasers, by Mor and 
Carmon in 1975, other researchers including Kenton and colleagues in 1980 described 
recording of event related brain potentials by pure thermal stimulation of skin using 
lasers (Kenton et al. 1980).  Study of nociceptors using CO2 lasers and recording of 
cerebral potentials was described by Bromm and Treede in 1984 (Bromm and Treede 
1984).  The wavelength of infrared radiation has to meet one of the water absorption 
maxima of the tissue to be stimulated.  This results in the heat energy being 
completely absorbed within the most superficial skin layers and activation of 
nociceptors specifically, presumably through capsaicin-sensitive ion channels.  Most 
investigations on LEPs were performed with the CO2-laser (10.6 mm) usually with 
pulse durations between 20 and 60 ms (Bromm and Treede 1991).   
 
Within certain limits of stimulus durations (5–50 ms), the threshold energy (intensity 
times duration) to elicit pain using CO2-pulses was found to be constant (Biehl et al., 
1984).  Higher energies are needed with longer pulse durations due to heat conduction 
into neighbouring tissues.  Similarly, density of threshold energy (energy per skin 
area) was found to be constant for areas between 5 and 40 mm
2
.  Smaller and greater 
areas require higher and lower energy densities, respectively, because of spatial 
summation and interaction with the size of the receptive fields.  Laser stimuli are felt 
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as sharp, pungent pain, less localizable and scalable with respect to intensity than the 
conventionally applied pinprick.  The stimulus evokes late brain potentials which 
consist of a negativity (usually called N2) followed by a large positive component 
(P2) both with vertex (Cz) position maxima.  The peak latencies depend on the kind 
of laser stimulator used, the conduction velocity of the fibre spectrum activated and 
the body site stimulated.  The second pain of burning character mediated by C-fibres 
producing the ultra-late LEPs can be recorded by blocking Aδ fibres by techniques 
including application of pressure over the peripheral nerves (Bromm and Treede 
1987).  This burning pain can also be elicited by repeated application of stimuli at 
short intervals producing a wind-up of C-fibres by temporal summation (Price 1972; 
Price et al. 1977).   
 
The relative activation of Aδ and C-fibers seems to depend upon intensity of the laser 
beam.  Using the temperature- controlled CO2-laser both in monkeys and human 
subjects Treede et al. (1994) studied stimulus response curves of human LEPs and the 
correspondent pain ratings with recruitment curves of Aδ and C-nociceptors of 
monkeys.  At 48°C, 50% of Aδ -fibres were activated, and more than 50% of the 
stimuli were perceived as pricking pain.  At a stimulus of 50°C more than 90% of the 
stimuli were rated as pricking pain (Bromm and Lorenz 1998).   
 
LEPs have been studied in patients with altered pain states including polyneuropathy, 
syringomyelina, multiple sclerosis and fibromyalgia syndromes (Bromm and Treede 
1991; Kakigi et al. 1991a; Kakigi et al. 1992; Gibson et al. 1994).  Using lasers to 
stimulate nociceptors have certain disadvantages.  Delivering short -duration heat 
stimuli to the skin using lasers, due to the small stimulation area of <5mm diameter 
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may not replicate natural activation as in contact heat.  In addition the very brief 
duration may not resemble the nagging quality of pain produced by thermal injury.  
Lasers can also cause superficial burn with hyperpigmented spots lasting a few days.  
The laser apparatus are also expensive, difficult to calibrate and operate and needs use 
of protective glasses to prevent eye damage.   
 
2.1.1.2 Contact heat evoked potential stimulator (CHEPS) 
 
Stimulators delivering contact heat using a probe with a Peltier element held on to the 
skin have been developed (Fruhstorfer et al. 1976).  Recent technologies using heat 
foil technology have enabled induction of rapid heat changes in the thermode.  They 
can generally evoke slow and fast pain.  They activate noxious- thermal thin fibres in 
the C-fibre range in addition to the mechano-thermal Aδ fibres.  Brain potentials have 
been shown to follow a neurophysiological sequence similar to that of LEPs.  CHEPS 
produced a late Cz/N550 component in association with Aδ fibre activation and a very 
late Pz/P1000 component in association with C-fibre activation (Chen et al. 2001).  
Study of these two components enables evaluation of thin fibre pathology in altered 
pain states.  
 
2.1.1.3 Chemical pain models - the topical TRP agonist pain model 
 
Acute injury results in pain, hyperalgesia and allodynia over the affected area.  These 
are protective responses serving to prevent further injury.  Enhanced pain or pain 
disproportionate to injury which persists even after the danger from injurious agents 
has passed serves no useful function.  Underlying the pathophysiology of all such pain 
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is the release of mediators such as interleukin-6, SP, CGRP and NGF from damaged 
tissues and nerve endings (Omoigui 2007).  The peripheral nociceptors are sensitised 
by these mediators leading to hyperalgesia.  Acute and inflammatory pain following 
injury needs to be adequately treated before they lead to secondary changes in central 
processing.  Using pain models, the investigator can control the experimentally 
induced pain (including the nature, localisation, intensity, frequency and duration of 
the stimulus), and provide quantitative measures of the psychological, behavioural or 
the neurophysiological responses.  Techniques to activate the peripheral nociceptors is 
the principle underlying initiating a pain response in a model.  Mechanical, electrical, 
thermal and chemical methods are used to induce hyperalgesia and allodynia.  As 
discussed earlier, lasers and CHEPS can be used to produce short intensity heat and 
the pain response measured.  There are few human inflammatory pain models 
available for research (Staahl and Drewes 2004).  Pain in inflammation and following 
injury is long lasting.  Such long lasting hyperalgesia can be induced in the skin by 
chemicals or by Ultra violet radiation of skin causing burns in animal models (Chizh 
et al. 2009).  Other ways of inducing changes typical of inflammation and 
degeneration is by application of chemicals to activate nociceptors.  
 
Capsaicin pain model 
The discovery of the heat/ capsaicin receptor TRPV1 as a mediator of pain and 
localisation of TRPV1 receptors in the peripheral nervous system has led to research 
into the development of TRPV1 antagonists to treat hyperalgesia and pain following 
injury (Anand et al. 2008; Gunthorpe and Szallasi 2008).  The TRPV1 receptor can be 
activated by heat, capsaicin and inflammatory mediators; and psychophysical (pain 
threshold and tolerance) and peripheral afferent (capsaicin-evoked flare) responses to 
73 
the target-specific challenges (heat, capsaicin, inflammation) have shown the ability 
to detect TRPV1 antagonism in humans (Chizh et al. 2007).   
 
Capsaicin ((E)-N-[(4-hydroxy-3-methoxyphenyl) methyl]-8-methylnon-6-enamide), 
the primary pungent ingredient in hot chilli peppers, is a highly selective agonist for 
TRPV1.  The initial effect of topically applied capsaicin is the activation of TRPV1-
expressing (capsaicin sensitive) cutaneous nociceptors, resulting in burning 
sensations, hyperalgesia, allodynia, and erythema.  After chronic exposure to 
capsaicin, nociceptive sensory axons can become less sensitive to a variety of stimuli 
(Szallasi and Blumberg 1999).  These later-stage effects of capsaicin are frequently 
referred to as “defunctionalization” or “desensitisation” and are the rationale for the 
development of capsaicin formulations for the treatment of various pain syndromes 
(Bley 2004).  Capsaicin is a fat soluble, odourless, pungent tasting, off-white solid 
with a melting point of 62–65 C and a molecular weight of 305.4 kDa. As it is not 
water soluble, alcohols and other organic solvents are used to solubilise capsaicin in 
topical preparations and sprays (Kasting 2001).  Topical capsaicin creams are well 
absorbed through the skin, achieve high cutaneous concentrations rapidly and have a 
half life of 24 hours (Pershing et al. 2004).  The binding of capsaicin to TRPV1, a non 
specific membrane cation channel permeable to calcium and sodium, in small fibre 
sensory afferent nerve endings activates the receptor and this leads to an influx of 
calcium and the release of inflammatory neuropeptides (Holzer 1991).  This leads to 
burning pain and hyperalgesia.  Following chronic use of capsaicin there is 
desensitisation and degeneration of nociceptors (Nolano et al. 1999).   
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An up-regulation of TRPV1 receptors has been reported in inflammatory conditions.  
In addition TRPV1 receptors are sensitised by extracellular cations such as Ca
2+
, Mg
2+
 
and Na
+
.  Physiological concentrations of these cations contribute to bradykinin 
mediated activation and sensitisation of TRPV1 (Ahern et al. 2005).  Topical 
capsaicin by activating TRPV1 receptors leads to a similar state of hyperalgesia and 
would be an ideal model for research into mechanisms of nociception.  Studies have 
also shown that the type of hyperalgesia to heat and mechanical stimuli caused by 
topical application of capsaicin does not differ in quality to normal heat and 
mechanical stimuli induced pain but occur at a lower degree of stimulation (Fluhr et 
al. 2009).  This lends further support to the use of topical capsaicin in pain models.  
Long term use of capsaicin down regulates voltage activated calcium channels by 
dephosphorylation (via a calcium dependent activation of calcineurin).  This 
mechanism results in reduction of inflammatory hyperalgesia (Baamonde et al. 2005; 
Wu et al. 2005).  Capsaicin, causing a sustained influx of calcium leading to calcium 
induced cytotoxicity and cell death of TRPV1 neurons  can also be a cause of such 
analgesia (Olah et al. 2001).  This phenomenon can be exploited in studies of small 
fibre neuropathies where degeneration and regeneration of small fibres are implicated. 
 
Menthol pain model 
As in the case with heat hyperalgesia, following injury or pathology affecting nerve, 
patients can develop pain to innocuous cooling and is termed cold allodynia 
(Lindblom and Verrillo 1979; Woolf and Mannion 1999).  Sensation of cold pain is 
thought to be a result of combination of sensation of cold mediated by cold specific 
Aδ fibres and unmyelinated C-fibres mediating pain (LaMotte and Thalhammer 1982; 
Saumet et al. 1985).  In cultured
 
cold-sensitive neurons of rats, a cold- and menthol-
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sensitive
 
receptor (TRPM8) has been identified that was present primarily in
 
small-
diameter neurons, which typically are involved in sensing 
 
pain (McKemy et al. 2002).  
Electrophysiological
 
in vitro studies in mice have identified a subgroup of menthol-
sensitive
 
C-fibres containing CGRP that
 
is a typical feature of vasoactive nociceptors 
(Wasner et al. 2004).  Under normal conditions Aδ fibres are thought to exert an 
inhibitor affect on C-fibre mediated cold pain perception.  Recently topical menthol 
application has been reported as a model to study cold allodynia.  In this study it was 
noted that blockade of Aδ fibres lead to hypoaesthesia to mechanical stimulation and 
cold perception but increased cold-mediated pain.  Pain sensation evoked by topical 
menthol increased following the blockade of Aδ fibres (Wasner et al. 2004).  In 
another study it was noted that menthol did not change the quality of pain felt during 
cold stimulation and only increased sensitivity to cold stimuli (Fluhr et al. 2009).  
Cold hypersensitivity in pathological conditions, hence, could be due to two reasons; 
a degeneration of A-delta fibres, or sensitisation of TRPM8 receptors.  Topical 
application of menthol has a potential to be developed as a pain model to help study 
these causes of cold allodynia. 
 
Cinnamaldehyde pain model   
Noxious cold is mediated by TRPA1 channel activated at a temperature <17˚C.  
Pungent natural compounds found in cinnamon oil (cinnamaldehyde-CA), 
wintergreen oil (methyl salicylate), clove oil (Isoeugenol-IE), mustard oil, and ginger 
(zingerone), all activate TRPA1, to produce a burning sensation (Bandell et al. 2004; 
Jordt et al. 2004).  TRPA1 has been shown to co-localise with TRPV1 in rodent 
sensory neurons and both are thought to transduce signals perceived as burning 
sensation (Patapoutian et al. 2003).  TRPA1 has been localised in human DRG 
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neurons, spinal cord motoneurones and nerve roots, peripheral nerves, intestinal 
myenteric plexus neurones, and skin basal keratinocytes (Anand et al. 2008).  
Preincubation with lower concentrations of cinnamaldehyde enhanced or sensitized 
capsaicin responses in rat DRG neurons, whereas higher concentrations caused 
desensitization to further capsaicin stimulation.  This study suggested that TRPA1 
activation may cause desensitization of TRPV1 by dephosphorylation (Anand et al. 
2008).  The localisation of TRPA1 in peripheral nerves and its role in producing a 
burning sensation following activation support a role for clinical studies and 
development of topical cinnamaldehyde in pain models.  
 
 
2.2 A NOVEL HUMAN VOLUNTEER PAIN MODEL USING CONTACT 
HEAT EVOKED POTENTIALS FOLLOWING TOPICAL SKIN 
APPLICATION OF TRP AGONISTS CAPSAICIN, MENTHOL AND 
CINNAMALDEHYDE
2
 
 
2.2.1 Study Rationale 
 
Development of biomarkers to enable objective assessment of pain and compare 
effects of therapeutic agents is difficult to validate in clinical pain states due to the 
psychophysical variations between individuals and their responses to pain.  Clinical 
models need to be developed which replicate pain states such as inflammatory and 
                                                 
2
 The results from this study have been published: Roberts K, Shenoy R, Anand P. A novel human 
volunteer pain model using contact heat evoked potentials (CHEP) following topical skin application of 
transient receptor potential agonists capsaicin, menthol and cinnamaldehyde. J Clin Neurosci. 2011 
Jul;18(7):926-32. 
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degenerative neuropathy, and activation characteristics of nociceptors in such models 
need be validated in a reproducible manner.   
 
In this study my colleagues and I investigated the influence of topical capsaicin, 
menthol and cinnamaldehyde on thermal sensibility, contact heat evoked Aδ 
potentials, and pain scores, in human volunteers.  Interactions between these TRP 
agonists were also investigated. 
 
2.2.2 Materials and Methods 
 
2.2.2.1 Subjects 
 
Fourteen healthy volunteers (7 male, mean age 28.5 years [range 19-56]) were 
recruited.  Informed consent was taken, and the study approved by Hammersmith and 
Queen Charlotte‟s & Chelsea Ethics Committee, London, UK (REC reference no. 
06/Q0406/138). 
 
2.2.2.2 Experimental Design 
 
Subjects attended three „treatment‟ visits where they were exposed to one of the three 
different, topically applied TRP agonists in an unguent format; capsaicin 
(GlaxoSmithKline, Cambridge, UK), menthol (Martindale Pharmaceuticals, Romford, 
UK) and cinnamaldehyde (manufactured at Charing Cross Hospital Pharmacy, UK).  
Each visit was separated by between 7-14 days. 
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Three concentrations of each TRP agonist and a control (Unguentum Merck) were 
used (capsaicin 0.075%, 1% and 3%, menthol 2.5%, 5% and 10%, and 
cinnamaldehyde 1%, 5% and 10%; Table 2.1).  In a random order, 0.5 ml of the 
control and each concentration of TRP agonist were applied to one of four 5 x 3.5 cm 
areas on the volar forearm (2 areas on each arm).  After 15 minutes, excess cream was 
removed and sensory tests carried out in the area of application.  For the purpose of 
this study, in healthy volunteers, we have assumed that there are no significant 
differences in sensory thresholds between the right and left forearm, or between areas 
of skin on the mid-volar forearm. 
 
After application of the highest concentration of each TRP agonist, the treated area 
was exposed to a defined concentration of one of the two other TRP agonists (Table 
2.1). 
 
Sensory tests were then repeated.  The secondary TRP agonist was applied 
immediately after the final tests were completed on the highest concentration of the 
initial TRP agonist applied (approximately 15 minutes).  We aimed to minimize the 
time between applications so that any effects triggered by the initial agonist would not 
have diminished by the time the secondary TRP agonist was applied. 
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Table 2.1 Experimental design for application of topical TRP agonists. 
 
 
1
Each study participant was exposed to 3 concentrations of each TRP agonist in a 
randomised order.  Following application of the highest concentration of each 
agonist, a secondary compound at a defined concentration was applied (capsaicin at 
1 %, menthol and cinnamaldehyde at 5 %). 
 
2.2.2.3 Pain Assessment 
 
Pain scores were obtained using a visual analogue scale (VAS) pre and post 
application.  Subjects placed a mark on a 10 cm line graded linearly from 0 to 10 (0 
being no pain, 10 being the worst pain imaginable).  The distance of the mark from 0 
was noted as the pain score. 
 
2.2.2.4 Quantitative Sensory Testing 
 
Thermal thresholds were performed using a TSA II Neurosensory Analyser (Medoc 
Advanced Medical Systems, Ramat Yishai, Israel).  A 30 × 30 mm thermode was 
Concentration 1 Concentration 2 Concentration 3 Secondary Compound
1
 
Capsaicin  
0.075 % 
Capsaicin  
1 % 
Capsaicin  
3 % 
50 % subjects menthol 5 % 
50 % subjects 
cinnamaldehyde 5 % 
Menthol  
2.5 % 
Menthol  
5 % 
Menthol  
10 % 
50 % subjects capsaicin 1 % 
50 % subjects 
cinnamaldehyde 5 % 
Cinnamaldehyde  
1 % 
Cinnamaldehyde  
5 % 
Cinnamaldehyde  
10 % 
50 % subjects capsaicin 1 % 
50 % subjects menthol 5 % 
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used and thermal thresholds determined over the test area for warm and cool 
perception; cold and heat pain, from a baseline temperature of 32°C, with a change in 
temperature of 1°C/sec.  The mean of three consecutive tests for each modality was 
recorded.  Testing was performed using the method of limits.  Testing was performed 
within a temperature range of 0°C and 50°C.  Data reported for thermal thresholds 
represent absolute temperatures in °C; therefore any increases and decreases in 
thermal thresholds described correspond to absolute temperature changes. 
 
2.2.2.5 Contact Heat Evoked Potentials 
 
A Contact Heat Evoked Potential Stimulator (CHEPS) (Medoc Advanced Medical 
Systems, Ramat Yishai, Israel) was used to evoke Aδ fibre responses.  We used a 
thermode  with an area of 572.5 mm
2
, and a heating thermo-foil (Minco Products, 
Inc., Minneapolis, MN) covered with a 25 μm layer of thermo-conductive plastic 
(Kapton
®
, thermal conductivity at 23°C of 0.1 – 0.35 W/m/K).  The thermode heating 
rate was 70°C/s and the cooling rate 40°C/s.  The baseline temperature was 32°C, 
destination temperature 51°C, and stimulus interval 7 seconds.  Ten 51 °C stimuli 
were applied to the area of application.   
 
EEG was acquired from eight electrodes (FCz, Cz, C3, C4, Pz, P3, P4, infra-orbital 
EOG, reference electrode Fz, ground TP9), with impedance below 5 kΩ.  A low and 
high cut off filter (with frequencies of 0.531 Hz and 70 Hz respectively) were applied, 
and the EEG recorded and digitized at a sampling rate of 500 Hz.  All EEG data is 
reported from Cz. 
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The recorded EEG data was analysed using Vision Analyser © Version 1.05.001 
(BrainProducts GmbH, Munich, Germany).  Recordings of eye movement artefacts 
from infra-orbital electrodes were subtracted from the cerebral trace, and the mean of 
resulting sweeps obtained.  Within each waveform, the latency was measured from 
the first definitive negative peak (N2), and the amplitude measured peak-to-peak (N2 
to P2).  The sweep speed used when the waveform was measured was 225 ms per cm. 
Verbal „evoked pain‟ ratings using the numerical scale (NRS) described above were 
noted after contact heat stimulation. 
 
2.2.2.6 Statistical Analysis 
 
Statistical tests (Mann Whitney) were performed using GraphPad Prism version 3.02 
for Windows, (GraphPad Software, San Diego California USA).  Differences between 
groups of patients was compared with p <0.05 considered to be significant.  
Relationship between variables was assessed by calculating the Spearman correlation 
coefficient 
 
2.2.3 Results 
 
2.2.3.1 Capsaicin  
Capsaicin elicited an unpleasant, sometimes painful sensation, most commonly 
described as “burning” (VAS mean ± SEM: 0.075% 1.1±0.44; 1% 2.1±0.49; 3% 
2.5±0.67; maximum 7.6).  Capsaicin also significantly decreased heat pain threshold 
[HPT] (0.075%, p=0.0084; 1%, p<0.0001; 3%, p=0.0018), unaffected by secondary 
cinnamaldehyde or menthol (Figure 2.1a).  This decrease in HPT seems to be a purely 
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nociceptive effect, since warm detection thresholds [WDT] were not changed (Figure 
2.1 b).   
 
   a      b  
 
 
 
 
 
 
Figure 2.1 Effect of capsaicin (0.075%, 1% and 3%) and secondary menthol 
(5%)/ cinnamaldehyde (5%) on heat pain thresholds (a) and warm detection 
thresholds (b).  Cap, capsaicin; Men, menthol; Cin, cinnamaldehyde.  Error bars 
represent ± standard error of the mean. (**0.075%, p=0.0084;***1%, p<0.0001; 
**3%, p=0.0018) 
 
Secondary menthol increased cool detection threshold [CDT] (p=0.0239), and 
secondary cinnamaldehyde reduced cold pain threshold [CPT] (p=0.0199).  A trend 
for a decrease in EP amplitude after capsaicin was noted, but was not significant 
(Figure 2.2 a).  Evoked pain scores increased following capsaicin (significant at 1% or 
greater; 1%, p=0.0436; 3%, p=0.0503; Figure 2.2 b).  No effects on EP latency were 
observed.  
 
 
 
 
 
83 
   
   a      b  
 
Figure 2.2 Effect of capsaicin (0.075%, 1% and 3%) and secondary menthol or 
cinnamaldehyde on (a) contact heat evoked potential amplitude, and (b) NRS scores 
after CHEPS.  NRS, Evoked Pain Numerical Rating Scale; Cap, capsaicin; Men, 
menthol; Cin, cinnamaldehyde.  Error bars represent ± standard error of the mean.  
(* Cap 1%,, p=0.0436; * cap 3%,, p=0.0503) 
 
2.2.3.2 Menthol  
 
Menthol caused a cooling sensation not reported as unpleasant by any subject (VAS 
mean ± SEM: 2.5%, 0.5±0.16; 5%, 0.5±0.18; 10%, 0.5±0.08).  Menthol caused a 
significant increase in CPT at 10% (p=0.0182) which was attenuated by secondary 
capsaicin and cinnamaldehyde, but significantly reversed only by the latter (p=0.0076; 
Figure 2.3 a).  HPT was unchanged by menthol (2.5% p=0.1731, 5% p=0.4543, 10%  
p=0.1851), but secondary capsaicin and cinnamaldehyde caused a significant decrease 
(p=0.0011 and p=0.0075 respectively) (Figure 2.3 b).  
 
 
 
 
 
   a      b  
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Figure 2.3 Effect of menthol and secondary capsaicin or cinnamaldehyde on (a) 
cold pain threshold and (b) heat pain threshold.  Cap, capsaicin; Men, menthol; Cin, 
cinnamaldehyde.  Error bars represent ± standard error of the mean.(*Men 10%, 
p=0.0182; **Cin 5%, p=0.0076;** Cap1%, p=0.0011;**Cin 5%, p=0.0075)  
 
There were no significant changes in EP latency or amplitude after menthol (2.5% 
latency p=0.4179, amplitude p=0.3481; 5% latency p=0.2168, amplitude p=0.4181; 
10% latency p=0.4179, amplitude p=0.2526).  Secondary capsaicin and 
cinnamaldehyde had no additional effect (Figure 2.4 a).  However, menthol caused 
increased evoked pain scores (2.5%, p=0.0268; 5%, p=0.0261; 10%, p=0.0368), 
which were not significantly affected by secondary capsaicin (p=0.1211) or 
cinnamaldehyde (p=0.4848) (Figure 2.4 b).  
 
 
 
 
 
 
 
   a      b  
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Figure 2.4 Effect of menthol and secondary capsaicin or cinnamaldehyde on (a) 
contact heat evoked potential amplitude, and (b) NRS scores after CHEPS.   
NRS, Evoked Pain Numerical Rating Scale; Cap, capsaicin; Men, menthol; Cin, 
cinnamaldehyde.  Error bars represent ± standard error of the mean. (*Men 2.5%, 
p=0.0268; *Men 5%, p=0.0261; *Men10%, p=0.0368) 
 
2.2.3.3 Cinnamaldehyde  
 
Cinnamaldehyde elicited a “burning” sensation at all concentrations, which in some 
cases was more painful than following capsaicin (VAS mean ± SEM: 1% 0.5±0.25, 
5% 1.8±0.51, 10% 2.3±0.63, maximum 9.1).  Cinnamaldehyde reduced HPT (1%, 
p=0.0215; 5%, p=0.0002; 10%, p=0.0006), whilst secondary capsaicin caused a 
further decrease (p=0.013) and secondary menthol returned thresholds to normal 
levels (p=0.0183) (Figure 2.5).  
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Figure 2.5 Effect of cinnamaldehyde and secondary capsaicin and menthol on 
heat pain threshold  Cap, capsaicin; Men, menthol; Cin, cinnamaldehyde. Error bars 
represent ± standard error of the mean.(*Cin1%, p=0.0215; ***Cin5%, p=0.0002; 
***Cin 10%, p=0.000;, **Cap1%, p=0.013; *Men5%, p=0.0183) 
 
The 1% cinnamaldehyde induced a slight sensitisation of EP amplitude, followed by 
desensitisation after 5% and 10% cinnamaldehyde, although this was not significant 
(1% p=0.2675, 5% p=0.3826, 10% p=0.4002; Figure 2.6 a).  There was also an 
increase in evoked pain scores, reaching significance at 10% (p=0.0458; Figure 2.6 b).  
 
a     b 
 
Figure 2.6 Effect of cinnamaldehyde and secondary capsaicin and menthol on (a) 
contact heat evoked potential amplitude, and (b) NRS score after CHEPS  
NRS, Evoked Pain Numerical Rating Scale; Cap, capsaicin; Men, menthol; Cin, 
cinnamaldehyde.  Error bars represent ± standard error of the mean.(*Cin 10%, 
p=0.0458) 
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2.2.3.4 Correlations  
 
Analysis of post-capsaicin data (all subjects at all concentrations i.e. n=42) revealed 
negative correlations between EP amplitude and HPT with evoked pain scores (EPs 
rs=-0.6027, p<0.0001; HPT rs=-0.2775, p=0.0376).  There was also a positive 
correlation between EP amplitude and HPT (rs=0.4658, p=0.0009) (Figure 2.7 a, b 
and c).   
 
 
Figure 2.7 Post capsaicin negative correlation between (a) amplitude of Aδ 
evoked potentials and NRS scores following CHEPS, and (b) heat pain threshold and 
NRS scores following CHEPS. (c) Positive correlation between Aδ evoked potential 
amplitude and heat pain threshold.  NRS, Evoked Pain Numerical Rating Scale. 
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In the menthol trials, there was no significant correlation between EP amplitude and 
VAS, or amplitude and HPT after CHEPS.  However, there was a negative correlation 
between heat pain threshold and evoked pain scores (rs=-0.4305, p=0.0022).  
 
The cinnamaldehyde application data also revealed a negative correlation between 
HPT and evoked pain scores (rs=-0.4557, p=0.0012). 
 
2.2.4 Discussion  
 
Our results are in agreement with other studies demonstrating increased sensitivity of 
nociceptive C and Aδ fibres following application of capsaicin leading to heat 
hyperalgesia (Konietzny and Hensel 1983; Culp et al. 1989; Baumann et al. 1991; 
Simone and Ochoa 1991; LaMotte et al. 1992; Kilo et al. 1994).  This has also been 
shown in recordings from patients with peripheral neuropathy and positive sensory 
symptoms (Campero et al. 1998).  
 
The trend for the decrease of EP amplitude observed here following capsaicin 
supports studies using laser EPs (Beydoun et al. 1996; Romaniello et al. 2002; 
Valeriani et al. 2003a).  This decrease is possibly due to asynchronous firing of 
nociceptive fibres, or damage/desensitisation of nerve fibres.  We note that this 
attenuation of EP amplitude correlated negatively with evoked pain scores and 
positively with heat pain threshold (HPT). 
 
Menthol, a TRPM8 receptor agonist sensitises these receptors located in C-fibres 
leading to cold allodynia.  Preservation of menthol mediated cold sensation following 
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blockade of A-fibres supports this observation (Wasner et al. 2004).  Our findings are 
in agreement with other studies on the role of menthol in sensing coldness (McKemy 
et al. 2002; Peier et al. 2002; Wasner et al. 2004; Hatem et al. 2006; Albin et al. 2008; 
Namer et al. 2008).  Despite an overall increase in CPT, three subjects displayed no 
cold sensitisation after menthol.  A possible explanation could be the varied response 
to cold present normally in healthy (Hatem et al. 2006).  Menthol application did not 
result in a change in heat evoked potentials.  This being an agonist of cool receptor, 
studies with cold evoked potentials, are perhaps needed to demonstrate changes in EP. 
 
TRPA1 has been implicated in the transduction of noxious cold (Story et al. 2003; 
Bandell et al. 2004; Sawada et al. 2007; Karashima et al. 2009).  However, 
cinnamaldehyde elicited no cold sensation in any subject, only burning sensations.  
This concurs with other studies where cinnamaldehyde sensitises responses to noxious 
heat (Namer et al. 2005; Albin et al. 2008; Merrill et al. 2008; Namer et al. 2008), 
which may be the result of co-localisation in a sub-set of TRPV1 expressing sensory 
neurons.  The magnitude of cinnamaldehyde induced heat hyperalgesia was increased 
by secondary capsaicin, suggesting an additive effect (Story et al. 2003; Jordt et al. 
2004; Kobayashi et al. 2005; Anand et al. 2008).  Conflicting data has been presented 
about the effects of cinnamaldehyde upon cold pain sensation (Namer et al. 2005; 
Albin et al. 2008) and animal studies are also inconsistent (Story et al. 2003; Babes et 
al. 2004; Bandell et al. 2004; Jordt et al. 2004; Nagata et al. 2005; Kwan et al. 2006; 
Sawada et al. 2007; Karashima et al. 2009).  
 
Secondary menthol reversed cinnamaldehyde-induced heat hyperalgesia, which could 
result from block of TRPA1 by menthol or central effects, findings that have been 
90 
reported in animal studies (Macpherson et al. 2006; Karashima et al. 2009).  
Secondary menthol also reduced VAS post-application.  Bimodal modulation of the 
TRPA1 receptor by menthol in vitro has been proposed, suggesting low 
concentrations cause activation of TRPA1, whilst higher concentrations lead to 
reversible block (Karashima et al. 2007).  
 
Data from our laboratory has illustrated that the number of TRPA1-expressing 
small/medium human dorsal root ganglion (DRG) neurons is increased after DRG 
avulsion injury, and in cultured human DRG neurons after exposure to the 
neurotrophic factors nerve growth factor, glial-derived neurotrophic factor and 
neurotrophin-3(Anand et al. 2008).  This indicates that the receptor may be valid 
target in the investigation and treatment of neuropathic pain. 
 
 
2.3 SUMMARY 
 
Validated pain models are needed to replicate disorders of nociception in 
inflammatory and degenerative states.  Method of activating nociceptors include 
CHEPS and LEPS.  These however produce only short lasting pain, not typical of 
chronic pain seen in neuropathic states.  With the known effects of TRP agonists 
capsaicin, menthol and cinnamaldehyde, volunteer human models with topical 
application of these compounds have been developed. 
 
Capsaicin application results in hyperalgesia similar to that seen in neuropathic 
conditions (Cline et al. 1989; Culp et al. 1989).  We postulate that topical capsaicin 
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model can mimic symptoms of neuropathy, by eliciting spontaneous discharges from 
TRPV1 expressing Aδ and C fibre nociceptors causing spontaneous pain, reduced EP 
amplitudes (as reported in patient studies from our institution previously (Atherton et 
al. 2007) but high reported evoked pain scores.  The correlation observed between 
amplitude and evoked pain scores could be a useful surrogate for neuropathic pain, or 
a biomarker for use in studies of novel analgesics, specifically TRPV1 antagonists.  
However, correlation with studies in specific neuropathic pain patient sub-groups is 
needed to confirm how accurately the proposed biomarker identified in this model 
reflects the biology of disease states.  
 
Central and peripheral mechanisms have been proposed to explain cold allodynia 
reported in neuropathic pain states, such as following chemotherapy with oxalipatin 
(Binder et al. 2007). Centrally, sensitisation to cold specific fibre input, or release of 
the central inhibition of cold sensitive C nociceptors by cold-specific Aδ afferents 
may occur (Yarnitsky and Ochoa 1990).  Peripherally, sensitisation, increased 
expression of, or pathological, de novo expression of TRPM8 on normally non-
nociceptive fibres may occur (Proudfoot et al. 2006; Facer et al. 2007; Namer et al. 
2008).  Menthol‟s ability to produce cold allodynia and at high concentrations, painful 
“burning” sensations, is suggestive of an effect on the TRPM8 receptor if co-
expressed with TRPV1 or TRPA1, which both produce painful burning sensations 
when their respective agonists are applied.  However, there are conflicting animal 
studies regarding co-expression of TRPV1, TRPM8 and TRPA1, so extrapolation to 
observed effects of menthol in humans remain unclear, particularly where 
inflammation may be involved, as this may cause phenotypic changes in sensory 
fibres.  
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Application of cinnamaldehyde, a TRPA1 receptor agonist, did not result in changes 
in cold pain perception.  It, however, resulted in a burning sensation, and augmented 
the reduction in heat pain thresholds as described by other authors (Namer et al. 2005; 
Albin et al. 2008; Merrill et al. 2008; Namer et al. 2008), which may be the result of 
co-localisation in a sub-set of TRPV1 expressing sensory neurons.  There are 
conflicting results on the role of cinnamaldehyde in eliciting cold pain sensations.  
Further studies are needed to study interactions between the various TRP receptors 
and cinnamaldehude. 
 
In summary we have systematically studied the sensory effects of topical TRP 
agonists, capsaicin, menthol and cinnamaldehyde and their interactions.  The heat 
hyperalgesia produced by topical capsaicin and cold allodynia produced by menthol 
are similar to those seen in neuropathic pain states and could provide a useful model 
to study biomarkers and analgesics. 
 
Topical application of these compounds, particularly capsaicin, in combination with 
changes observed in Aδ EP amplitude and evoked pain ratings, could provide a 
biomarker for the development of novel analgesic compounds. 
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Chapter 3 Functional Magnetic Resonance Imaging (fMRI) - A Biomarker for 
Pain 
 
 
3.1 fMRI  
 
Introduction 
Increase in neural cell activity leads to increase in energy utilization.  This is reflected 
by a change in haemodynamics in the involved part of the brain.  There is an increase 
in blood flow to the active part of the brain following a delay of 1-5 seconds, which 
rises to a peak over 4 - 5 seconds before returning back to baseline.  This change in 
local blood flow and change in oxy and deoxy haemoglobin concentration can be 
measured while performing an MRI scan of the brain.  Blood-oxygen-level-
dependence (BOLD) is the MRI contrast of blood deoxyhaemoglobin, based on 
magnetisation between oxyhaemoglobin (diamagnetic) and deoxyhaemoglobin 
(paramagnetic).  This was first described in rat models by Ogawa and colleagues and 
in human brain by Belliveau and colleagues (Ogawa et al. 1990; Belliveau et al. 
1991).  Increase in the concentration of oxygenated haemoglobin results in high 
BOLD signal.  By using sequence parameters while performing an MRI scan changes 
in BOLD contrast can be recorded thereby providing information about changes in 
blood flow and neuronal activity.  fMRI needs a reference state for comparison as it 
does not measure absolute states.  Pain centres need to be activated while performing 
the scan to reveal areas of activation. 
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Studies using positron emission tomography (PET) have delineated patterns of 
activation in the brain following application of a painful stimulus.  This includes the 
insular cortex, primary and secondary somatosensory cortices (S1 and S2), anterior 
cingulated cortex (ACC), the thalamus, and areas in the prefrontal cortex, collectively 
termed the “pain matrix” (Casey et al. 1996; Moisset and Bouhassira 2007).  
Depending on the individual and the types of stimuli applied the basal ganglia, 
cerebellum, amygdale, hippocampus, periaqueductal grey (PAG), supplementary 
motor area (SMA) and areas within the parietal and temporal cortices can be 
activated.  The spatial and temporal resolution of fMRI is significantly better than 
PET in the order of 1-3 mm spatially and a fraction of a second temporally (Becerra 
and Borsook 2006).   
 
In a healthy state, consistent activation in normal brains during acute painful stimuli 
has been observed in the ACC (81%), S1 (76%), S2 (81%), insula (100%) thalamus 
(81%) and pre-frontal cortex (PFC) (70%) (Apkarian et al. 2005).  Other structures 
have been found to a lesser extent; periaquedeuctal grey mater (PAG) (15%), and 
amygdala/hippocampus (10%) (Peyron et al. 2000).  In clinical pain conditions 
although many of these structures are also activated: ACC (45%), S1 (28%), S2 
(20%), insula (58%), thalamus (59%) and PFC (81%), sensory/discriminatory 
structures seem to activate less frequently in patients than in controls and, the opposite 
is true for affective/emotional ones (Apkarian et al. 2005).  Studies have been 
conducted to study the effect of analgesics in pain.  Morphine, a μ opioid agonist, has 
been demonstrated to elicit activation in pain pathway structures such as the PAG, 
ACC, thalamus, and prefrontal cortices.  In addition, infusion of naloxone, a μ-opioid 
antagonist, has shown similar activation patterns (Becerra and Borsook 2006).  In 
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experimental pain models such as following application of injected or topical 
capsaicin, fMRI has helped reveal the role of central sensitization in chronic pain 
(Moylan Governo et al. 2006).  Studies using fMRI have also been performed in 
studies of acute pain in animals which has provided a background leading to similar 
studies in humans (Borsook and Becerra 2010). 
 
With growing interest in the application of fMRI for pain research, there is a potential 
to develop this technique in studying pain objectively, and evaluate the effects of 
analgesics.  Effects of drugs on the various components of the pain pathway can be 
studied, which when combined with studies to reveal altered activity in these 
structures in painful states, can lead to tailoring of drugs to a particular individual.  
Before such studies are conducted, there needs to be sufficient evidence defining the 
activation patterns in human models.  
 
 
3.2 FUNCTIONAL MRI BRAIN IMAGING STUDIES USING THE 
CONTACT HEAT EVOKED POTENTIAL STIMULATOR IN A HUMAN 
VOLUNTEER TOPICAL CAPSAICIN PAIN MODEL 
 
3.2.1 Rationale 
 
Capsaicin as described earlier, when applied topically, causes a burning or tingling 
sensation due to the activation of polymodal C and Aδ nociceptive fibres, and the 
release of SP and CGRP (Winter et al. 1995).  Repeated application of 0.0075% 
capsaicin to skin for 3 weeks results in the degeneration of PGP 9.5 immunoreactive 
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intra-epidermal nerve fibres (IENF) in skin blisters and biopsies (Nolano et al. 1999).  
Within 24 hours, 0.075% capsaicin applied four times daily causes a dramatic loss of 
intra-epidermal nerve fibres immunoreactive for PGP 9.5, the pan neuronal marker 
(Khalili et al. 2001).  Short term application of a high dose (8%) capsaicin patch or 
intra-dermal injection of capsaicin also causes significant degeneration (Simone et al. 
1998; Malmberg et al. 2004).  Regeneration of epidermal nerve fibres after 
discontinuation of capsaicin treatment has been shown to occur, with a return of 
sensory function to baseline levels (Carpenter and Lynn 1981; Simone and Ochoa 
1991; Simone et al. 1998; Nolano et al. 1999; Khalili et al. 2001; Polydefkis et al. 
2004).  Repeated application of capsaicin leads to functional desensitisation to 
mechanical, thermal or chemical noxious stimuli with clinical studies showing 
efficacy in reducing pain associated with post herpetic neuralgia, diabetic neuropathy, 
osteoarthritis and musculoskeletal disorders (Caterina et al. 1997; Mason et al. 2004; 
Hempenstall et al. 2005).   
 
Acutely, capsaicin (either intra-dermally injected or applied topically) has been used 
in human models of neuropathic pain, to reproduce the symptoms commonly reported 
by neuropathic pain patients, including spontaneous burning pricking and stinging 
pain around the site of injection/application.  Primary and secondary hyperalgesia to 
mechanical and thermal stimuli, and neurogenic inflammation – an area of flare 
spreading from the point of injection/site of application – can be measured  (Culp et 
al. 1989; Kilo et al. 1994; Hughes et al. 2002).  Several investigators report variability 
in aspects of the response to intra-dermal and topical capsaicin, and that some subjects 
are non-responders.  However, with carefully designed methods to reduce variability, 
the pain phenomena induced by capsaicin can be reproducible (Liu et al. 1998; 
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Harding et al. 2001; Hughes et al. 2002; Dirks et al. 2003) and the model is acceptable 
for pharmacological profiling of novel analgesics (Hughes et al. 2002). 
 
Recently, our research team has reported that contact heat evoked potentials using a 
clinically practical stimulator (CHEPS) were suitable to assess nociceptive pathways 
in patients, particularly neuropathic pain patients (Atherton et al. 2007).  Further, as 
we have carried out a study to assess the feasibility of recording contact heat evoked 
potentials in the MRI environment, which revealed a positive correlation between the 
amplitude of contact heat evoked potentials and evoked pain scores in healthy 
volunteers, as reported by others (Chen et al. 2001; Ohara et al. 2004; Chen et al. 
2006; Qiu et al. 2006; Granovsky et al. 2008; Roberts et al. 2008).  Previous 
investigations of capsaicin-induced changes using imaging techniques such as PET 
and fMRI have illustrated that application of capsaicin to the skin causes activation in 
the primary and secondary somatosensory cortices, SMA, the cingulate gyrus, the 
insula cortex, the PFC, the thalamus and brainstem (Iadarola et al. 1998; Baron et al. 
1999; Baron 2000; Lorenz et al. 2002; Iannetti et al. 2005; Maihofner and 
Handwerker 2005; Zambreanu et al. 2005).  Exploiting the known effect of topical 
capsaicin and stimulation of nociceptors with CHEPS we aimed to develop a simple, 
rapid and practical potential biomarker (fMRI) of “neuropathic pain”.   
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3.2.2 Materials and Methods 
 
3.2.2.1 Subjects 
 
Twelve healthy volunteers were recruited to take part in this study (6 female, 6 male).  
The average age of participants was 26.08 years (range 20 – 34 years).  Informed 
consent was obtained from all subjects prior to commencement of the study and the 
study itself was approved by Riverside Research Ethics Committee (REC reference 
07/H0706/78). 
 
3.2.2.2 Capsaicin 
 
Capsaicin cream was purchased from The Specials Laboratory, Northumberland, UK 
and contained Capsicum Olesoresin BPC 1973 12.5% in Unguentum M (equivalent to 
1% Capsaicin). 
 
3.2.2.3 Experimental Protocol 
 
An event-related protocol was used during continuous fMRI acquisition.  The 
protocol consisted of thirty-two 51°C stimuli of approximately 800 ms duration, 
where the inter-stimulus interval varied between 8 and 32 s (Figure 3.1).  Stimuli were 
applied to the left volar forearm, and the thermode moved after each stimulus.  A well 
recognized adverse feature of CHEPS is that placement of the thermode on the skin 
can cause concomitant activation of mechanoreceptors in the skin.  Movement of the 
thermode after each heat pulse within the defined area of application of capsaicin was 
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deemed necessary in order to prevent habituation of the subjects to the stimulus, 
however as this is not synchronised with the paradigm we do not anticipate that it will 
result in any BOLD response. 
 
 
Figure 3.1 Event related paradigm 
 
Subjects were scanned twice using this protocol: 
 
1. Baseline (pre-capsaicin application). 
2. Following topical application of 1% capsaicin which was removed after 15 
minutes (post-capsaicin).   
 
During the pre- and post-capsaicin protocols, subjects were asked to rate the pain of 
each contact heat stimulus on an electronic visual analogue scale (VAS), by moving a 
marker along a sliding scale that was graded from 0 to 100, 0 being not painful at all, 
and 100 being the worst pain imaginable.  Each pain score was recorded and an 
average taken. 
 
A visual fMRI paradigm was also used as a control experiment.  Subjects were 
scanned using the same parameters as the pain paradigm pre and post capsaicin 
application.  A flashing checkerboard was used for the visual stimulation.  85 volumes 
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were acquired in a block design with 5 volumes rest followed by 10 volumes of 
activation and 10 volumes rest repeated 4 times.  
3.2.2.4 fMRI Acquisition 
 
In each scanning session, 275 fMRI scans were acquired on a 1.5 T Siemens Avanto 
magnetic resonance scanner (Siemens Medical Systems, Erlangen, Germany) with a 
standard head array coil.  19 slices parallel to the anterior commissure and the 
posterior commissure (AC/PC line) were acquired using a gradient echo EPI (Echo 
Planar Imaging) sequence (Repetition time/Echo time (TR/TE) = 2.3s / 53ms, flip 
angle = 90°, field-of-view (FOV) = 23cm, matrix = 64 x 64, voxel size = 3.6mm x 
3.6mm x 5mm).  A high resolution T1-MP-RAGE anatomical scan was also obtained 
(TR/TE = 11ms /5.2ms, flip angle = 15°, FOV = 23cm, matrix = 256 x 256, voxel size 
= 0.9mm x 0.9mm x 1mm). 
 
To achieve synchronization, the trigger output of the scanner was used to initialize the 
fMRI paradigm and triggers from CHEPS stimulation and the scanner were recorded 
together. 
 
3.2.2.5 fMRI Processing 
 
Processing of fMRI images was performed using SPM5 (Functional Imaging 
Laboratory, London, UK).  Due to T1 saturation effects, the first 5 volumes of each 
acquisition were discarded, leaving 270 volumes.  Each dataset was realigned to 
correct for any motion during the acquisition, the time was corrected to account for 
differences in image acquisition time between slices, followed by normalisation to 
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transform the data to match the SPM template.  The template images supplied with 
SPM conform to the space defined by the ICBM, NIH P-20 project, and approximate 
that of the space described in the atlas of Talairach and Tournoux (Talairach and 
Tournoux 1988).  Finally, images were smoothed using an isotropic Gaussian Kernel 
(8 mm full-width-at-half-maximum). 
 
Statistical analysis was based on the General Linear Model (GLM).  For intra-subject 
analysis, the scanning paradigm was specified in SPM and a first level model 
estimation performed.  The event responses were modelled onto a design matrix by 
specifying their onset times and duration.  For group analysis of 12 subjects, a 
canonical, random effects model (RFX) was used to make a population inference 
(corrected p < 0.05).  Spatial extend thresholding (voxel threshold = 135mm
3
) was 
carried out to exclude isolated voxels or small groups to show clusters of activation 
only.  An average brain, representative of all 12 subjects was determined by averaging 
the normalised structural brain volumes.  Significantly activated regions resulting 
from the group analysis were superimposed on the average brain.  The location of the 
activated regions was assessed using SPM Anatomy toolbox. 
 
3.2.2.6 Statistical Analysis 
 
Graphs were created and statistical tests (Mann Whitney) were performed using 
GraphPad Prism version 3.02 for Windows, (GraphPad Software, San Diego 
California USA).  Paired t- tests were used to compare variables before and after 
capsaicin application. 
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3.2.3 Results 
 
3.2.3.1 Pain Ratings  
 
All subjects reported that 1% capsaicin evoked an unpleasant burning sensation.  The 
mean pain rating during CHEPS stimulation at 51°C pre capsaicin was 26.40 ± 5.3 
and ratings increased significantly post capsaicin to 48.92 ± 6.0 (p <0.0001; Figure 
3.2). 
 
 
Figure 3.2 Pain ratings following 51°C stimulation with CHEPS, reported on an 
electronic visual analogue scale (VAS) pre and post capsaicin application. 
(**p<0.0001) 
 
3.2.3.2. fMRI 
 
Group analysis of fMRI data acquired from all twelve volunteers following CHEPS 
stimulation pre capsaicin revealed areas of BOLD activation across the pain matrix in 
a pattern similar to that observed in a previous feasibility study (Roberts et al. 2008)  
(Figure 3.3). 
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 Pre-capsaicin    Post-capsaicin 
 
Figure 3.3 Functional MRI group analysis results (a, b: sagittal; c, d: coronal; e, 
f: axial) in 12 healthy volunteers following CHEPS stimulation at 51°C, pre- and 15 
minutes post-capsaicin application (left and right panel respectively).  L: left side, R: 
right side, A: anterior, P: posterior, S: superior, I: Inferior, INS: insula, CingG: 
cingulated gyrus, S1: somatosensory area 1.  The intersection of the blue cross hairs 
represents the contralateral insula with significant increase in activation post-
capsaicin application. 
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Analysis of fMRI data acquired post capsaicin revealed increased levels of BOLD 
activation in the contralateral posterior cingulate gyrus, pre and post central gyrus and 
the superior frontal gyrus.  Increased activation was also seen in the left anterior 
cingulate gyrus, middle frontal gyrus and cuneus with bilateral activation in the 
caudate nucleus (Figure 3.3).  Overlaying the areas of contact heat induced BOLD 
activation both pre and post capsaicin onto a high resolution structural scan revealed 
that following the application of capsaicin there was an overall increase in the size of 
the area activation (Figure 3.4).  Changes in areas of activation in the regions of 
interest for this study are shown in Figure 3.5.  
 
 
Figure 3.4 Areas of BOLD activation following contact heat stimulation overlaid 
on a high resolution structural scan (a: sagittal; b: coronal; c: axial).  Blue indicates 
pre-capsaicin activation; red indicates post-capsaicin activation, and purple indicates 
overlapping areas. (L= left, R= right) 
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Figure 3.5 Graph of areas BOLD activation in regions of interest following 
application of capsaicin for 15 minutes (from group analysis data). 
 
There was a significant increase in BOLD signal over the insular region following 
capsaicin application (mean ± SEM; pre capsaicin 0.434 ± 0.03; post capsaicin 0.561 
± 0.07; p =0.047) (Figure 3.6).   
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Figure 3.6 fMRI signal intensity in the insula pre and post capsaicin application 
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Group analysis of fMRI data during visual stimulation showed no significant 
differences pre- and post-capsaicin application, illustrated in Figure 3.7. 
 
 
Figure 3.7 Visual fMRI group analysis results (a) before capsaicin application 
and (b) after capsaicin application.  
 
 
3.2.4 Discussion 
 
In this study topical application of 1% capsaicin (for 15 minutes) evoked a 
spontaneous, unpleasant burning sensation, and resulted in an increase in pain scores 
following heat stimulation (with CHEPS).  We were able to obtain fMRI images 
which showed areas of activation consistent with the pain “matrix” (Roberts et al. 
2008).  We have shown that the areas of activity which follow stimulation with 
CHEPS increased in size following acute application of capsaicin, with a significant 
increase in the signal intensity over the insula.  Correlation between perceived pain 
intensity and magnitude of signals over various areas such as the somatosensory 
cortex and the insula have been shown using fMRI and PET scans (Coghill et al. 
1999; Craig et al. 2000; Bornhovd et al. 2002).  Thus, in combination with a 
significant increase in the perceived pain score, and previously reported decrease in 
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Aδ evoked potential amplitudes, our findings would support the use of this topical 
capsaicin model with fMRI as a biomarker for pain.   
 
Topical capsaicin acts in the periphery by eliciting spontaneous discharges from 
TRPV1-expressing Aδ and C-fibre nociceptors, but after capsaicin treatment afferent 
volleys to the brain are less synchronous, leading to decreased amplitudes of pain 
evoked cerebral potentials described in the previous study.  In healthy volunteers, 
microneurographic recordings show that spontaneous burning sensations elicited by 
capsaicin are accompanied by firing of mechanical and heat sensitive polymodal C 
fibre nociceptors (LaMotte et al. 1992).  Spontaneous activity similar to this has also 
been shown in recordings from patients with peripheral neuropathy and positive 
sensory symptoms (Campero et al. 1998).  Topical capsaicin application may provide 
a correlate of clinical changes in peripheral neuropathy.   
 
Other models using laser stimuli produce transient pain.  Topical capsaicin application 
produces a longer lasting burning pain characteristic of neuropathic pain, and enables 
study of the effects of analgesics on such type of pain.  Changes in activation across 
the pain matrix can be assessed using fMRI, enabling dissection of the different 
components of pain, which would help develop drugs targeting the pathological 
mechanisms underlying chronic pain. 
 
We postulate that our capsaicin application protocol and fMRI can be developed as 
novel biomarker for neuropathic pain in healthy volunteers, to enable testing of novel 
analgesics, in particular TRPV1 antagonists.   
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3.3 SUMMARY 
 
We have developed a novel biomarker model for pain using fMRI and topical 
application of capsaicin.  For the objective assessment of nociception, models using 
TRP agonists and nociceptor activation by CHEPS are advantageous, as they produce 
reversible changes in nociceptor function.  Cerebral potentials recorded in such 
models can provide a useful biomarker.  The limitation of this, however, is the lack of 
spatial resolution.  fMRI enables us to overcome this limitation.  In previous studies 
our group has demonstrated the feasibility of recording CHEPS simultaneously with 
fMRI providing the advantages of both techniques, improved temporal and spatial 
resolution respectively (Roberts et al. 2008). 
 
In this study, exploring the use of fMRI as a novel biomarker, we observed that 
topical capsaicin application produced a burning pain with a corresponding increase in 
pain scores following CHEPS, an increase in areas of activation with fMRI, and 
increased signal change in the insula.  With the development of cool evoked potential 
stimulators similar studies can be studied with the cool allodynia model described in 
the previous chapter.  fMRI produces objective measures of activation of the centres 
processing pain signals, and offers a promising role in clinical and preclinical studies 
of pain and analgesics. 
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Chapter 4 Laser Evoked Potentials and Skin Biopsy Biomarkers  
 
 
4.1 OVERVIEW 
 
Introduction 
Radiant heat, delivered to the skin by using lasers, activate the free nerve endings of 
the C and Aδ nerve fibres.  The resultant evoked potentials have been measured.  Two 
components have been described; an initial potential with latencies corresponding to 
Aδ fibre activation and an ultra-late component which is identified following 
blockage of the myelinated fibres (Bromm and Treede 1983).  Similar potentials can 
be recorded by contact heat stimulation as described earlier.  The characteristics of 
LEPs and areas of activation have been described in earlier chapters.  Although it has 
certain disadvantages such as need for eye protection, causing skin burns and cost of 
the set up, lasers can be used to stimulate nociceptors with the resulting evoked 
potentials used as biomarkers in nociception.  In Chapter 2, I have discussed the 
development of topical capsaicin model and its validation by using CHEPS.  
Application of capsaicin to nerve fibres initially activates and subsequently 
desensitises nerve fibres.  This is secondary to degeneration of nerve fibres with a 
resultant loss of cutaneous sensitivity.  The underlying mechanisms that have been 
postulated include a conduction block following repeated activation, reversible 
changes in nerve fibres or an irreversible degeneration of nociceptive neurons 
(Simone et al. 1998).  The sensory changes that have been reported include altered 
response to sharp stimuli and heat (Simone et al. 1998).  Using the objective novel 
biomarker, LEP these changes can be quantified. 
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Skin biopsy and immunostaining of intraepidermal nerve fibres with antibodies to 
PGP9.5 are recommended in the diagnosis of small fibre neuropathies.  Our research 
group has previously reported on the correlation of CHEPS and histamine-induced 
flare reaction with IENF counts in small fibre neuropathies (Atherton et al. 2007).  
Following intradermal application of capsaicin in humans a complete degeneration of 
intraepidermal nerve fibres has been reported, along with a reduction in 
immunoreactivity to CGRP (Simone et al. 1998).  These nerve fibres regenerate over 
a period of few weeks with a gradual return of sensation.  This process of nerve 
degeneration and regeneration can be studied by exploring other biomarkers such as 
immunostaining for the heat capsaicin receptor TRPV1 and GAP43 found in 
sprouting cones of axons.   
 
The non-invasive objective marker LEPs and and its relation to immunostaining of 
nerve fibres in skin biopsies for markers of nerves, nociceptive channels and markers 
of regenerating axons need to be explored, and correlated  with clinical symptoms. 
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4.2 THE TIME COURSE OF CO2 LASER-EVOKED RESPONSES AND OF 
SKIN NERVE FIBRE MARKERS AFTER TOPICAL CAPSAICIN IN HUMAN 
VOLUNTEERS
3
 
 
4.2.1 Rationale 
 
Repeated topical application of capsaicin has been shown to elevate warm detection 
and heat pain thresholds (Carpenter and Lynn 1981), (Lynn 1990) and (Simone and 
Ochoa 1991), and to cause reduction of LEPs (Beydoun et al. 1996), followed by their 
restoration when topical capsaicin is discontinued.  This is secondary to reversible 
superficial skin denervation based on which a validated experimental model of 
chemical axotomy, to resemble changes of small fibre neuropathy (SFN) has been 
developed (Nolano et al. 1999) and (Polydefkis et al. 2004). 
 
The purpose of the present study was to determine the validity and sensitivity of CO2 
laser stimulation for diagnostic and pharmacological investigations in the “volunteer 
capsaicin model” of SFN, and its relationship to QSTs.  We aimed to develop novel 
markers of skin biopsy and LEPS to study SFNs by comparing these with QSTs.  
Researchers from Unité READ, Faculty of Medicine, Université Catholique de 
Louvain, Brussels, Belgium conducted the clinical part of this collaborative study at 
their centre, and I, with help of scientists at the Peripheral Neuropathy Unit, Imperial 
College, analysed skin biopsies for markers of nerve regeneration and heat pain, 
GAP43 and TRPV1 respectively, and correlated these with clinical and LEP findings.   
                                                 
3
 This findings from this study has been published: Ragé M, Van Acker N, Facer P, Shenoy R, 
Knaapen MW, Timmers M, Streffer J, Anand P, Meert T, Plaghki L. The time course of CO2 laser-
evoked responses and of skin nerve fibre markers after topical capsaicin in human volunteers. Clin 
Neurophysiol. 2010 Aug;121(8):1256-66 
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We investigated the temporal relationship between functional and morphological 
measures, and the sensitivity of these measures to change during the regeneration of 
the epidermal fibres.  Although the time lag between functional and morphological 
recovery after topical capsaicin has been reported by several authors (Simone et al. 
1998), (Nolano et al. 1999), (Khalili et al. 2001) and (Malmberg et al. 2004), it has, to 
our knowledge, never been investigated using electrophysiological methods such as 
LEPs, or histochemically with the nerve markers TRPV1 (heat/capsaicin receptor) and 
GAP43 (marker of regenerating nerve fibres). 
 
4.2.2 Materials and Methods 
 
4.2.2.1 Subjects 
 
Twelve paid healthy volunteers, with a mean age of 42 years (age range 30–55; 7 
men) were included in the study.  Ten of these subjects were right-handed with a body 
mass index (mean ± SD) of 25.3 ± 4.1 kg/m2.  The subjects had no history of alcohol 
or drug abuse, significant illnesses, or clinical findings suggestive of peripheral or 
central nervous system disorders.  All had normal routine lab testing (blood sampling 
and urine analysis).  Written informed consent was obtained from all subjects.  The 
Local Ethics Committee approved the study. 
 
4.2.2.2 Experimental design 
 
After having given informed consent, subjects underwent a screening evaluation to 
assess their eligibility for study participation.  The screening evaluation included a 
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medical history, concomitant medication recording, physical and neurological 
examination and routine laboratory testing.  Within 14 days prior to the start of 
capsaicin application, baseline QST, CO2 laser stimulation and skin punch biopsies 
were performed on the non-dominant leg.  The contralateral leg served as a control. 
 
All subjects had normal QST and LEPs at the screening evaluation and were invited 
to receive a topical capsaicin application on three consecutive 24-h cycles (total 72 h). 
At the end of the third cycle (Day 1), subjects visited the clinical unit for CO2 laser 
stimulation, QSTs and skin biopsies (Figure 4.1). 
 
 
Figure 4.1 Experimental schedule 
 
Topical capsaicin application procedure 
An occlusive hydroactive bandage (DuoDerm 10 X 10, ConvaTec, Deeside, UK) 
measuring 10 X 10 cm with a central window of 50 X 50 mm was applied to the 
lateral site of the distal calf, approximately 10 cm above the lateral malleolus of the 
non-dominant leg of each subject (Figure 4.2).  The fenestrated area of this montage 
was filled with approximately 3.5 g of capsaicin cream (Axsain 0.075%, Cephalon 
Ltd., Oxford, UK) and covered for 24 h with a transparent dressing (Tegaderm 6 X 6 
cm, 3 M Health Care, Neuss, Germany).  After that period, the transparent dressing 
and remaining cream were removed and replaced.  This procedure was repeated twice 
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to obtain a total of 72 consecutive hours of capsaicin cream exposure.  The procedure 
was well tolerated in all volunteers but one, who presented with a slight allergic 
eczema during the study.  A causative role of the capsaicin cream formulation or the 
occlusive bandage itself could not be excluded. 
 
 
Figure 4.2 Capsaicin model and testing sites:  Thermal threshold testing and CO2 
laser stimulation were performed in the dashed part of the capsaicin application area.  
Skin punch biopsies were performed in the other half of the capsaicin application 
area. 
 
Quantitative sensory testing 
QST was limited to the assessment of thermal perception using a contact thermode 
measuring 30 X 30 mm (TSA 2001-II, Medoc, Israel).  Stimuli were delivered at the 
distal calf as shown in Figure 4.2 on one half of the capsaicin application area in the 
treated leg, and on a mirror site in the contralateral leg.  A baseline thermode 
temperature of 32°C and a heating rate of 1°C/s were used.  Thresholds were 
measured according to the method of limits previously described (Fruhstorfer et al. 
1976).  Briefly, increasing or decreasing heating ramps were applied to the skin.  For 
each stimulus the subject was instructed to press a button that reversed the thermal 
stimulation as soon as he/she detected a change in skin temperature, either cool 
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detection threshold (CDT) or warm detection threshold (WDT), or as soon as the 
stimulation became painful (cold pain threshold or CPT and heat pain threshold HPT). 
CDT and WDT were estimated by the mean of four successive stimulus presentations. 
CPT and HPT were estimated by the mean of three successive stimulus presentations.  
An inter-stimulus interval of 6–8 s was used when testing perception thresholds 
whereas intervals of 15–20 s were used for HPT and of 20–30 s for CPT.  To prevent 
tissue damage, the maximum and minimum temperatures were set at 50 °C and 5 °C. 
 
CO2 laser stimulation 
CO2 laser stimuli were applied to the same sites used for QST as shown in Figure 4.2.  
The CO2 laser was designed and built in the Department of Physics of the Université 
Catholique de Louvain (Plaghki et al. 1994). 
 
In a first series of laser stimuli, the absolute detection threshold, defined as the lowest 
stimulus intensity detected with a probability of 0.5, was determined using the method 
of limits.  Then, a series of 30 stimuli (surface area: 79 mm2; duration: 50 ms; 
intensity of 10 ± 1 mJ/mm2) producing a clear pricking sensation (“first pain” which 
is Aδ-nociceptor related) in normal subjects were applied on each site (Figure 4.2). 
Inter-stimulus interval was 6–12 s.  During that interval, the laser beam was slightly 
displaced randomly to avoid sensitization and habituation.  Skin laser stimulation was 
well tolerated, though a slight hyperaemic skin reaction was sometimes observed in 
some volunteers after laser stimulation, which resolved within a few hours.  Reaction 
times (RTs) were measured by instructing the subject to press a micro-switch 
mounted on a hand-controller as soon as he/she perceived any type of sensation at the 
stimulation site. 
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Laser-evoked potentials 
Laser-evoked brain potentials were recorded from 19 Ag–AgCl scalp electrodes, 
based on the international 10–20 system, with linked earlobes (A1/A2) as reference.  
Impedance was kept below 5 kΩ.  In addition, electro-oculogram (EOG) of the right 
eye was recorded with disposable Ag–AgCl surface electrodes (Nessler 
Medizintechnik, Innsbruck, Austria).  Evoked potentials, EOG, RTs and laser trigger 
signals were recorded on a PLEEG (Walter Graphtec, Germany).  Signals were 
filtered (low-pass 75 Hz) and digitized at 167 counts per second with a 10-bit 
resolution.  Data were stored on disk and analyzed off-line with the BrainVision 
Analyzer (Brain Products GmbH, Germany).  The time window for analysis was – 
500–2500 ms according to laser stimulus onset.  All trials containing EOG artefacts 
were rejected from subsequent analysis after visual inspection.  Artefact-free trials 
were time averaged and corrected for baseline offset using the pre-stimulus interval of 
500 ms for each channel. 
 
For every subject, latency (in ms) and amplitude (in μV) of evoked potentials was 
measured on the averaged waveform for each site.  Latencies were measured from 
stimulus onset to peak.  Amplitudes were measured from peak to the averaged 
amplitude of the 500-ms pre-stimulus interval.  Three well-known LEP components 
were individualized: N1, N2 and P2. Component P2 was identified at electrode CZ as 
the positive component with maximal amplitude between 300 and 500 ms after 
stimulus onset. N2 was then defined at electrode CZ as the negative component 
preceding P2 and occurring between 150 and 300 ms after stimulus onset. N1 was 
then defined at the temporal electrode contralateral to the stimulation site as well as 
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by trace superposition, as the negative deflection preceding N2 between 120 and 200 
ms after stimulus onset. 
 
In this study, neurodegeneration after chronic topical capsaicin application was 
defined by the “absence” of Aδ-fibre laser activation, i.e. (1) no pricking pain, (2) a 
detection rate of less than 5% with reaction times (RTs) shorter than 750 ms and (3) a 
reduction in amplitude of the late (Aδ-fibre related) and/or ultra-late (C-fibre related) 
N2–P2 complex in the laser-evoked vertex potentials by at least 95%.  All volunteers 
fulfilled these criteria. 
 
Subjects were re-assessed at regular intervals thereafter, i.e. Day 5, Day 12, Day 26 
and Day 54 for QST and CO2 laser stimulation.  Skin punch biopsies were performed 
on fixed time points Day 1 and Day 54 and at one additional time point in between, on 
Day 5 or Day 12 or Day 26. 
 
Skin punch biopsies 
Nine skin punch biopsies (diameter 4 mm) were performed on each subject under 
local anesthesia (Lidocaine 1%) and aseptic techniques by an experienced investigator 
in the clinical unit.  Prior to capsaicin application (baseline), two biopsies were taken 
from the non-dominant calf and one from the contralateral leg as a control.  After 
capsaicin application, only the non-dominant calf was considered and biopsies were 
performed, as shown in Figure 4.2, on one half of the capsaicin application area.  Two 
pairs of biopsies were taken at fixed time points, i.e. Day 1 and Day 54, and one pair 
at a randomly chosen time point either Day 5 (1 subject) or Day 12 (6 subjects) or 
Day 26 (5 subjects).  According to the methods described previously (Polydefkis et al. 
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2004), a distance of 0.5 cm between the biopsies and from the borders of the skin 
region exposed to capsaicin was respected in order to reduce the “contamination” of 
collateral reinnervation by sprouting. 
 
Two different processing techniques were used for subsequent immunohistochemical 
purposes.  One biopsy per time point was Zamboni-fixed and further processed as 
described below.  The other biopsy was snap frozen in optimum cutting tissue (OCT) 
compound (Sakura TissueTek Europe, Zoeterwoude, the Netherlands) and used for 
the TRPV1 and GAP43-staining procedures.  Both processing techniques were always 
used, except for the single sample on Day 5, in which, for technical reasons, only 
PGP9.5 staining was performed. 
 
Immunohistochemistry/immunofluorescence 
 PGP9.5 immunohistochemistry/immunofluorescence (at the research centre in 
Belgium) 
For immunohistochemistry (IHC) at HistoGeneX, 16 μm serial sections were air dried 
and placed in the autostainer (DAKO, Denmark).  After endogenous peroxidase 
blocking, sections were incubated with anti-human PGP9.5 (Table 4.1) and visualized 
by a B-labeled secondary system and ABC detection (Vectastain ABC kit, Vector 
Laboratories, Ltd., UK), using DAB (DAKO, Denmark) as a chromogen.  Tissue 
sections were counterstained using neutral red (Sigma–Aldrich, Inc.).  For 
immunofluorescence (IF), tissue sections were incubated with the same primary 
antibody and visualized by a Cy3-labeled secondary antibody (Jackson 
Immunoresearch Laboratories, Inc., PA, USA).  Counterstain was performed using 
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Hoechst (Invitrogen Corporate, Molecular Probes, California, USA). Quality control 
steps were included for all stains to validate each run. 
 
Table 4.1 List of primary antibodies and dilutions used in this study 
Antibody Host Source Titre 
HistoGeneX, Antwerp, B 
PGP9.5 Rabbit 
Ultraclone: RA 
95/101 
1:5000 
Hammersmith Hospital, London, UK 
TRPV1 Rabbit GSK: C22 1:10,000 
GAP-43 Mouse 
Sigma G 9264: 
clone 7B10 
1:100,000 
 
Image analysis was performed using Mirax Virtual Slide scanner (for IHC, minimally 
5 X 2500 μm epidermis length) (Carl Zeiss, Germany) and the Axiovision Mozaik 
Imaging Software (Axiovision Rel 4.6) (for IF, minimally 3 X 2500 μm epidermis 
length) (Carl Zeiss, Germany).  The quantification method used in this study was 
modified from the EFNS guidelines (Lauria et al. 2005) since thinner tissue sections 
were handled.  Intra-epidermal nerve fibres (IENF) included all single stained nerve 
fibres crossing the dermal–epidermal junction (defined here as transbasal membrane 
nerve fibres, TBMNF).  In addition, clearly branched epidermal nerve fragments that 
did not cross the basement membrane were also counted.  This method was used 
throughout the entire study, from baseline to Day 54.  Tissue sections of skin biopsies 
in our studies are processed at 15–16 μm thickness (exception made for the GAP43 
staining, see below) to enable staining for multiple markers in the same biopsy, with a 
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number of sections for each marker ((Facer et al. 1998), (Facer et al. 2007) and 
(Atherton et al. 2007). 
 
 TRPV1 and GAP43 immunohistochemistry (at Hammersmith Hospital, 
London)  
Tissues were supported in OCT medium (RALamb Ltd., Eastbourne, UK) to allow for 
best orientation.  Frozen sections (15 μm for TRPV1 post-fixed in freshly prepared, 
4% w/v paraformaldehyde in 0.15 M phosphate-buffered saline (PBS) for 30 min and 
30 μm for GAP-43 pre-fixed in Zamboni) were collected onto poly-l-lysine (Sigma, 
Poole, UK) coated glass slides.  Thicker sections were used for GAP43 in order to 
increase the sensitivity of this marker in the epidermis.  Endogenous peroxidase was 
blocked by incubation in Industrial methylated spirit containing 0.3% w/v hydrogen 
peroxide for 30 min (for both frozen and Zamboni-fixed specimens).  After 
rehydration, sections were incubated overnight with primary antibodies (see table 
above).  Sites of primary antibody attachment were revealed using nickel-enhanced, 
avidin–biotin peroxidase (ABC – Vector Laboratories, Peterborough, UK) as 
previously described (Facer et al. 2007).  For specificity studies (TRPV1), 
experiments were performed with the primary antibody incubated with antigenic 
peptide for 2 h prior to incubation with the sections.  Omission of primary antibodies 
and sequential dilution of antibodies gave appropriate results, as in previous 
publications ((Smith et al. 2002) and (Facer et al. 2007)).  The monoclonal GAP43 
antibody recognises an epitope present on both kinase C phosphorylated and 
dephosphorylated forms of GAP43 (Sigma product G9264 datasheet, clone 7B10); it 
immunostains and reacts with GAP43 in immunoblots, and detects increase of GAP43 
in a cell injury model ((Meiri et al. 1991) and (Galbiati et al. 1998)).  Sections were 
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counterstained for nuclei in 0.1% w/v aqueous neutral red and mounted in xylene-
based mountant (DPX; BDH/Merck, Poole, UK), prior to analysis. 
 
TRPV1 intra-epidermal fibres were counted as described above for PGP9.5 and 
expressed as fibres per mm length of epidermis.  For sub-epidermal GAP43 fibre 
analysis digital photomicrographs were obtained using an Olympus BX50 
microscope.  Olympus analySIS® FIVE software was used to define and measure a 
sub-epidermal area with a depth of 200 μm below the basal epidermis.  This software 
was also used to measure length of each of the fibres within the defined area.  GAP43 
immunoreactive fibre numbers were counted manually within the same area.  Values 
were expressed as total number and total length of fibres per square millimetre. 
 
4.2.2.3 Statistical analysis 
 
Repeated measures analysis of variance (ANOVA) was used for estimating 
differences in morphological, psychophysical and electrophysiological data at the 
different time points.  Fisher‟s least significant difference (LSD) procedure was used 
for comparing treatment group means when the ANOVA null hypothesis for equal 
means was rejected.  Bivariate correlations were assessed using Pearson‟s correlation 
coefficient.  When testing for equality of means of IENFd, CDT/WDT or LEPs 
between different skin areas, paired t-tests or non-parametric Wilcoxon signed-rank 
tests were used (α-level = 0.05).  Statistical analyses were performed with SigmaStat 
software version 3.5 (Systat Software, San Jose, CA). 
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4.2.3 Results 
 
4.2.3.1 Quantitative sensory testing 
 
On the non-dominant leg, CDT at baseline was on average 30.0 ± 0.98 °C, which 
means that, starting at 32 °C, a decrease in skin temperature of less than 1 °C was 
readily detected. WDT was 37.7 ± 2.79 °C and HPT was 47.5 ± 1.26 °C.  However, 
this threshold assessment was possibly flawed by the fact that, for safety reasons, 
there was an upper limit of 50 °C imposed on the heating ramp of the thermode.  For 
the same reason, the lower limit of the cooling ramp was set at 5 °C.  Ten subjects did 
reach that low temperature without reporting pain.  That is why we had to dismiss the 
assessment of cold pain thresholds.  The results of QST are detailed in table 4.2. 
 
Table 4.2 Quantitative sensory testing results.  
Thresholds °C ± SD Mean difference with baseline (°C) 
Critical 
Δa (°C) 
 Baseline Day 1 Day 5 Day 12 Day 26 Day 54  
Warm 
detection 
37.7 ± 2.79 +4.7** +3.6 ** +3.1** +4.3** +2.1 2.32 
Cool 
detection 
30.0 ± 0.98 −2.4** −0.5 −1.3** −1.1* −1.1* 0.85 
a Fisher’s PLSD., *p < 0.05, **p < 0.01.  
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These QST assessments at baseline for the control leg yielded similar threshold 
values.  At Day 54, WDT was slightly increased (t = −1.118; p = 0.29) whereas CDT 
remained stable (t = 0.802; p = 0.43). 
 
The 72-h consecutive capsaicin application had a significant influence on cool and 
warm thresholds as shown in Table 4.2.  At Day 1, CDT increased significantly by an 
average of −2.4 °C cooler compared to baseline values.  There was no significant 
difference between Day 5 and baseline CDT (p = 0.198).  However, at all later time 
points, CDT remained significantly increased (lower temperature) as compared to 
baseline (p = 0.004 at Day 12, p = 0.013 at Day 26 and p = 0.011 at Day 54). 
 
WDT evolved in a similar fashion as CDT after capsaicin application.  It increased 
significantly at Day 1 (+4.7 ± 3.66 °C) and evolved progressively towards baseline 
values by the following time points.  WDT remained significantly different from 
baseline (p = 0.008 at Day 12, p < 0.001 at Day 26) until Day 54 (p = 0.074). 
 
The imposed upper limit of 50 °C on the heat ramp interfered with the determination 
of the HPT after capsaicin application.  Indeed, five subjects reached this limit 
without reporting pain at Day 1, two subjects at Day 12 and one subject at Day 26.  
Given the missing data points for these subjects, HPT data were not taken into 
consideration. 
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4.2.3.2 Laser-evoked potentials 
 
Baseline values of LEPs of both legs are reported in Table 4.3 and are within the 
range of those reported in the literature for similar stimulations and recording settings 
(Truini et al. 2005).  
 
Table 4.3 LEP components: latencies (ms ± SD) and amplitudes (μV ± SD) at 
baseline  
 Control leg Capsaicin-treated leg 
Latencies (ms) 
N1 203 ± 53 210 ± 32 
N2 269 ± 34 273 ± 33 
P2 445 ± 78 432 ± 71 
Amplitudes (μV) 
N2–P2 22.1 ± 10.5 26.0 ± 11.4 
 
Latencies of LEP components, when detectable, did not differ among time points (p = 
0.479 for N1; p = 0.149 for N2 and p = 0.360 for P2).  There was no statistical 
difference in these values between LEPs obtained after stimulation of dominant and 
non-dominant legs.  As all subsequent analyses are based on within subject 
comparisons we did not adjust LEP data for age and for height.  
 
N2–P2 amplitudes of LEPs varied dramatically after exposure to capsaicin.  At Day 1, 
there were no identifiable LEP complexes in the time-averaged records of 11 subjects.  
Only one subject presented a small late N2–P2 complex.  Presence of late-LEPs was 
defined by the existence of a negative–positive biphasic signal within a characteristic 
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time window (180–500 ms) and displaying a typical topographic scalp projection in 
the time-averaged EEG recordings time-locked to the laser stimulus.  Of note there 
were no ultra-late-LEPs, i.e. N2–P2 complexes related to the selective and isolated 
activation of C-nociceptors.  Already by Day 5, a late N2–P2 complex was identified 
in all but three subjects; the N2–P2 complex was 56% of baseline. From Day 12 on, 
the N2–P2 complex returned to baseline values (Figure 4.3). 
 
 
Figure 4.3 Plots of N2–P2 amplitude of LEPs (% of baseline values, mean ± SE) 
as a function of time after three consecutive days of topical capsaicin 
 
Detection thresholds, detection rates and reaction times for laser stimuli 
The average absolute detection threshold (C-fibre related) for CO2 laser stimulations 
at baseline was of 4.5 ± 0.6 for the capsaicin-treated leg.  The temporal evolution after 
topical capsaicin applications for the absolute detection threshold is summarized in 
Table 4.4 (first row).  One-way repeated measures ANOVA revealed a highly 
significant (F = 35.382; p < 0.001) increase of absolute detection thresholds at Day 1 
compared to baseline and a fast return to lower values as early as Day 5 (p = 0.643). 
The thresholds returned to baseline values from Day 12 onwards. 
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Table 4.4 Detection thresholds (mJ/mm2 ± SD), detection rates (%) and reaction 
times (ms) for CO2 laser stimulation over the leg  
 Baseline Day 1 Day 5 Day 12 Day 26 Day 54 
C-related 
detection 
threshold 
(mJ/mm2) 
4.5 ± 0.6 8.3 ± 1.1 5.2 ± 1.1 4.0 ± 1.2 4.1 ± 0.4 4.1 ± 0.4 
Aδ-related 
detection 
threshold 
(mJ/mm2) 
7.5 ± 1.1 
a 
8.0 ± 1.0 7.1 ± 1.0 7.4 ± 1.0 7.7 ± 1.0 
Total 
detection rate 
(%) 
92 23 67 78 79 85 
Detection rate 
<750 ms (%) 
82 <3 31 60 68 69 
Reaction 
times (ms) 
378 1403 465 394 359 352 
a
 No Aδ-related detection threshold could be obtained for energy densities up to 12 
mJ/mm2. 
 
The average pricking pain threshold (Aδ-fibre related) was 7.5 ± 1.1 mJ/mm2 for the 
leg.  The temporal evolution after topical capsaicin applications for the pricking pain 
threshold is also summarized in Table 4.4 (second row).  At Day 1, neither painful nor 
pricking sensations were felt by the volunteers therefore no Aδ-fibre-related activation 
thresholds could be determined, as for safety reasons no laser stimuli above 12 
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mJ/mm2 were delivered.  The threshold for pricking pain returned to baseline values 
from Day 5 onwards. 
 
At baseline the total detection rate for laser stimuli was 90% and 92%, for the 
dominant and non-dominant leg, respectively.  The total detection rates after exposure 
to capsaicin are reported in Table 4.4 (row 3).  At Day 1, there was an important 
reduction in detection performance to 23%.  The detection performance increased 
from Day 5 on, but was still below baseline values at Day 54.  The trade-off between 
RTs ascribed to Aδ-nociceptor activations and those in response to C-nociceptor 
activations was set at 750 ms according to previous studies (Mouraux and Plaghki 
2004); see also Figure 4.4).  The detection rates with RTs < 750 ms, and thus Aδ-fibre 
related, are also reported in Table 4.4 (row 4).  These results are better illustrated by 
the relative frequency distributions of RTs as shown in Figure 4.4.  As commonly 
observed, these frequency distributions are fairly skewed with a long tail to the right. 
As already shown in Table 4.4, most RTs ( 80%) were shorter than 750 ms and 
could only result from the activation of Aδ-nociceptors.  The ±10% of RTs with 
longer latency were possibly misses or either resulted from the selective activation of 
the much slower conducting C-nociceptors.  At baseline, the peak latencies of RTs 
reached 370 ms for the control leg and 378 ms for the contralateral leg.  At Day 1, as 
shown in Table 4.4 (row 4), still 23% of the 360 stimulations were detected by the 
subjects, but less than 3% (2.8%) had a RT below 750 ms.  The remaining RTs were 
considerably increased (peak value = 1403 ms) and spread over large time window.  
At Day 5, a more symmetrical bimodal distribution of RTs appeared with an overall 
stimulus detection rate of 67% (31.1% Aδ-fibre-related RTs peak value 465 ms).  
From Day 12 on, the shape of the distributions appeared quite similar to the baseline 
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with a return to normal peak values.  At Day 54, overall detection rate at the 
capsaicin-exposed leg equalled 85% (peak value 352 ms) whereas the opposite control 
leg had a detection rate of 92% (peak value 342 ms). 
 
4.2.3.3 Nerve fibre densities in skin biopsies 
 
At baseline, skin biopsies taken from the capsaicin-treated leg of the 12 volunteers 
yielded a significantly higher IENFd using immunofluorescence of PGP9.5 (Mean IF 
IENF/mm ± SD: 13.8 ± 7.02) as compared to the chromogen assay (Mean IHC 
IENF/mm ± SD: 6.6 ± 5.04) (z = −0.483; p < 0.013).  Furthermore, there was no 
significant difference observed in baseline IENF/mm between the dominant (control) 
and non-dominant leg for both staining techniques (z = −0.454; p = 0.65).  All 
subsequent data and analyses of PGP9.5 IENFd will be restricted to the IF assay.  The 
number of fibres (mean ± SD) immunoreactive to TRPV1 in the epidermis and GAP-
43 in the sub-epidermis was 7.4 ± 3.8/mm and 32.9 ± 8.52/mm2, respectively. 
 
After 72 h of topical capsaicin application (Day 1), IENFd, based on PGP9.5 staining, 
dramatically decreased towards 7 ± 4% of baseline (Figure 4.4).  Twelve days later a 
very slight but non-significant increase was observed.  During the two following 
weeks there was a considerable and significant change in the rate of regeneration as at 
Day 26 the density of IENFd reached 40 ± 20% of baseline.  Subsequently, the 
regeneration rate waned as by Day 54 IENFd density reached on average 56 ± 39% of 
baseline.  A one-way repeated measures ANOVA indicated that IENFd had 
significantly increased at Day 54 compared with Day 1 but not at Day 12 and Day 26.  
The early stage of regeneration was characterized by an increase in transbasal 
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membrane nerve fibres followed at a later stage by branching of those fibres and a 
concomitant increase in IENFd. 
 
 
Figure 4.4 Plot of nerve fibre densities (% of baseline values, mean ± SE) as a 
function of time after three consecutive days of topical capsaicin using different 
staining techniques (PGP9.5 and TRPV1 IENF and GAP-43 SEF).  The number n of 
samples per time point was as follows: n = 12 for baseline, Day 1 and Day 54, n = 6 
for Day 12, n = 5 for Day 26 and n = 1 for Day 5 (for technical reasons, TRPV1 and 
GAP-43 staining was not performed on Day 5). 
 
TRPV1 immunoreactive IENFd showed a similar pattern of decrease and recovery as 
PGP9.5 stained fibres (figures 4.4 and 4.5).  Following application of capsaicin (Day 
1) there was a dramatic reduction in TRPV1 immunoreactive IENFd (mean ± SD 
2.7 ± 1.5% of baseline values) followed by a progressive increase reaching a 
mean ± SD of 68.2 ± 42% on Day 54. 
 
. 
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Figure 4.5 TRPV1 IENF nerve fibres (arrowed) in calf skin before (Day 0) and 
after capsaicin application (Days 1, 12, 26 and 54), magnification x40 
 
GAP43 antibodies did not stain intra-epidermal nerve fibres, though a few fibres 
appeared to enter the basal keratinocyte layer. The mean (±SD) number and length of 
GAP-43 immunoreactive sub-epidermal fibres decreased on Day 1 to 36.5 ± 6.2% and 
38.8 ± 8% of baseline values, respectively.  There was a rapid recovery of GAP43 
immunoreactive fibres (number of fibres/mm2: mean ± SD % of baseline values: 85 ± 
24.2 on Day 12, 118 ± 15.5 on Day 26 and 92 ± 14.5 on Day 54; total length of 
fibres/mm2: mean ± SD % of baseline values 96 ± 35.1 on Day 12, 120 ± 41.5 on Day 
26 and 99 ± 18.5 on Day 54) (Figures 4.4 and 4.6) 
Day 26 
Day 0 
Day 1 
Day 12 
Day 54 
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Figure 4.6 Sub-epidermal GAP43 nerve fibres (arrowed) in calf skin before (Day 
0) and after capsaicin application (Days 1, 12, 26 and 54), magnification x40 
 
The morphological appearance of intra-epidermal and sub-epidermal nerve fibres was 
fragmented and very few axonal swellings were observed in the early stages.  Using 
PGP9.5 immunostaining, up to three sub-epithelial fibres per biopsy showed axonal 
swellings in 3/11, 2/5 and 1/4 biopsies at Day 1, 12 and 26, respectively.  Similar 
swellings were seen in only one intra-epithelial fibre and in only one biopsy, at Day 
12.  Axonal swellings were not detected in any biopsy at Day 54. 
 
Skin biopsies were also screened for inflammation.  No pathological inflammatory 
reaction was observed in all except one subject who showed a mild perivascular and 
Day 26 
Day 0 Day 1 
Day 12 
Day 54 
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perifollicular inflammatory reaction without epidermal involvement, as a consequence 
of slight allergic eczema during the study. 
 
4.2.3.4 Correlations between functional and morphological variables 
 
The relationships between warm (WDT) and cool (CDT) detection thresholds vs 
IENFd using different staining methods are reported in Table 4.5.  Most correlations 
were statistically significant.  Nevertheless, the strength of the linear dependence is 
rather low.  As expected, the correlations were negative for WDT (the lower IENFd 
the higher the temperature at WDT) and positive for CDT (the lower the IENFd the 
lower the temperature at CDT). 
 
No significant correlations were found between absolute detection thresholds and Aδ-
related pricking pain thresholds obtained after laser stimulation and skin nerve fibre 
densities, exception made for absolute detection threshold and GAP43-stained SEF (r 
= 0.434; p = 0.006). 
 
The N2–P2 amplitude of LEPs was correlated with skin nerve fibre densities 
measured using the three different markers.  Results are reported in Table 4.5.  There 
was a significant correlation between N2–P2 amplitude and IENFd based on PGP9.5, 
TRPV1 and SEF number of GAP-43 immunoreactive fibres. 
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Table 4.5 Correlative analyses between functional variables and skin nerve fibre 
densities.  
Correlation variables r value p value 
QST 
PGP9.5 IENFd vs CDT (°C) 0.438 0.002 
PGP9.5 IENFd WDT (°C) −0.359 0.013 
TRPV1 IENFd vs CDT (°C) 0.514 <0.001 
TRPV1 IENFd vs WDT (°C) −0.523 <0.001 
GAP43 SEFd vs CDT (°C) 0.302 0.046 
GAP43 SEFd vs WDT (°C) −0.413 0.005 
LEP N2–P2 amplitude 
PGP9.5 IENFd vs LEP N2–P2 amplitude (μV) 0.417 0.004 
TRPV1 IENFd vs LEP N2–P2 amplitude (μV) 0.539 <0.001 
GAP-43 SEFd vs LEP N2–P2 amplitude (μV) 0.599 <0.001 
 
Phase plots of relative (% of baseline values) N2–P2 amplitudes vs relative IENF 
densities are shown in Figure 4.7.  These diagrams illustrate the time lag between LEP 
amplitudes and IENF densities.  During the process of nerve fibre regeneration, LEP 
amplitudes were clearly in advance of PGP9.5 (Figure 4.7a) and TRPV1 (Figure 4.7b) 
IENF densities.  This was clearly in contrast with GAP43 SEFd.  Indeed, except for 
Day 1, N2–P2 amplitudes closely followed the changes in GAP-43 SEFd (Figure 
4.7c). 
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Figure 4.7 Phase plots of N2–P2 amplitude of LEPs as a function of nerve fibre 
densities using three different staining markers: PGP9.5 IENF, TRPV1 IENF, and 
GAP-43 SEF, expressed as % of baseline values (mean ± SE) at different time points 
following topical capsaicin exposure. For technical reasons, TRPV1 and GAP-43 
staining was not performed on Day 5 
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4.2.4 Discussion 
 
The results of this study confirmed earlier findings of capsaicin application resulting 
in nerve degeneration along with change in cutaneous sensitivity (Nolano et al. 1999).  
Previous studies from our unit along with research from other centres have 
demonstrated IENF counts to be sensitive marker of small fibre neuropathy (Lauria et 
al. 2005; Atherton et al. 2007).  Hence chronic application of capsaicin can be used as 
a pain model in preclinical studies of small fibre neuropathy. 
 
Following degeneration of fibres, both small fibre counts and neurophysiological tests 
using QST and LEP followed parallel changes.  However during the regenerative 
process, morphological recovery using intra epidermal nerve fibre staining with the 
conventional marker PGP9.5 lagged behind functional recovery.  This early functional 
recovery was most markedly demonstrated using LEPS.  We have shown that the 
recovery seen with LEPs parallels the subepidermal nerve fibre density on 
immunostaining with GAP43.  GAP43 is normally seen in growth cones of axons, and 
this early recovery of subepidermal fibres immunoreactive to GAP43 suggests a 
process of active regeneration occurring in these fibres (Benowitz and Routtenberg 
1997). 
 
The rationale for our model is based on work by (Reilly et al. 1997) and (Simone et al. 
1998) and (Nolano et al. 1999) who demonstrated that the functional effects of 
capsaicin (i.e., burning pain and hyperalgesia followed by hypoalgesia with increased 
detection threshold and diminished heat pain sensation) were due to destruction of 
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epidermal nerve fibres in blister roofs (Reilly et al. 1997) and skin biopsies, either 
after injection (Simone et al. 1998) or repeated skin applications (Nolano et al. 1999).  
The mismatch in the relationship between the density of regenerated IENFs 
(immunostained with PGP9.5) and evoked sensation after capsaicin application has 
been reported by several investigators ((Nolano et al. 1999), (Simone et al. 1998), 
(Khalili et al. 2001) and (Malmberg et al. 2004).  Here we show that this was also the 
case with CO2 laser stimulation and more specifically with the late-LEPs (i.e., Aδ-
nociceptor related brain responses 
 
It may be possible that the early evoked sensations and LEPs arise from nociceptors 
located on sub-epidermal neural plexus.  Indeed, density of sub-epidermal neural 
structures revealed by GAP43 staining increases in the early stages of regeneration 
and is in phase with the recovery of LEPs.  Although we cannot confirm or deny this 
possibility with the large thermal probes and long duration (tens of seconds) heat 
ramps, it seems unlikely that sub-epidermal heat sensitive nerve endings can 
significantly contribute to these responses.  As a fact, the short laser stimulus (50 ms) 
and the very low transparency of skin for CO2 laser radiation (Bromm and Treede 
1983) confine the thermal energy to a tiny volume of epidermal tissue as attested by 
the very small amount of energy needed to bring the skin temperature above the 
activation threshold of polymodal nociceptors.  Laser sources emitting in the short IR 
range of wavelengths (e.g., 1.34 μm for the Nd:YAP-laser) may possibly activate 
nociceptors into the sub-epidermal layers since skin has higher transmittance.  These 
lasers have to heat up a much larger volume of tissue to exceed AMH thresholds, as 
attested by the more than tenfold increase in energy density ((Leandri et al. 2006), 
(Perchet et al. 2008) and (Iannetti et al. 2006)).  If true, the CO2 laser radiation may be 
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considered as a better choice to explore more selectively the functional state of the 
free nerve endings in the epidermal layer. 
 
Previous studies (Polydefkis et al. 2004) have ruled out the possibility that the 
regenerative responses were the result of collateral sprouting emanating from the 
capsaicin treatment border, which according (Rajan et al. 2003) is much slower and 
incomplete as compared to regenerative sprouting.  Indeed, our data also showed that 
the early stage of regeneration was characterized by an increase in transbasal 
membrane nerve fibres followed at a later stage by branching of those fibres and a 
concomitant increase in IENFd.  Furthermore, they rigorously addressed also the 
possibility that capsaicin-induced loss of IENFs staining might not represent sensory 
fibre loss, but rather loss of PGP9.5 staining, and provided clear evidence that topical 
capsaicin induces a loss of IENFs by degeneration. 
 
However, one may speculate that the functional vs morphological mismatch might 
only be apparent.  Indeed, PGP9.5, a component of the ubiquitin system involved in 
protein degradation and turnover of axonal cytoskeletal components (Fraile et al. 
1996) is transported exclusively with the slow axonal component b.  The long time 
needed for these proteins to reach distant axonal locations may explain why PGP9.5 
appears delayed by several weeks as compared to the functional recovery.  The 
similar time course of TRPV1 immunoreactivity may suggest that expression of 
TRPV1 receptors is delayed by a similar mechanism, in addition to the disconnection 
of sensory nerve terminals from their major source of NGF in the basal epidermis 
(Anand et al. 1996); NGF is known to regulate TRPV1 expression (Winston et al. 
2001).  As reported by (Hiura and Ishizuka 1989), capsaicin-induced dysfunction of 
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the endoplasmic reticulum (ER) can result in improper synthesis and trafficking of 
TRPV1.  Like PGP9.5, TRPV1 is also believed to be transported through the slow 
axonal component b towards the periphery (Brown 2000).  Capsaicin may delay or 
impair axonal transport by disassembly of dynamic microtubules necessary for the 
axonal flow (Goswami et al. 2006).  Further, the absence of TRPV1 immunoreactivity 
may not preclude detection of noxious thermal stimuli, since they may be transduced 
through multiple molecular pathways, only some of which may involve TRPV1 
(Caterina et al. 2000).   
 
However, the close temporal relationship between the early recovery of LEPs and the 
increase in SEFs immunostained for GAP43, which is transported axonally, indicates 
a mechanism related to regenerating nerve fibres, and that PGP9.5 and TRPV1 
expression may be relatively decreased in early regeneration.  Injury to axons 
stimulates increase in the synthesis of GAP43, which utilises fast axonal transport to 
the growth cone (Benowitz and Routtenberg 1997), (Bisby and Tetzlaff 1992) and 
(Denny 2006).   
 
 
4.3 SUMMARY 
 
The topical capsaicin model for SFN used in the present study follows previous  work 
on cutaneous nerve regeneration (Polydefkis et al. 2004) model.  This model allows 
tests of pharmacological agents in short time periods, and small groups, on 
regenerative rates of epidermal nerve fibres. 
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By applying of 0.075% topical capsaicin cream on three consecutive days, complete 
degeneration of IENF was induced as may be seen in small fibre neuropathies.  This 
“reversible small-fibre neuropathy” model can be used to study the effects of novel 
agents inducing nerve regeneration. 
 
An important process in assessing recovery in patients is by identifying tests which 
monitor nerve recovery.  Our study has highlighted LEPs as one of the earliest 
functional signs during the nerve regenerative process.  This non invasive measure 
could be used to detect early regeneration.  Comparative assessment of CO2 laser 
stimulation and IENFd with the standard PGP9.5 and also TRPV1 immunostaining 
revealed a mismatch at approximately 12 days post-capsaicin, with a full functional 
but not morphological recovery – the IENF fibres recovered by only 50% after 54 
days.  In contrast, the GAP43 fibres in the sub-epidermis closely followed the 
amplitudes recorded with CO2 laser stimulation.  We speculated that the mismatch 
might result from the delay in expression of PGP9.5 and TRPV1 in regenerating 
IENFs otherwise sensitive to thermal stimuli, which are marked by GAP43 
immunostaining.  Traditional immunostaining with PGP9.5 may not be sufficient to 
identify regenerating subepidermal fibres.  GAP43 could be a potential biomarker that 
could be used either independently or with LEPs in studying nerve regeneration.   
 
Based on these findings, clinical studies need to be conducted in patients with 
neuropathic pain, using GAP43 and LEPs to characterise patients based on the 
presence or absence of subepidermal nerve sprouting and LEPs.  This could help 
explain states of hypersensitivity in patients. 
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Chapter 5 Use of novel biomarkers in the clinical assessment of nociception 
 
 
5.1 NOVEL OBJECTIVE METHODS FOR CLINICAL ASSESSMENT OF 
CONGENITAL INSENSITIVITY TO PAIN 
 
5.1.1 Introduction 
 
Clinical diagnosis of congenital insensitivity to pain can be challenging, due to a 
combination of rarity of the condition and the selective insensitivity to pain.  Patients 
have been reported to present with deformities of skeleton caused by fractures, lesions 
of skin and mucous membranes such as burns and tongue bites, loss of teeth and 
abscess formation (Ingwersen 1967).  Osteomyelitis, avascular necrosis, growth 
disturbance and joint involvement leading to Charcot joints, joint swelling, instability 
and dislocations are the other reported presentations (Bar-On et al. 2002).  Patients 
with such injuries have been mistaken to have non-accidental injuries (Spencer and 
Grieve 1990).  Bony lesions tend to appear after 4- 6 years of age, reflecting lower 
mechanical load at a younger age.  Loss of pain sensation results in children engaging 
in activities that lead to injuries and self-mutilation, and there is often a delay in 
presentation and diagnosis of fractures and joint sepsis (Minde et al. 2006).  
Treatment of injuries in these patients is demanding and prone to failures leading to 
non-union, pseudarthrosis and deformities, as loss of pain sensation results in poor 
motivation to wear braces.  Surgical treatment needs careful planning, focusing on 
long-term management due to injuries to the physis and growth disturbance.  Limb 
lengthening, corrective osteotomies and arthrodesis of joints may be needed in 
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children and young adults, while older adults with painless deformities may need 
orthosis (Uehara et al. 2001; Minde et al. 2006).  Early diagnosis, prevention and 
education to prevent injuries form the mainstay of treatment.   
 
Quantitative sensory tests (QST) have been shown to be useful for the evaluation of 
function of sensory nerve fibre subsets (Backonja et al. 2009).  Function of small and 
unmyelinated nerve fibres mediating sensations of pain and temperature, which 
cannot be studied directly by standard nerve conduction tests, can be studied by 
measurement of thermal thresholds.  A combination of nerve conduction studies and 
QST has been shown to be useful for the diagnosis of polyneuropathies in diabetes, 
and radiculopathy (Quraishi et al. 2004; Bird et al. 2006).   
 
We have described novel methods using biomarkers in skin biopsies, CHEPS and 
fMRI to objectively assess nociception.  While nerve biopsies are useful for the 
evaluation of pathology with involvement of large diameter axons, they are of limited 
value in conditions with selective involvement of small sensory nerve fibres as in 
Hereditary Sensory and Autonomic Neuropathies (Nilsen et al. 1989; Vallat et al. 
2009).  Study of intraepidermal nerve fibres (IENF) in skin biopsies has been shown 
to be useful in the diagnosis of small fibre neuropathy (Sommer and Lauria 2007; 
Lauria et al. 2009).  A recent study has shown good correlation between CHEPS, skin 
flare responses and skin biopsies in the diagnosis of small fibre neuropathies 
(Atherton et al. 2007).   
 
Hereditary sensory and autonomic neuropathy (HSAN) comprises a heterogeneous 
group of disorders with varying sensory and autonomic involvement.  They have been 
142 
classified into five types, each having a different degree of involvement of these 
components (Dyck 1993; Houlden et al. 2004).  HSAN V, an autosomal recessive 
condition, is characterised by a loss or reduction of pain sensation, with normal 
autonomic function and no mental retardation.  There have been advances in the 
understanding of HSANs, with the identification of genetic defects.  In HSAN IV a 
mutation in the genes for the Nerve Growth Factor (NGF) β and its high affinity 
receptor TRKA have been implicated as a cause, although in HSAN type V with no 
such mutations have been described (Houlden et al. 2001; Toscano et al. 2002; 
Einarsdottir et al. 2004).  Recently loss-of-function mutations in the gene for the 
sodium channel subunit Nav 1.7 (a sodium channellopathy) have been shown to 
underlie congenital indifference to pain in HSAN V (Goldberg et al. 2007).   
 
In this study I describe a series of five patients with presenting with presumed 
congenital pain insensitivity, and discuss the advantages of novel methods such as 
skin biopsy and CHEPS in aiding clinical diagnosis.   
 
5.1.2 Materials and Methods 
 
5.1.2.1 Subjects 
 
Five patients referred with presumed insensitivity to pain were studied.  A detailed 
clinical history, including developmental and family history and reaction to physical 
injury in the past, was recorded.  Results of blood tests and other investigations 
performed previously were reviewed.  A full clinical examination including tests for 
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sensory and motor function was performed.  Electrophysiological tests were 
performed in all patients.  In some cases genetic screening has yet to be performed. 
 
5.1.2.2 Quantitative sensory testing 
 
QSTs including touch, thermal and vibration thresholds were performed in patients 
who were able to follow instructions, in accord with their age.  Thresholds for touch 
were measured using Semmes-Weinstein monofilaments (made by A. Ainsworth, 
University College London, UK).  The number of the hair with the lowest force 
reliably detected by the patient (at least 3 out of 5 trials) on the dorsum of the most 
affected big toe was recorded.  The „abnormal‟ value was designated as >No. 3 
monofilament (0.0479 g).  Sharp mechanical pain was assessed using Neurotips
TM
 
(Owen Mumford, UK) and the response graded as normal, increased (hyperalgesia) or 
reduced/ absent.  Vibration perception thresholds were measured using a 
biothesiometer (Biomedical instrument Co., Newbury, OH, USA) placed on the 
metatarsophalangeal joint of the big toe.  Three ascending and three descending trials 
were carried out, and the mean value obtained.  Vibration thresholds with values >12 
V were considered „abnormal‟.  Sweating was measured in the palm and sole using an 
evaporimeter (Servomed, Stockholm, Sweden).  Values lower than 24 were 
considered to be abnormal.   
 
Thermal thresholds were recorded using the TSA-II neurosensory analyser (Medoc 
Ltd, Ramat Yishai, Israel, TSA thermode 3x 3cm) using methods described earlier in 
chapter 2. 
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5.1.2.3 Histamine flare  
 
A histamine induced flare response was measured.  Histamine (0.03 ml of 1 mg/ml. 
Martindale Pharmaceuticals, Romford, UK) was injected intra-dermally and the area 
of flare measured after 10 minutes by scanning Laser Doppler imaging (Moor 
Instruments Ltd, Axminster UK).  On the flux image the region of interest (defined by 
the edge of the flare) was drawn, and the area measured using the Moor Laser 
Doppler Imager (LDI) version 3.11 software (Krishnan and Rayman 2004). 
 
5.1.2.4 Contact heat evoked potentials 
 
CHEPS, (Medoc, Israel) with a thermode area of 572.5 mm
2
, and a heating thermo-
foil (Minco Products, Inc., Minneapolis, MN) covered with a 25 μm layer of thermo-
conductive plastic (Kapton
®
, thermal conductivity at 23°C of 0.1 – 0.35 W/m/K) was 
recorded using methods described in Chapter 2.  The EEG waveforms were analysed 
with the software from Brainvision as described earlier. 
 
5.1.2.5 Skin biopsy immunohistology 
 
Two small (approximately 3mm) skin biopsies were taken under local anaesthesia 
from the arm of three patients and the lateral calf of one patient.  Biopsies from 
normal subjects were used as controls.  One of the two skin biopsies was snap frozen 
and stored at -70°C, and the other immersed in fixative (modified Zamboni's fluid – 
2% formalin; 0.01 M phosphate buffer; 15% saturated picric acid (pH 7.2), then 
washed in phosphate buffered saline (PBS; 0.1 M phosphate; 0.9% w/v saline; pH 
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7.3) containing 15% w/v sucrose for an hour, before snap freezing in optimum cutting 
tissue embedding medium (Tissue-Tek OCT, RA Lamb Ltd, Eastbourne, U.K.) to 
allow for best orientation.  Frozen sections (15µm thickness) of pre-fixed (Zamboni‟s) 
were collected onto coated glass slides (Superfrost Plus, VWR UK) and allowed to air 
dry.  Unfixed, frozen sections were collected as above and post-fixed in freshly 
prepared, 4% w/v paraformaldehyde in 0.15M phosphate buffered saline (PBS) for 30 
min.  Endogenous peroxidase was blocked by incubation in industrial methylated 
spirit containing 0.3% w/v hydrogen peroxide for 30 minutes for both post- and pre- 
(Zamboni) fixed sections.  After rehydration, sections were incubated overnight with 
primary antibodies to the structural nerve marker PGP 9.5 (Ultraclone, Rabbit, 
RA95/06, 1:40,000; UK) or the heat and capsaicin receptor transient receptor potential 
vanilloid 1 TRPV1 (GSK, Rabbit, C22, 1:10,000; UK).  Sites of primary antibody 
attachment were revealed using nickel-enhanced, avidin-biotin peroxidase (ABC - 
Vector Laboratories, Peterborough, UK) as previously described (Facer et al. 1998; 
Facer et al. 2000; Gopinath et al. 2005).  Sections were counter-stained for nuclei in 
0.1% w/v aqueous neutral red, air dried and mounted in xylene-based mountant 
(DPX; BDH/Merck, Poole, UK), prior to analysis.   
 
5.1.3 Results 
 
Case series (Table 5.1) 
 
1. This 6 year old male, the second child of non-consanguineous south Asian parents 
with no relevant family history, presented with a history of painless fracture of the 
3
rd
 metatarsal without any definite history of trauma.  An MRI scan of the foot and 
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ankle revealed avascular necrosis of the cuneiform bone and fragmentation of the 
talus and calcaneum.  Biopsy from the fracture site did not reveal any evidence of 
infection or malignancy.  
 
On examination he was found to have normal monofilament and vibration 
thresholds over the arms and legs.  Sweating rate was normal.    Thermal 
thresholds were normal.  Histamine flare response in the calf was reduced.  
CHEPS from the calf (Figure 5.1) did not elicit any response (control values Calf, 
Aδ amplitude, mean µV ± SEM; 11.7 ± 1.95).   
 
 
Figure 5.1  EEG following stimulation of the right leg with CHEPS.  Aδ response 
recorded in a normal subject (a); this response was absent in patient 1 (b).  
 
In comparison to normal controls (Figure 5.2 a, b), skin biopsy from this patients 
arm (Figure 5.2 c, d) showed complete absence of IENFs with both the structural 
nerve marker PGP 9.5[Control, Arm, median (range), 12.3 (8.6- 14.3)] and 
nociceptor/heat receptor TRPV1 [Control, Arm, median (range), 11.6 (9-14.2)].  
Subepidermal nerve fibres were present but appeared reduced in numbers.  A sural 
nerve biopsy had been performed on this patient at another hospital and was found 
to be well populated with large myelinated fibres but small myelinated fibres were 
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almost completely absent.  Standard nerve conduction studies showed features of 
a sensory axonal polyneuropathy.   
 
2. This patient presented at the age of 2 years and 10 months with painless burns 
after sitting in a hot water bath.  He was the only child of a non consanguineous 
Caucasian couple and was born pre term at 28 weeks.  There was no family 
history of insensitivity to pain.   
 
On investigations, he was found have multiple rib and phalangeal fractures.  There 
was no indication of child abuse as a cause of these injuries.  He demonstrated a 
normal response to touch but did not exhibit any signs of pain on performing 
venepuncture.  There was a lack of response to painful heat and cold stimuli.  
Intradermal histamine elicited a normal flare response.  Neurophysiological 
studies revealed normal sensory and motor nerve conduction studies and a normal 
EMG.  There was no recordable response using the CHEPS.  Skin biopsy from the 
arm showed normal intraepidermal nerve fibres and subepidermal nerve fibres for 
both PGP9.5 (12.7 fibres/mm, IENF) and TRPV1 (11.8 fibres/mm, IENF) (Figure 
5.2g, h).   
 
3. An 18 year old female born of consanguineous parents presented with a history of 
painless blisters over the right sole.  She had a past history of wounds around the 
ankle and osteomyelitis for which she had undergone multiple surgical procedures 
and an ankle fusion.  There was no family history of insensitivity to pain. 
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On examination she had normal monofilament, vibration and thermal thresholds 
over hands and calf with a mild elevation of warm threshold over the sole.  The 
skin flare response to intradermal histamine was reduced.  Sensory and motor 
nerve conduction studies were within normal limits.  No response was elicited 
over the calf with CHEPS.  Skin biopsy from the calf showed complete loss of 
intraepidermal nerve fibres and reduced subepidermal nerve fibres. 
 
4. This female patient second child of a non consanguineous Caucasian couple was 
initially noted to have very little pain response during childhood immunisation.  
The parents noted a lack of response to pain on teething at the age of 6 months.  
Subsequently she was seen with numerous bite marks over the fingers, ulcer on 
the tongue and scars over the toes at the age of 15 months.  There was no history 
of insensitivity to pain in the family and her older brother was clinically normal.  
Her developmental milestones were normal. 
 
On examination, she was found to have normal touch sensation, tears and 
sweating.  She did not exhibit a pain response to pin prick over the forehead and 
hands, nor did she respond to painful mechanical or noxious thermal stimuli. 
Motor power and deep tendon reflexes were normal.  She demonstrated a normal 
flare response following intra dermal histamine injection.  Standard 
neurophysiological studies revealed features of a sensory axonal neuropathy with 
absent or low amplitude sensory action potentials in the lower and uppers limbs 
respectively.  Motor nerve conduction was normal.  There was no response 
recordable using CHEPS.  Skin biopsy from the arm showed a gross reduction of 
intraepidermal nerve fibres (IENF) with both, the structural nerve marker PGP 9.5 
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(1.7 fibres/mm) and nociceptor/heat receptor marker TRPV1 (0.83 fibres/mm) 
although sub-epidermal nerve fibres (SENF) were present (Figure 5.2 e, f).  
 
5. This patient presented at the age of 24 months with a burn injury over the forearm 
and a history of burn injuries since the age of 9 months.  He was the fourth child 
of a consaguinous Iranian couple with his siblings clinically normal.   
He had normal touch and vibration thresholds.  Sweating rate was normal and he 
had normal pain response to pin prick.  There was a lack of response to painful 
heat or cold.  Histamine flare response was normal over the calf.  Sensory and 
motor nerve conduction studies were normal.  CHEPS from the calf did not elicit 
any response from the calf.  Skin biopsy from the arm revealed absence of intra 
epidermal fibres and reduced subepidermal fibres.  Genetic tests were negative for 
TRPA/ NTRK1 gene mutation. 
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Table 5.1 Summary of five patients with congenital insensitivity to pain 
Case 
no. 
Age at 
examination 
Sensory tests Nerve 
conduction 
tests 
CHEPS 
from 
Calf 
Skin biopsy 
1  6 years Monofilament threshold 
- Normal 
 
Vibration threshold- 
Normal 
 
Pressure pain - 
Decreased 
 
Thermal thresholds - 
Normal 
Sensory action 
potentials - 
Decreased 
 
Motor - Normal 
Absent Intraepidermal 
nerve fibres -
Absent 
 
Subepidermal 
nerve fibres -
Decreased 
2  34 months Cotton wool sensation - 
Normal 
 
Pin prick response - 
Absent 
 
Heat and cold pain - 
Absent 
Sensory action 
potentials - 
Normal 
 
Motor - Normal 
Absent Intraepidermal 
nerve fibres -
Normal 
 
Subepidermal 
nerve fibres –
Normal 
3  18 years Monofilament 
thresholds - Normal 
 
Vibration threshold - 
Normal 
 
Thermal thresholds - 
Normal over hands.  
Mild elevation of warm 
threshold over the sole 
Sensory action 
potentials - 
Normal 
 
Motor - Normal 
Absent Intraepidermal 
nerve fibres -
Absent 
 
Sub-epidermal 
nerve fibres –
Decreased 
4  15 months Cotton wool sensation - 
Normal 
 
Pin prick response - 
Absent 
 
Heat and cold pain - 
Absent 
Sensory action 
potentials - 
Decreased 
(lower limb), 
absent( upper 
limb)  
 
Motor - Normal 
Absent Intraepidermal 
nerve fibres  -
Decreased 
 
Subepidermal 
nerve fibres –
Normal 
5. 24 months Cotton wool sensation- 
Normal 
 
Pin prick response- 
Present 
 
Heat and cold pain- 
Absent 
Sensory action 
potentials - 
Normal 
 
Motor - Normal 
Absent Intraepidermal 
nerve fibres -
Absent 
 
Sub-epidermal 
nerve fibres –
Decreased 
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Figure 5.2 Skin biopsies immunostained with antibodies to the structural nerve 
marker (PGP9.5) or the nociceptor/capsaicin receptor (TRPV1).  Skin biopsies from a 
normal subject (PGP9.5, a; TRPV1, b) showing normal of intraepidermal nerve fibres 
(arrows).  Only subepidermal nerve fibres (arrows) are seen in Patient 1 (PGP9.5, c; 
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TRPV1, d) and Patient 4 (PGP9.5, e; TRPV1, f).  Patient 2 (PGP 9.5, g; TRPV1, h) 
has normal intra-epidermal nerve fibres (arrows).  Scale bars = 50µm. 
5.1.4 Discussion 
 
Neurotropic factors and their receptors play a key role in sensory neuropathies (Anand 
2004).  Genetic studies are beginning to unravel the causes of HSAN V.  Failure of 
development of small nerve fibres or a failure of transmission pain signals due to 
abnormalities in their receptor or sodium channels are some of the possible effects of 
gene mutation.  Common to all of these is the inability to perceive pain and clinical 
diagnosis relies on identifying this selective sensory loss.  Such patients have been 
reported to present at different ages with Charcot arthropathy, fractures or dental 
injuries (Minde et al. 2006) (Cassidy and Shaffer 2008) (Erdem et al. 2000; Bar-On et 
al. 2002).  All five patients described here had an absent or decreased response to pain 
which manifest in early childhood without any autonomic abnormalities suggesting a 
diagnosis of HSAN V.  However their age at presentation and their clinical and 
investigative results varied.  In two patients inability to feel heat pain resulting in 
burns led to further investigations.  In the remainder, the inability to feel pain 
resulting in fractures, blisters or ulcers was the initial complaint.  An investigation 
into child abuse as a cause of these fractures led to a diagnosis in one patient.  All 
patients were able to feel touch.  None of our patients had a family history of 
insensitivity to pain.  All patients had absent responses to CHEPS, and most had loss 
of nerve fibres on skin biopsy. 
 
QST can be used to reliably assess the function of nerve fibre subsets.  QST are 
psychophysical tests which depend upon patient co-operation which limits their use in 
young children.  QST have been used effectively in children as young as 3 years for 
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vibration detection thresholds, and as young as 6 years for thermal detection 
thresholds (Hilz et al. 1998a; Hilz et al. 1998b; Meier et al. 2001).  Of the two older 
patients on whom we were able to perform warm and cold detection threshold tests, 
one showed mildly elevated thermal thresholds to warmth over the foot and the other 
had normal thermal thresholds.   
 
Nerve conduction studies objectively evaluate large calibre myelinated nerve fibres. 
This test is hence of limited diagnostic value if the large fibres are normal (Krarup 
2003).   Three of our patients had a normal nerve conduction study and the others had 
reduced sensory action potential but normal motor conduction.  Neurogenic flare 
response elicited following injection of intradermal histamine is mediated by small 
diameter nerve fibres and the reduction or absence of a flare indicates small fibre 
neuropathy (Facer et al. 1998; Bickel et al. 2002).  The size of this flare has been 
shown to correlate to intraepidermal nerve fibre density (Bickel et al. 2009).  In our 
patients the flare response was present despite the absence of intraepidermal nerve 
fibres.  The likely explanation would be that the reflex is mediated by subepidermal 
fibres which were present in our patients.   
 
Novel tests such as  CHEPS, unlike thermal threshold detection tests, are not 
dependent on patients co-operation for the study of nociceptive pathways (Chen et al. 
2001).  CHEPS has also be shown to be very sensitive, and can detect dysfunction of 
small nerve fibres in patients without significant loss of intraepidermal nerve fibres or 
QST abnormalities (Atherton et al. 2007).  Lasers can be used to deliver similar 
stimuli.  CHEPS has the advantage over LEPs of being safer to use in a clinic setting 
without needing eye protection, and without the risk of causing skin burns (Atherton 
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et al. 2007).  CHEPS did not elicit an EEG response from the calf in all of our 
patients.  
 
Measurement of IENF densities following a skin biopsy are efficient and reproducible 
tests to detect disorders of small nerve fibres (McArthur et al. 1998; Smith et al. 
2005).  Normal values of IENF density at different regions of the body and the 
variation among age groups have been described (McArthur et al. 1998; Goransson et 
al. 2004; Umapathi et al. 2006).  Skin biopsy revealed an absence of intraepidermal 
nerve fibres (TRPV1 and PGP9.5) in three patients, a grossly reduced number of 
intraepidermal nerve fibres in one patient and a normal number in one patient.  The 
absence pain perception in four of our patients is likely to be due to loss of 
intraepidermal fibres.  In the patient who had normal intraepidermal nerve fibres we 
hypothesise that the disorder has a more central cause or alternatively is due to a 
chanellopathy.   
 
Diagnosis of this condition can hence be challenging and a varying degree of 
involvement of nerves in the pain pathway makes it difficult to have a single test to 
diagnose this condition.  Although dysfunction of small calibre sensory nerve fibres is 
a common feature in HSAN IV and V, patients affected can have many genotypic and 
phenotypic variations.  More than one genetic mutation affecting the development of 
the nerves and sodium channel adds to the diagnostic difficulty.  It is therefore 
necessary to utilize a variety of clinical and laboratory tests for the diagnosis of 
HSAN IV and V.  Novel methods such as CEHPS and skin biopsy complement other 
investigations in the clinical diagnosis of HSAN IV and V. 
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5.2 ABNORMALITIES OF SENSORY NERVE FIBRES EXPRESSING 
THE HEAT AND COOL RECEPTORS TRPV1 AND TRPM8 IN COMPLEX 
REGIONAL PAIN SYNDROME 
 
5.2.1 Introduction 
 
Complex regional pain syndromes (CRPS), mainly seen in limbs, are characterised by 
intractable pain and hypersensitivity.  They are frequently associated with other 
abnormalities in sweating, swelling and trophic changes of skin and subcutaneous 
tissue (Stanton-Hicks et al. 1995).  In some patients these symptoms can lead to 
chronic disability.  CRPS has been classified into two types, I and II based on the 
absence or presence of a nerve lesion but the underlying mechanisms are uncertain 
(Merskey 1994).  Both types present with identical signs, symptoms and response to 
treatment, suggesting a similar pathological mechanism.  The presence of pain, 
autonomic features and osteopenia in CRPS indicates that small diameter C and Aδ 
fibres might be at least partly involved in the pathogenesis, since they normally 
mediated these functions.  There is evidence of axonal degeneration and altered 
cutaneous and vascular innervation in patients with CRPS I (Wasner et al. 2001; 
Albrecht et al. 2006; Oaklander et al. 2006).  Other mechanisms including changes in 
central nervous system, sympathetic function and inflammation have been postulated 
to cause the symptoms characteristic of CRPS (Oyen et al. 1993; Thimineur et al. 
1998; Eisenberg et al. 2005; Schattschneider et al. 2006; Schinkel et al. 2006).  We 
postulate that abnormal degeneration and regeneration of small diameter fibres form a 
common pathway in CRPS I and II and abnormalities in the sensory ion channels 
markers results in the signs and symptoms characteristic to this syndrome.   
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5.2.2 Materials and Methods 
 
Skin and nerve specimens were obtained from two patients, one with CRPS I and the 
other with CRPS II who underwent below knee amputations for intractable pain and 
failed conservative management.  Both patients had a clinical examination including 
recording of clinical history, quantitative sensory testing using Semmes-Weinstein 
hairs (A. Ainsworth, University College London, UK) for touch thresholds and a 
biothesiometer (Biomedical instrument Co., Newbury, OH, USA) applied over a bony 
prominence at the affected region to measure vibration perception thresholds.  
Thermal thresholds (heat and cold perception thresholds and heat and cold pain) were 
recorded using the Medoc TSA 2001 neurosensory analyser (Medoc Ltd, Ramat 
Yishai, Israel).  The patients had surgery at the Royal National Orthopaedic Hospital 
Stanmore and the tissues were collected for analysis at our Unit under a Material 
Transfer Agreement (MAT).  Following amputation I dissected samples of skin from 
areas which had sensory abnormalities. 
 
5.2.2.1 Immunohistochemistry 
 
Immunostaining was performed for TRPV1, TRPM8, NGF and the neuronal marker 
PGP 9.5, using methods previously described (Gopinath et al. 2005; Facer et al. 
2007).  Briefly, tissues were snap frozen and stored at –70 °C or immersed in fixative 
[4% w/v paraformaldehyde in phosphate buffered saline (PBS: 0.1M phosphate; 0.9% 
w/v saline; pH 7.3) for 1- 2 hours then washed in PBS containing 15% w/v sucrose 
and sodium azide (0.1% w/v) before snap freezing in embedding medium (Tissue-Tek 
OCT compound, Sakura Finetek, USA).  Frozen tissue sections (15µm) were 
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collected onto poly-L-lysine-coated (Sigma, Poole, Dorset, UK) glass slides.  Unfixed 
tissue sections were post-fixed in 4% w/v paraformaldehyde (for TRPV1 and 
TRPM8), whilst tissue sections from immersion fixed biopsies were allowed to dry on 
the slide (for PGP9.5).  Endogenous peroxidase was blocked by incubation in 0.3% 
w/v hydrogen peroxide in industrial methylated spirit (IMS).  After rehydration in 
PBS, sections were incubated overnight with primary antibody.  Controls included 
omission of primary antibodies, or their replacement with pre-immune serum.  Sites 
of antibody attachment were revealed using nickel-enhanced, immunoperoxidase 
method (avidin-biotin complex – ABC elite; Vector Laboratories, High Wycombe, 
Bucks., U.K.).  Nuclei were counterstained with 0.1% w/v aqueous neutral red. 
 
5.2.3 Results 
 
Clinical details 
Case 1: A 26 year old lady developed back pain radiating to the left foot and an ankle 
sprain while training for a run.  Over the next few weeks she developed allodynia to 
touch, changes in colour and sweating and altered foot posture.  Initial management 
was in the form of serial splinting to correct the deformity.  At 2 years she underwent 
a soft tissue release followed by plaster casting.  By 35 months she had developed 
cold feeling in her foot associated with a burning sensation and blue coloration.  She 
was diagnosed as having CRPS I.  A series of botulinum toxin injections did not bring 
about any permanent relief of symptoms.  There was no relief of symptoms with 
analgesics.  Clinical examination revealed pin prick hyperalgesia below the level of 
the mid shin on the left lower limb, diminished sweating over the left sole, elevated 
cold threshold (less cold sensitivity) and reduced heat pain threshold (heat 
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hypersensitivity) over the dorsum of left foot.  Vibration and joint position sense was 
preserved over the left toes and ankle. 
 
 
Figure 5.3 Examples of skin from case 1 immunostained with various nerve 
markers.  a) Sub-epithelial PGP9.5 fibres (arrowed), b) Unusual PGP9.5 fibres 
around a blood vessel in skin, c) Increased intra-epithelial TRPV1 fibres and d) rare 
sub-epithelial TRPM8 fibres, magnification x40. 
 
Grossly abnormal, enlarged, nodular nerve fascicles and fibres immunoreactive to 
PGP9.5 and TRPV1 were seen in tissue sections of skin and nerve from the amputated 
specimen (Figure 5.3).  Penicillate nerve fibres were seen along the sub-epithelium/ 
epithelium junction.  Intra-epidermal nerve fibres and nerves showed morphological 
abnormalities.  Fibres immunoreactive to TRPM8 in the calf skin and skin over the 
ankle and foot were scanty (compared to our internal controls).  NGF was present in 
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basal keratinocytes but with unusually prominent, NGF-immunoreactive nerve fibres 
in dermal nerve fascicles. 
 
Case 2:  Following a road traffic accident a 31 year old lady developed a Lisfranc 
injury to the left foot.  Initially this was treated non-operatively using a plaster cast.  
She continued to have pain and stiffness over the foot and ankle which, one year 
following the injury, became discoloured, painful and deformed.  On examination she 
had numbness over the medial aspect of the foot with sensory disturbance and 
elevated monofilament thresholds in a sock-like distribution.  In addition, she had 
mechanical allodynia over the lateral calf, decreased sensation to pin prick over the 
medial aspect of leg and foot in a sock-like distribution.  Vibration and joint position 
sense was normal.  There was hypersensitivity to heating and cooling over the lateral 
calf.  She was diagnosed as having CRPS II.  Following unsuccessful response to non-
operative treatment over a period of 10 years she underwent a below knee amputation. 
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Figure 5.4 Examples of skin from case 2 immunostained with various nerve 
markers. a) unusually long sub-epithelial TRPM8 fibres (arrowed), b) PGP9.5 
immunostaining of injured nodular nerve fasicles c) Increased intra-epithelial 
(arrowed) and sub-epithelial TRPV1 fibres and d) basal cell (arrow head) and sub-
epithelial NGF fibres (arrows), magnification x40. 
 
Biopsy of skin, and nerve fibres revealed abnormal nodular and thickened appearance 
of fibres immunoreactive to PGP9.5 and TRPV1.  There were abnormal TRPM8 
fibres and unusual NGF immunoreactivity in basal keratinocytes and skin nerve fibres 
(Fig 5.4).  
 
5.2.4 Discussion 
 
The criteria used to describe CRPS are general and descriptive.  Common to the two 
subtypes of CRPS are the presence of sensory, vasomotor, sudomotor and motor/ 
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trophic signs (Harden et al. 2007).  Effective prevention and treatment of this 
condition has been hampered by controversies surrounding the causative pathology.  
Small diameter myelinated and unmyelinated fibres are involved in the transmission 
of pain impulses, and autonomic functions such as the control of sweating and 
capillary blood flow.  Motor signs of CRPS could be secondary to adaptive changes 
within the motor system (Maihofner et al. 2007).  Coupling between the sympathetic 
and the sensory system, either centrally or peripherally within the skin along with α- 
adrenoceptor mediated supersensitivity has been proposed to be the mechanism 
causing pain and autonomic changes (Gibbs et al. 2008).  
 
Activation of the vanilloid receptor (TRPV1), highly expressed in nociceptive primary 
afferent sensory neurons results in pain and inflammation.  Endogenous inflammatory 
mediators can increase expression of TRPV1.  We have previously shown that there is 
an increased expression of TRPV1 in injured brachial plexus nerves and 
hypersensitive skin after injury (Facer et al. 2007).  Alterations in cutaneous 
innervation and evidence of focal small fibre degeneration have been described in 
patients with CRPS I (Albrecht et al. 2006; Oaklander et al. 2006).  We have noted 
morphological abnormalities in nerves immunoreactive to PGP9.5 and TRPV1 of the 
affected limb in both patients despite the absence of any nerve injury in the patient 
with CRPS I.  The identical symptoms and treatment responses in patients with either 
of these types of pain syndromes suggests a common cause (Hord and Oaklander 
2003).  The menthol sensitive cold receptor (TRPM8) is implicated in the causation of 
cold allodynia following nerve injury (Xing et al. 2007).  In the first patient, with 
elevated cool threshold, there was a reduction in TRPM8 fibres over the affected area, 
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while in the second patient, who had cold allodynia, TRPM8 positive fibres were 
abnormal and increased in density  
 
Our study suggests that patients with both CRPS I and CRPS II have demonstrable 
changes in the nerves of the affected region.  In the absence of a history of nerve 
injury in CRPS I, the pathological changes in the nerve could be due to minimal distal 
nerve injury (MDNI) or secondary to inflammation.  Nerve growth factor (NGF), 
initially characterised as a neurotrophic factor, has been shown to have multiple roles, 
mediating nerve growth, inflammation, endocrine function and body defence (Levi-
Montalcini et al. 1995).  In both of our patients we have seen an unusually high NGF 
immunoreactivity in basal keratinocytes and nerve fibres.  This would further 
strengthen the hypothesis of nerve degeneration and regeneration in CRPS 
irrespective of the type and explain the phenotypic changes seen in such patients.  By 
studying tissues from the affected individual and immunostaining them for ion 
channel markers it is possible to identify possible mechanisms underlying the patients 
symptoms. 
 
 
5.3 EVALUATION OF PAIN IN OSTEOARTHRITIS OF THE HAND 
USING FUNCTIONAL MRI 
 
5.3.1 Introduction 
 
Osteoarthritis is the most common form of arthritis.  Symptomatic osteoarthritis 
frequently affects the joints of the hand, hip and knee, leading to significant limitation 
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in mobility and performance of everyday tasks (Creamer and Hochberg 1997; Felson 
and Zhang 1998).  Various risk factors have been associated with the prevalence of 
osteoarthritis including body weight, joint laxity, bone mineralisation, joint loading 
and genetics (Felson et al. 2000a).  Osteoarthritis affecting the hand if severe enough 
to limit function due to pain and restricted movements can be managed by non 
operative means such as physiotherapy, analgesics, and local corticosteroid injection.  
Operative treatments in cases who do not respond to non operative methods include 
joint replacement, arthrodesis or excision arthroplasty (Felson et al. 2000b).  Deciding 
the best form of treatment is often based on a combination of evaluation of 
radiographic extent of involvement, severity of pain and limitation felt by the patient.   
 
As pain felt by the patient is subjective it is difficult to compare this indication 
between patients, both to enable decision making for treatment and monitor response 
to treatment.  Studies have shown a poor correlation between pain felt by the 
individual and radiographic changes in osteoarthritis (Davis et al. 1992; Hannan et al. 
2000).  Tools such as the Oxford knee score have been devised to enable decision 
making and monitoring progress in knee osteoarthritis (Dawson et al. 1998) while 
functional scores such as DASH (disability of arm shoulder hand) have been used to 
evaluate functional deficits in hand arthritis (Hudak et al. 1996).  As pain is one of the 
most significant disability dictating treatments, it is essential to devise methods to 
objectively assess pain, which can also be used to develop novel analgesics and 
monitor response to treatment.  We have used the technique of measuring blood 
oxygen level dependence (BOLD) signal using functional magnetic resonance 
imaging (fMRI) while moving the painful joint in osteoarthritis of the hand, to assess 
the effect on regional brain activation.  I recruited patients for this research with 
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approval from the ethics committee (Riverside Research Ethics Committee; REC ref. 
no.: 07/H0706/78).  With the help of colleagues from the Department of Medical 
Imaging at Charing Cross Hospital, fMRI scans were conducted. 
 
5.3.2 Materials and Methods 
 
5.3.2.1 Patients 
 
Five patients (all females) with a median age of 56 years (range 53- 58 years) with 
osteoarthritis of the hand were recruited.  These patients had painful osteoarthritis 
affecting the carpometacarpal joint of the thumb (left, n= 3; right, n= 1), and left 
middle finger proximal interphalangeal joint (n=1).  All patients had symptoms lasting 
more than 1 year and had previous treatment in the form of splints and joint injections 
with partial relief.   
 
5.3.2.2Methods 
 
The motor task consisted of the patients moving their painful joint or the non-painful 
corresponding joint on the opposite limb.  The frequency was self-paced, although the 
training session used a pace of approximately every 3-4 seconds.  
 
Each study began with a 15 second of rest during which the patient performed no 
motor activity.  These data were discarded in the analysis to reduce effects of T1 
saturation that occur during acquisition of the first few datasets.  This was followed by 
30-second active phase and 30 seconds of rest, repeated 4 times.  The patient was 
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given instructions on when to start moving and when to stop through an LCD monitor 
positioned at the back of the magnet and connected to a laptop computer.  Images 
were acquired on a Siemens Verio 3T scanner. In total 85 volumes were collected for 
each session.  A 3D structural data set was acquired prior to the fMRI scans 
(MPRAGE TR/TE 1.9s/2.48ms 176 slices, 1mm thick, 250 mm field of view(FOV), 
256 x 256 matrix, resolution 1mm x 1mm x 1mm, acquisition time 4 minutes 18 
seconds.  An EPI gradient echo sequence was used for the fMRI scans (TR 3 seconds, 
TE 30 ms, 36 contiguous slices acquired interleaved, 4mm thick, 220 FOV, 64 x 64 
matrix, resolution 3.4mm x 3.4mm x 4mm, acquisition time 4 minutes 26 seconds). 
 
Data were analyzed using Statistical Parametric Mapping (SPM5) (Wellcome 
Department of Cognitive Neurology, London, UK) implemented in MatLab 
(Mathworks Inc., Sherborn, MA).  To correct for any motion during the fMRI 
acquisition, images were realigned to the mean image using a least squares approach 
and a 6 parameter (rigid body) spatial transformation.  Images were then normalised 
to match the SPM template.  The template images supplied with SPM conform to the 
space defined by the ICBM, NIH P-20 project, and approximate that of the space 
described in the atlas of Talairach and Tournoux (1988).  Finally, images were 
smoothed using an isotropic Gaussian Kernel (6 mm full-width-at-half-maximum).  
 
Statistical analysis was based on the General Linear Model (GLM).  The scanning 
paradigm was specified in SPM and a first level model estimation was performed.  
Significantly activated regions resulting from the analysis were superimposed on the 
structural scan.  The location of the activated regions was assessed using SPM 
Anatomy toolbox. 
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5.3.3 Results 
 
Scanning was successfully conducted in all five patients, although the images were of 
poor quality in one patient due to artefacts caused by the patient moving her head. 
While moving the painful joint patients had a median pain score of 5 on the visual 
analogue scale (range 2- 6.5).  
 
Group analysis of functional MRI showed a significantly increased area of activation 
in the primary somatosensory cortex on moving the painful joint (Figure 5.5). 
 
              
 
 
Figure 5.5 Coronal (a), axial (b) and sagittal (c) fMRI scans of brain following 
activation during movements of the painful joint (red) and non painful joint (blue). 
a b 
c 
167 
5.3.4 Discussion 
 
We have, for the first time to our knowledge, conducted a pilot study demonstrating 
increased activation of the cerebral cortex while moving the painful joint compared to 
a non-painful joint in osteoarthritis.  The use of fMRI has been widely reported in the 
study of processing of sensory stimuli, including pain perception (Roberts et al. 2008; 
Leaver and Rauschecker 2010; Hoffmann et al. 2011).   
 
Painful hand osteoarthritis offers a clinically important condition to model and 
evaluate nociception.  We selected patients with unilateral symptomatic osteoarthritis, 
to enable comparison with the opposite asymptomatic joint as a control.  Pain in 
osteoarthritis is worse with movements.  Hence we incorporated a protocol to study 
BOLD activation of the sensory response to movement.  Group analysis in our study 
revealed a significantly large area of activation on moving the painful joint.  Further 
studies are needed in a greater number of patients to correlate pain scores with 
changes in regional brain activation.   
 
Joint inflammation in arthritis can lead to peripheral and central sensitisation 
(Schaible et al. 2002; Bradley et al. 2004).  While these can result in result in rest 
pain, pain during movement is thought to be mainly due to peripheral sensitisation 
(Woolf 2004; Curatolo et al. 2006).  Successful response to treatment depends on 
addressing the mechanisms underlying chronic pain and sensitisation.  Cutaneous 
detection thresholds have been used to detect sensitisation states in osteoarthritis of 
the knee (Kosek and Ordeberg 2000; Schuelert and McDougall 2006).  Studies in 
other chronic pain states such as back pain using fMRI have shown alteration in the 
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normal resting activity of brain (Tagliazucchi et al. 2010).  Assessment of pain using 
fMRI has mainly been performed following stimulation with heat and mechanical 
stimulus in volunteers (Baumgartner et al. 2010; Seifert et al. 2010), and in patients 
the use of fMRI has been reported in the study of a range of painful conditions from 
trigeminal neuralgia to medication over-use in chronic migraine (Grazzi et al. 2010; 
Moisset et al. 2011).  Our pilot study on osteoarthritis of the hand using fMRI adds an 
important new finding for this technique, which needs further exploration for validity 
and reproducibility in osteoarthritis of other joints. 
 
5.4 NOVEL INTRA-EPIDERMAL NERVE MARKERS TRPV1 AND 
GAP43 COMBINED WITH CHEPS FOR THE ASSESSMENT OF PATIENTS 
WITH SYMPTOMS OF SMALL FIBRE NEUROPATHY 
 
5.4.1 Introduction  
 
Patients with classical small fibre neuropathy (SFN) present with altered sensation 
and have abnormal findings on QST, decreased histamine-induced flare area and 
contact heat evoked Aδ potential amplitudes from the lateral calf, along with reduced 
PGP 9.5 and TRPV1 IENF in skin biopsies (Atherton et al. 2007).  Sensitive measures 
(such as contact heat evoked Aδ potentials) that can detect nociceptor loss or 
dysfunction could be used to distinguish between neuropathic pain states and have a 
potential role as biomarkers in the development of novel analgesics.   
 
In contrast to patients with classical small fibre neuropathy (i.e. decreased IENF), 
some patients present with symptoms of sensory disturbance of acute or sub-acute 
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onset, often after a viral or “flu-like” illness, and yet have preserved or increased 
IENF upon skin biopsy.   
 
Studies described in earlier sections have revealed promising results with contact heat 
evoked Aδ potentials, and skin biopsies immunostained using the pan-neuronal 
marker PGP 9.5, the nociceptive fibre marker TRPV1, and GAP43 a marker of 
regenerating nerve fibres, in investigating experimental pain states.  The growth-
associated protein (GAP43), also known as neuromodulin, is a nervous system 
specific protein thought to be involved in axon growth and regeneration (Benowitz et 
al. 1987).  It has been demonstrated in dermal and epidermal nerve fibres in human 
skin where it was thought to be involved in the continuous remodelling of synapses 
and has been shown to be a good neuronal marker for nerve in intestine (Fantini and 
Johansson 1992; Vento and Soinila 1999).  In the present study, we have used 
antibodies to GAP 43 as a marker of regenerating/sprouting nerve fibres in the 
periphery (skin) especially since neuronal GAP 43 mRNA is increased during both 
regeneration and collateral sprouting (Mearow et al. 1994).   
 
In this study we used the range of biomarkers to identify underlying mechanisms in 
patients who presented with sensory disorders resembling small fibre neuropathy.  We 
conducted sensory tests including CHEPS, and performed skin biopsies.   
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5.4.2 Material and Methods 
 
5.4.2.1 Patients 
 
Fifty one patients (mean age 48.1 years [range 17 – 72]; 18 male) referred to the 
Peripheral Neuropathy Unit at Hammersmith Hospital, London for investigation of 
symptoms suggestive of small fibre dysfunction were studied.  Full history, clinical 
examination, CHEPS and skin punch biopsies were performed on all patients.  All 
procedures were undertaken with written patient consent and approval of the local 
research ethics committee (Hammersmith and Queen Charlotte‟s & Chelsea Research 
Ethics Committee). 
 
5.4.2.2 Skin Biopsies and Immunohistology 
 
Two 3 mm diameter skin punch biopsies were collected under local anaesthesia from 
the CHEPS stimulated region of one leg (right lateral calf) of all patients and controls 
(n = 9 mean age 36.1 years [range 17 – 59] 5 male). 
 
One of the two skin biopsies was snap frozen and stored at –70 °C, and the other 
immersed in fixative (modified Zamboni‟s fluid - 2% formalin; 0.01 M phosphate 
buffer; 15% saturated picric acid pH 7.2), then washed in phosphate buffered saline 
(PBS; 0.1 M phosphate; 0.9% w/v saline; pH 7.3) containing 15% w/v sucrose for an 
hour, before snap freezing in embedding medium (Tissue-Tek OCT, RA Lamb, 
Sussex, UK).  Frozen sections of pre-fixed and unfixed samples were collected onto 
poly-L-lysine-coated (Sigma, Poole, Dorset, UK) glass slides (at 15µm for all markers 
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except GAP43, where 30µm sections were used).  Unfixed sections were post-fixed in 
freshly prepared, 4% w/v paraformaldehyde in PBS. Sections were immunostained 
with antibodies to PGP9.5, TRPV1 and GAP43 as described earlier. 
 
Immunoreactive IENF were counted in a blinded manner, from a minimum of 4 
sections per biopsy, and the length of the epidermis measured using a calibrated 
microscope eyepiece graticule.  Results were expressed as fibres per mm length of 
epidermis.  GAP43-immunoreactive IENF were often rare, of very fine calibre and 
more easily detected in thicker (30µm) sections.  Quantification of these fibres was 
carried out exclusively on 30µm sections.  Sub-epidermal nerve fibres (SENF) were 
assessed also in 30µm skin biopsy sections where the average length of fibres in all 
patient groups was expressed as mm/mm
2
.   
Epidermal thickness was measured from post-fixed frozen tissue sections.  Three 
sections were selected for each control or patient, and epidermal thickness measured 
at three points along the length of the epidermis using a calibrated microscope, 
eyepiece graticule (X 40 objective).  Epidermal thickness was defined as the distance 
between the epidermal-dermal junction and the outermost stratum corneum. 
 
5.4.2.3 Contact heat evoked potentials 
 
CHEPS was recorded from the lateral calf of patients using the MEDOC device 
(MEDOC ltd, Ramat, Yishai, Israel) as described earlier with a 30 mm 30 mm probe 
and the EEG analysed with the Vision Analyser© Version 1.05.001 (BrainProducts 
GmbH, Munich, Germany).  We report latencies (N2) and amplitudes (N2-P2) of Aδ 
evoked potentials from the vertex (Cz) position following contact heat stimulation. 
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5.4.2.4 Quantitative Sensory Testing 
 
Quantitative sensory tests including thermal thresholds, monofilament and vibration 
detection thresholds were carried out as described earlier  
 
5.4.2.5 Statistical Analysis 
 
Statistical tests (Mann Whitney) were performed using GraphPad Prism version 3.02 
for Windows, (GraphPad Software, San Diego California USA).  Differences between 
groups of patients was compared with p <0.05 considered to be significant. 
 
5.4.3 Results 
 
5.4.3.1 Skin Biopsies 
 
Nerve fibres immunoreactive for PGP 9.5, TRPV1, or GAP43 were detected within 
the epidermis (IENF) and in plexuses immediately below (sub-epidermal -SENF) in 
most biopsies.  Counts of PGP 9.5 IENF in sections of routine (15µm) thickness, 
revealed two subgroups of patients, those with decreased and those with preserved or 
increased PGP 9.5 IENF (Mean IENF/mm ± SEM [15µm]: Controls 6.99 ± 0.84, 
Decreased IENF group 1.21 ± 0.4, p < 0.0001; Preserved/increased group 7.44 ± 0.5, 
p = 0.4177) (Figures 5.6 and 5.7). 
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Figure 5.6 PGP 9.5 intra-epidermal innervations (arrows) in controls (a), 
decreased PGP 9.5 group (b) and preserved/increased PGP 9.5 subgroup (c), 
magnification x20. 
 
 
 
Figure 5.7 PGP9.5 IENF counts in three groups of patients (***p<0.0001) 
 
Thicker sections (30m) showed a similar distribution  pattern of innervation for PGP 
9.5 in each of the subgroups and data analysis of IENF counts gave similar results to 
those obtained for 15µm section thickness (Mean IENF/mm ± SEM [30µm]: Control 
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8.21 ± 1.0; Decreased IENF group 1.19 ± 0.4, p < 0.0001; preserved/increased IENF 
group 9.88 ± 0.8, p = 0.2319).  Our control values for PGP 9.5 IENF at 30µm 
compare favourably with those of other authors using similar section thicknesses of 
calf skin (Smith et al. 2001). 
 
5.4.3.2 Patient subgroups 
 
1. Patients with decreased PGP 9.5 IENF 
 
This group of patients (n = 14; mean age 57.8yrs [range 41-71]; 9 male) included 
those who were referred for investigation of sensory symptoms indicative of small 
fibre neuropathy.  None of these patients had any history of injury or preceding 
illness.  Their mean duration of symptoms was 4.7 years (range 4 months to 15 years).  
Associated medical conditions included type II diabetes in three patients and one case 
each of stroke, ankylosing spondylitis and breast cancer treated with chemotherapy.  
One patient suffered from incontinence and multiple joint pains. 
 
Nine patients reported painful symptoms such as burning, „shooting‟ and “shock-like” 
sensations, six reported numbness and four, paraesthesia.  Most patients (85.7%) had 
altered thermal thresholds, 7.1% had an abnormal monofilament threshold, and 35.7% 
had abnormal vibration detection thresholds.  Nerve conduction studies were carried 
out on eleven patients, of which nine were normal and two abnormal. 
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Skin biopsies showed evidence of a marked reduction of TRPV1 IENF [Mean 
IENF/mm ± SEM (15µm): Controls 5.85 ± 0.61; Decreased IENF group 1.40 ± 0.3, p 
= 0.0001; Figures 5.8, and 5.9 b].   
 
 
Figure 5.8 TPRV1 (IENF) counts in the three groups of patients with normal, 
decreased and increased PGP9.5 (IENF) counts. (***p=0.0001) 
 
 
 
Figure 5.9 TRPV1 intra-epidermal innervations (arrows) in controls (a), 
decreased PGP 9.5 group (b) and preserved/increased PGP 9.5 subgroup (c), 
magnification x20. 
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Figure 5.10 GAP43 (IENF) counts in the three groups of patients with normal, 
decreased and increased PGP9.5 (IENF) counts (**p =0.0075) 
 
GAP43-immunoreactive IENF were observed in only 27.3% of control skin biopsies 
sectioned at 30µm and in only one patient from the decreased IENF subgroup (Mean 
IENF/mm ± SEM: Controls - 0.14 ± 0.08 ; Decreased IENF subgroup - 0.02 ± 0.02, p 
= 0.0978; Figure 5.10,and 5.11 b).   
 
Figure 5.11 GAP43 intra-epidermal innervations (arrows) in controls (a), 
decreased PGP 9.5 group (b) and preserved/increased PGP 9.5 subgroup (c), 
magnification x20. 
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The decreased IENF subgroup also showed significantly reduced lengths of PGP 9.5 
SENF [Mean length (mm/mm
2
) of SENF ± SEM: Controls 3.85 ± 0.2; Decreased 
IENF subgroup 1.93 ± 0.3, p = 0.0001], and GAP43 SENF [Mean length (mm/mm
2
) 
of SENF ± SEM: Controls 1.21 ± 0.1; Decreased IENF subgroup 0.43 ± 0.1, p = 
0.0002; Figure 5.12].  Epidermal thickness was reduced in this subgroup (Mean 
thickness [µm] ± SEM: Control – 85.75 ± 7.1; Decreased IENF subgroup – 63.38 ± 
3.3, p = 0.0068). 
 
Figure 5.12 GAP43 (SENF) length/mm
2
 in the three groups of patients with 
normal, decreased and increased PGP9.5 (IENF) counts (*** p= 0.0002) 
 
CHEPS amplitude from the lateral calf were attenuated in the decreased IENF 
subgroup (Mean amplitude [µV] ± SEM: Controls 14.68 ± 2.5; Decreased IENF 
group - 2.95 ± 1.2, p = 0.0006; Figure 5.13).   
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Figure 5.13 Aδ amplitude with CHEPS from the lateral calf in the three groups of 
patient with normal, decreased and increased PGP9.5 (IENF counts) (*** p=0.0006), 
**p=0.0044) 
 
 
2. Patients with preserved or increased PGP 9.5 IENF 
 
This subgroup (n = 37; mean age 44.5yrs [range 17-72]; 8 male) described burning 
pain as the most common symptom (25/37 patients) but numbness (5/37 patients), and 
paraesthesia in (12/37 patients) were reported also.  The mean duration of symptoms 
was 4.3 years (range six months to 22 years).  Nerve conduction studies were carried 
out in 17 patients within this group; 15 were normal and two abnormal.  Infection or 
an autoimmune disease was suspected as the causative factor in 15 patients, with 
conditions including Crohn‟s disease, plantar fasciitis, carpel tunnel syndrome, 
diverticular disease, celiac disease, erythromelalgia, rheumatoid arthritis, post-
herpetic neuralgia and irritable bowel syndrome as co-existing illnesses.  In 6 patients 
there was a history of infection immediately prior to the onset of sensory symptoms.  
There was a family history of sensory disturbance in two patients.  One patient had a 
179 
history of diabetes mellitus and alcoholism which were suspected to have exacerbated 
his clinical symptoms.  Most cases were idiopathic. 
 
Current medications included two prescriptions of amitriptyline, three of Pregabalin, 
and one each of co-codamol, diclofenac, Duloxetine, diazepam, steroids, opiates, and 
tramadol.  These patients were mostly normal upon clinical examination (75% of 
patients had normal thermal thresholds, 68% had normal monofilament thresholds and 
73% had normal vibration thresholds). 
 
Skin biopsies revealed preserved TRPV1 IENF (Mean IENF/mm [15µm] ± SEM: 
Controls 5.85 ± 0.61; Preserved/increased IENF group 7.03 ± 0.7, p = 0.3338) 
(Figures 5.8 and 5.9).  Within the preserved/increased IENF group 46% of patients 
had a reversed ratio of PGP 9.5: TRPV1 IENF, i.e. more TRPV1 than PGP 9.5 IENF.  
GAP43 IENF were significantly increased in the preserved/increased IENF subgroup 
(Mean IENF/mm ± SEM: Controls - 0.14 ± 0.08, Preserved/increased IENF subgroup 
- 2.75 ± 0.6, p = 0.0075; Figures 5.10 and 5.11), where 57% of patients showed 
GAP43 IENF.  PGP 9.5 SENF were not changed in the preserved/increased IENF 
group but GAP43-immunoreactive SENF were significantly increased (Mean length 
[mm/mm
2
] of SENF ± SEM: Controls 1.21 ± 0.1, Preserved/increased IENF subgroup 
2.43 ± 0.2, p = 0.0002; Figure 5.12).  Epidermal thickness was reduced in this 
subgroup (Mean thickness [µm] ± SEM: Control – 85.75 ± 7.1; Preserved/increased 
IENF subgroup – 68.20 ± 2.5, p = 0.0062). 
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CHEPS amplitudes from the lateral calf were attenuated in the preserved/increased 
IENF subgroup (Mean amplitude [µV] ± SEM: Controls 14.68 ± 2.5; 
Preserved/increased IENF group 7.89 ± 2.1, p = 0.0044; Figure 5.13).   
 
5.4.4 Discussion  
 
In this study, using contact heat evoked potentials and skin biopsies, we have 
investigated two subgroups of patients with small fibre dysfunction.  The decreased 
IENF subgroup with a classical dying back small fibre neuropathy are similar to 
patients described previously (Atherton et al. 2007).  In contrast, patients in the 
preserved/increased IENF subgroup had prominent symptoms of spontaneous and 
evoked pain with preserved or increased epidermal innervation.  Within this subgroup 
almost half of the patients had a reversed ratio of PGP 9.5: TRPV1 IENF.  PGP 9.5 is 
a gold standard nerve marker, thought to detect all nerve fibres in human and animal 
tissue.  The significance of increased TRPV1 IENF in patients from this subgroup 
suggests TRPV1 over expression in very fine nerve fibres, making them easier to 
detect.  Some patients in this group reported symptoms of acute or sub acute onset, 
and presented with evidence of inflammation after viral or flu-like illnesses, 
suggesting that inflammation and inflammatory mediators associated with peripheral 
and/or central nociceptive fibres may be responsible for their symptoms.  TRPV1 may 
be up-regulated by inflammation e.g. in the dorsal root ganglia.  NGF is present 
during inflammation and may lead to increased expression of TRPV1 or co-
expression in fibres that are not normally capsaicin sensitive (Anand 2003; Zhang et 
al. 2005).  In pre-clinical animal models, inflammation leads to changes in the 
expression of receptors and ion channels, changing the excitability of affected nerve 
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fibres and allowing generation of ectopic discharges.  Of specific interest (in terms of 
the increased numbers of TRPV1-expressing fibres) are increases in TRPV1 
expression shown in inflamed rodent hind paw and rodent models of inflammatory 
hyperalgesia (Carlton and Coggeshall 2001; Wilson-Gerwing et al. 2005).  These 
studies suggest that changes in TRPV1 expression may be pivotal in the generation of 
peripheral sensitisation of nociceptive fibres under inflammatory conditions. 
 
GAP43, a marker of nerve regeneration is augmented in the preserved/increased IENF 
group particularly in those patients who have a reversed ratio of PGP 9.5: TRPV1 
IENF.  When patients with or without reversed PGP 9.5: TRPV1 IENF ratios are 
analysed separately, those with a reversed ratio have significantly more GAP43 IENF 
compared to controls whereas those with a normal ratio do not (Mean IENF/mm ± 
SEM: Controls 0.14 ± 0.08, reversed ratio 3.22 ± 0.8, p = 0.0009; preserved ratio 2.33 
± 0.9, p = 0.0934).  Increased GAP43 in this subgroup may suggest an ongoing 
process of degeneration and regeneration of nerve fibres that, although not reduced in 
number, are functioning abnormally.  The previously described study (section 4.2) of 
IENF regeneration following topical capsaicin application in healthy volunteers has 
shown that GAP43 immunostaining provides a better correlate of LEP amplitude 
recovery than PGP9.5 alone (Rage et al. 2010). 
 
Other investigators have reported clinical data from patients presenting with sensory 
predominant, painful, idiopathic small fibre dysfunction, often of acute onset (Holland 
et al. 1998; Kelkar et al. 2002; Moghekar et al. 2004) and observed the presence of 
inflammatory infiltrates in sural nerve biopsy (Kelkar et al. 2002).  However, non-
length dependent axonal loss was apparent also in sural nerve and skin biopsy from 
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the patients in these studies, whereas in the group presented here, cutaneous 
innervation was preserved and in some cases increased. 
 
It is also possible that our patients have a selective disorder of the dorsal root ganglia 
subserving small sensory nerve fibres (ganglionopathy).  Clinical features of such 
patients have been described recently, with proximal neuropathic symptoms 
developing over days or months, and potential metabolic or immune processes 
detected in some cases (Lauria et al. 2001; Gorson et al. 2008).  Yet, upon skin 
biopsy, non-length dependent overall loss of IENF was reported in these patients. 
 
Contact heat evoked Aδ potentials recorded from the leg were significantly reduced 
across both groups.  Attenuation in the amplitude of contact heat evoked potentials in 
the decreased IENF subgroup is expected as being due to loss of cutaneous 
innervation.  Attenuation of laser evoked potentials is well known in patients with 
neuropathic pain states, even sub-clinically in diabetic neuropathy (Bromm et al. 
1991; Agostino et al. 2000a; Agostino et al. 2000b; Rossi et al. 2002).  These changes 
in amplitude have been shown to correlate with clinical impairment of pain sensation 
and the density of small myelinated fibres in sural nerve biopsies (Kakigi et al. 
1991b).  This is also the case with contact heat evoked Aδ potentials and levels of 
PGP 9.5 and TRPV1 intra-epidermal innervation in skin biopsies (Atherton et al. 
2007), data supported by another study in a group of neuropathy patients with skin 
denervation (Chao et al. 2008). 
The attenuation of amplitudes in the preserved/increased PGP 9.5 IENF subgroup, 
who also had a raised GAP43 SENF density is in contrast to our previous study in the 
topical capsaicin human volunteer model (section 4.2) where LEPs were parallel to 
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GAP43 SEF counts.  This is not unexpected, given that in this model the lesion is 
distal to the DRG at the nerve terminals in normal subjects, whereas in the patients  
there is likely to be a conduction block proximally i.e. at the nerve root level, possibly 
secondary to inflammation or demyelination, which may prohibit conduction.   
 
Contact heat evoked Aδ potential amplitudes in the legs of three patients within the 
preserved/increased PGP 9.5 IENF subgroup were augmented compared to controls 
and the rest of the subgroup (Patients amplitudes - 46.33µV, 49.50µV and 29.74µV 
vs. mean amplitude (µV) ± SEM controls – 14.68 ± 2.5µV).  Hypersensitivity to 
thermal stimuli has been shown to be associated with increases in LEP amplitude 
particularly in fibromyalgia but also in patients with migraine (Gibson et al. 1994; 
Lorenz et al. 1996; Valeriani et al. 2003b), and this deserves further study.   
 
CHEPS has advantages over other clinical tests such as skin biopsy since it is non-
invasive, quick, reliable and reproducible, can be used on any area of the body, and 
can be used repeatedly for follow up.  However, unlike skin biopsies, CHEPS cannot 
localise pathology within the peripheral nervous system.  Thus the use of a 
combination of the whole array of clinical tests available to diagnose neuropathy is 
desirable.  We have shown in these studies that CHEPS and specific 
immunohistochemical markers such as TRPV1 and GAP43 are vital tools for 
dissecting possible mechanisms in patients who, although symptomatic, may have no 
abnormalities in other clinical tests. 
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5.5 CONCLUSIONS 
 
We explored the use of novel biomarkers in clinical pain states.  In congenital 
insensitivity to pain syndrome, this study has enabled diagnosis in pre-verbal patients 
who have normal nerve conduction tests.  Genetic studies in these conditions can 
reveal diverse abnormalities, while techniques of clinical assessment described in this 
study, particularly CHEPS provide a quick and inexpensive method of supporting the 
diagnosis. 
 
In osteoarthritis, our pilot study has shown a larger area of activation in the 
nociceptive processing areas.  Further studies confirming this and quantifying 
correlation of pain with fMRI signals could in future provide a reliable marker to 
monitor therapy and develop new analgesics. 
 
As the causative pathology in CRPS and idiopathic small fibre neuropathies is 
unclear, the biomarkers in skin biopsies combined with CHEPS provide indicators 
with regard to the location of the lesion and the causative pathology.  This biomarker 
study has distinguished two subgroups of patients with small fibre neuropathies, one 
with the classical dying back neuropathy, and the second one with preserved or 
regenerating nerve fibres.  This classification is useful for diagnosis and selection of 
therapy. 
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Chapter 6 Clinical trial of a novel analgesic linked to pain biomarkers  
 
 
6.1 p38 MITOGEN ACTIVATED PROTEIN KINASE, A MARKER OF 
TRPV1-RELATED MECHANISMS OF PAIN 
 
Introduction 
p38 mitogen-activated protein (MAP) kinase phosphorylates a number of intracellular 
proteins, including signal transduction molecules and transcription factors that are 
involved in regulating the biosynthesis of inflammatory cytokines such as IL-1 and 
TNFα (Strniskova et al. 2002).  p38 also regulates many of the biological actions of 
these cytokines, such that p38 activation is involved in a cytokine amplification loop.  
Activation of this enzyme has also been strongly implicated in inflammatory pain (Ji 
and Suter 2007).  It has been shown that inhibitors of cytokine action (e.g. anti-TNFα 
treatments) significantly reduce inflammation and related pain in rheumatoid arthritis 
(RA) and lumbosacral radiculopathy (Redlich et al. 2003; Cohen et al. 2009b).  p38 
MAP kinase has been identified as the target for a novel class of cytokine suppressive 
anti-inflammatory drugs (CSAIDS).  Inhibition of MAPK has been shown to reduce 
neuropathic pain in animal models, which involve TRPV1 (Ji et al. 2009).  In the rat 
chronic constriction injury (CCI) model, the p38 inhibitor SB-203580 reduced heat 
hyperalgesia and mechanical allodynia (Obata et al. 2004a).  Studies with the p38 
MAPK inhibitor SD-282 have shown attenuation of hyperalgesia in rat models of 
diabetic neuropathy and capsaicin injection (Sweitzer et al. 2004a; Sweitzer et al. 
2004b). 
 
186 
6.2 P38 MAP KINASE- HUMAN AVULSION INJURED DRG  
 
6.2.1 Rationale 
 
To study p38 mechanism in injured DRG neurons, avulsion injured human DRGs 
were obtained during surgery for brachial plexus repair.  Patients were operated upon 
at the Royal National Orthopaedic Hospital, Stanmore and tissues were collected for 
analysis at our Unit under a Material Transfer Agreement (MTA).  Control, post-
mortem DRG with a post-mortem delay of less than 12h were obtained from 
Netherlands Brain Bank.  Fully informed consent was obtained for all tissues which 
were collected with approval of the Local Ethics Committee.  Tissues were prepared 
for study by the as described below. 
 
6.2.2 Tissue methods 
 
Frozen sections (15µm thickness) were collected onto poly-L-lysine-coated (Sigma, 
Poole, Dorset, UK) glass slides and post-fixed in freshly prepared, 4% w/v 
paraformaldehyde in phosphate buffered saline (PBS).  All sections were washed in 
PBS and endogenous peroxidase blocked by incubation in 0.3% w/v hydrogen 
peroxide in methanol.  After rehydration, the tissue sections were incubated overnight 
with primary antibodies to P38 (Cell Signaling, Danvers MA, USA; P38 ref# 9212; 
Phospho-P38 ref# 9211; P38 α ref# 9218; 1/200)  The immunohistological methods 
and some of the antibodies used were as described in earlier studies (Facer et al. 1998; 
Gopinath et al. 2005).  Sites of antibody attachment were revealed using a nickel-
enhanced, immunoperoxidase method (avidin-biotin complex – ABC elite; Vector 
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Laboratories, High Wycombe, Bucks., U.K.).  Negative controls included omission of 
primary antibodies or replacement with pre-immune serum.  Nuclei were 
counterstained with 0.1% w/v aqueous neutral red.  Sections were photographed via 
video link to an Olympus BX50 microscope. 
 
6.2.3 Results 
 
The activated form of p38 was increased in injured DRG neurons but barely 
detectable in control DRG neurons (Figure 6.1) 
 
 
Figure 6.1 P38 in human dorsal root ganglion (DRG).  Control, uninjured (a, c, 
e) and injured (b, d, f) human DRG immunostained with antibodies to phosphoro- p38 
(a, b), p38 (c, d) or p38α (e, f).  Scale bars = 50µm.  
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6.2.4 Discussion 
 
We have confirmed earlier reports in rodents of activation of p38 MAPK in injured 
human dorsal root ganglia.  Studies have shown that p38α is the dominant isoform, 
and the activated form of p38 is found in synovial tissue in rheumatoid arthritis 
(Redlich et al. 2003).  Several neuropathic pain states have a substantial inflammatory 
component involving pro-inflammatory cytokines and NGF (Gopinath et al. 2005; 
Atherton et al. 2006; Facer et al. 2007).  There is evidence for their involvement in the 
development and maintenance of pain and sensitisation in peripheral nerve injury 
(PNI) (Durrenberger et al. 2004; Durrenberger et al. 2006; Ji and Suter 2007).  Pain 
and inflammation can also develop in patients with lumbosacral radiculopathy, and in 
carpal tunnel syndrome (CTS) (Quraishi et al. 2004; Carlson et al. 2010).  We 
postulate that in all these syndromes, p38 MAPK activation leads to pain and 
hyperalgesia, and can be exploited by developing inhibitors to alleviate pain.  
 
 
6.3 CLINICAL TRIAL OF THE P38 MAP KINASE INHIBITOR 
DILMAPIMOD IN NEUROPATHIC PAIN FOLLOWING NERVE INJURY
4
 
 
6.3.1 Rationale  
p38 MAPK inhibitors reduce cytokine production in both in vitro and in vivo models 
(Badger et al. 1996; Pocock and Liddle 2001).  p38 MAPK mediates nerve growth 
factor (NGF)-dependent up regulation of  TRPV1 expression in dorsal root ganglia 
(DRG), leading to heat hyperalgesia (Ji et al. 2002; Obata et al. 2004a; Obata et al. 
                                                 
4
  The results of this trial has been published-  Anand P, Shenoy R, Palmer JE, Baines AJ, Lai RY, 
Robertson J, Bird N, Ostenfeld T, Chizh BA. Clinical trial of the p38 MAP kinase inhibitor 
dilmapimod in neuropathic pain following nerve injury. Eur J Pain. 2011 May 14. 
189 
2004b).  Dilmapimod (SB-681323) has been identified as a potent, selective and 
reversible inhibitor of p38 MAPK, and has been tested in animal models of 
inflammation and hypersensitivity.  In humans it  has been shown to inhibit the 
production of cytokines; in patients with chronic obstructive pulmonary disease, 
systemically administered dilmapimod has been shown recently to reduce whole-
blood sorbitol-induced phosphorylated heat shock protein-27 levels [pHSP-27, a 
marker of p38 pathway activation (Alford et al. 2007), as well as lipopolysaccharide-
induced tumor necrosis factor (TNF)-alpha production (Singh et al. 2010).  In a 
separate study, dilmapimod administration was associated with a significant 
attenuation of the systemic inflammatory response compared to placebo following 
percutaneous coronary intervention, as measured by a reduction in high sensitivity C-
reactive protein (hsCRP) (Sarov-Blat et al. 2010). 
 
Neuropathic pain is present in a diverse group of syndromes associated with injury or 
disease of the nervous system, including nerve trauma or compression (Attal et al. 
2008).  The therapeutic agents currently used in patients with neuropathic pain include 
antidepressants, anticonvulsants, topical capsaicin, local anaesthetics and opioids 
(Dieleman et al. 2008).  With all available treatments only a partial pain relief can be 
achieved, often accompanied by side-effects (Shenoy 2008).  There is a high unmet 
need for effective treatments in neuropathic pain. 
 
Here we report the results of an exploratory clinical study undertaken to investigate 
the effects of dilmapimod on the symptoms and clinical signs of neuropathic pain in 
patients with nerve trauma and/or compression.  This was a multicentre study funded 
by GlaxoSmithKline. 
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6.3.2 Materials and Methods 
 
6.3.2.1 Study plan 
 
A double-blind, placebo controlled, two-period cross-over study, performed according 
to the principles of Good Clinical Practice and the Declaration of Helsinki  (GSK 
Protocol Number: MKN106762) was undertaken across a total of six sites, three in the 
United Kingdom, two in Australia and one site in the Russian Federation.  The study 
was approved by the relevant local Research Ethics Committees and the respective 
drug regulatory authorities (For the Hammersmith study centre: Eastern Multi-centre 
Research Ethics Committee; REC ref. no: 06/MRE05/35).  Written informed consent 
was obtained for all subjects prior to participation.  Fifty patients were enrolled in the 
study. A minimum of 40 evaluable patients were to be recruited into the trial based on 
sample size calculations. 
 
Screening involved quantitative sensory testing (QST) and neurophysiological tests to 
select subjects with functional evidence of nerve injury/compression.  Subjects were 
required to have a diagnosis of peripheral neuropathic pain which was:  
(1) Focal neuropathic pain related to nerve injury caused by trauma or surgery not 
associated with ongoing infection, or  
(2) Pain associated with lumbo-sacral radiculopathy; patients with radiculopathy were 
only included if they had pain radiating to or below the knee, and had loss of small 
fibre function as indicated by QST (change from thermode baseline temperature of 
either > 9.6°C for warm sensation or > 5.6 °C for cool sensation in L4, L5 or S1 
dermatomes) (Quraishi et al. 2004), or  
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(3) Carpal tunnel syndrome (CTS); patients with CTS were included only if there was 
a clinical diagnosis with evidence of loss of large and/or small fibre function, 
confirmed by electrophysiological nerve conduction examination or by QST (change 
from thermode baseline temperature of either > 5.2 
°
C for warm sensation, or > 4.5 
°
C 
for cool sensation, in the median nerve territory, based on consensus reference values 
from Departments of Clinical Neurophysiology, London, UK. 
 
The location of pain had to be consistent with the area innervated by the affected 
nerve(s), with or without other sensory symptoms in the affected area; pain had to be 
of at least three months duration.  Baseline pain intensity score was to average ≥ 4 
during the three days prior to randomisation [as reported on the 11-point pain intensity 
numerical rating scale (PI-NRS; 0=no pain, 10=maximum pain imaginable)].  Patients 
who had received nerve blocks or steroid injections for neuropathic pain were only 
included if their most recent intervention was at least 4 weeks prior to randomization.  
 
Other key eligibility criteria for subjects were:  
 age 18-80 years,  
 weight ≥ 50 kg for men and ≥ 45 kg for women, with a Body Mass Index 
(BMI) of 18.5-35 kg/m
2
.  
 Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) had to 
be within normal limits at screening, and  
 patient ECG parameters had to satisfy a QTc(b) interval of < 450 msec, or < 
480 msec for patients with bundle branch block at screening.  
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Patients were randomised using the GlaxoSmithKline Registration and Medication 
Ordering System (RAMOS) to receive either oral dilmapimod (SB-681323) or 
matching placebo for 14 days, before cross-over, to receive the other study treatment 
arm (placebo or dilmapimod) in a second 14-day period (Figure 1).   
 
 
 
Figure 6.2 Schematic of study design 
 
There was a washout period of two to four weeks between treatment periods.  Healthy 
volunteer studies [unpublished] have previously established the terminal elimination 
half-life (t½) of dilmapimod to be around 10 hrs following oral administration.  
Although the compound is extensively metabolised, the principle oxidative metabolite 
is at least an order of magnitude less potent than the parent.  A human radiolabelled 
investigation revealed that the decline of plasma radioactivity derived from the parent 
compound occurs rapidly with a terminal half life approximately 7.9 h.  As such it 
was thought that a washout period of no less than 2 weeks would enable complete 
elimination of dilmapimod and its metabolites prior to the next treatment period.  A 
variable washout period of 2 to 4 weeks was intended to provide flexibility for 
investigation sites and patients with respect to the scheduling of clinic visits and to 
facilitate the recruitment process. 
Follow-up 
Period 2 
Placebo/ 
Dilmapimod 
Period 1 
Dilmapimod/ 
Placebo 
3 wks 2 wks 2 - 4 wks 2 wks Approximately   4 
wks 
Screening Washout 
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Daily pain intensities were recorded on a diary card, before retiring to bed.  Patients 
visited the Clinical Units on Days 1, 7 and 14 of each treatment period for safety and 
efficacy assessments.  These included determination of thermal thresholds in the 
distribution of the affected nerves, mirror-image control area, and an evaluation of the 
area of intensity of static hyperalgesia and dynamic allodynia.  
 
6.3.2.2 Thermal thresholds 
 
For warmth perception, heat pain, cool perception and cold pain threshold 
measurements, the temperature of the thermode was changed from the baseline (32°C) 
at a rate of 1°C/s (Medoc Ltd, Ramat Yishai, Israel, TSA thermode 3x 3cm).  Testing 
was performed using the method of limits.  Testing was performed within a 
temperature range of 0°C to 50°C. 
 
6.3.2.3 Area and intensity of allodynia 
 
The area of dynamic tactile allodynia was determined using a one inch foam brush.  
The point on the skin where the brush caused an unpleasant sensation was marked 
with a felt tip pen.  If the painful area was on a limb, a total of four points (each 90° 
apart) were drawn on the skin at 1 cm intervals.  If the painful area was irregular, or 
was in the truncal or facial area, eight points with ticks at l cm intervals were drawn.  
A similar method was used to mark the area of static allodynia using a von Frey 
filament (26 g).  The points were transferred to a homunculus, and the area was 
measured. 
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The intensities of static and dynamic allodynia were assessed while recording 
allodynia on the 11 PI-NRS (0 = “No pain", 10= “Maximum pain imaginable”). 
 
6.3.2.4 Dose of Dilmapimod 
 
In the original clinical trial protocol, dilmapimod was administered twice daily, 2.5 
mg in the morning and 5 mg in the evening, to give a total daily dose of 7.5 mg.  
Three subjects received this dose level and completed the 14 day dosing period.  After 
initiation of the study additional safety data became available from a separate healthy 
volunteer repeat dose study to support the administration of a higher dose level.  The 
protocol then received regulatory and ethical approval for an amendment to enable a 
dose of 7.5mg BID (total daily dose of 15mg) for patients subsequently enrolled into 
the investigation.  Forty-four subjects received dilmapimod at this higher dose level 
and completed the 14 day dosing period. 
6.3.2.5 Concomitant Medications for Pain 
 
Patients were allowed to continue an established dosing regimen of medication for 
their neuropathic pain, provided it had not been changed for at least four weeks before 
randomisation, remained unchanged over the course of the study, and if it was not 
listed as a prohibited medication.  Permitted treatments for neuropathic pain included 
tricyclic antidepressants, anticonvulsants, opioids, gabapentin, pregabalin, duloxetine, 
tramadol, bupropion, venlafaxine, mexiletine and skeletal muscle relaxants (e.g. 
baclofen).  The following concomitant drugs and treatments for controlling 
neuropathic pain were prohibited: topical lidocaine, topical capsaicin and sedatives 
(except benzodiazepines taken for sleep), nerve blocks, steroid injections, NSAIDs, 
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COX-2 inhibitors and other inflammatory drugs.  Low dose aspirin was permitted for 
prophylaxis against thromboembolic events.  The use of a rescue medication 
(paracetamol, up to 2 g per day) was allowed if pain became intolerable.  Patients 
were asked to refrain from taking rescue medication within 24 hours of a treatment 
visit at the clinic.  
 
6.3.2.6 Statistical methods and analysis of end points 
 
The „Intent-to-Treat‟ (ITT) population consisted of all randomised patients who 
received at least the first dose of study medication and had at least one post-treatment 
efficacy assessment.  The primary statistical analyses were performed on patients in 
the ITT population who were randomised to receive dilmapimod (15 mg/day) and 
placebo.  In addition to the planned statistical analyses on the ITT population, a 
secondary analysis was also performed on the primary endpoint for subjects who 
received any dose of dilmapimod versus placebo.  This „All Doses‟ population 
included those subjects who had received the 7.5mg daily dose as well as recipients of 
the 15mg daily dose of dilmapimod.  The same statistical analysis was conducted as 
for the primary analysis. 
 
The per-protocol (PP) population consisted of all patients in the ITT-population with 
no major protocol deviations; however since only 2 subjects were excluded from the 
PP-population, only the ITT-population results are discussed.  The safety analyses 
were based on all patients randomised and who had taken at least one dose of study 
medication. 
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Analyses for the primary endpoint 
The primary endpoint was the average daily pain score recorded each night prior to 
retiring to bed during Week 2 of treatment based on the 11 point PI-NRS.  This score 
was also recorded over Week 1 of the treatment.  The average daily pain scores were 
calculated as the mean of the daily pain scores recorded on Days 2 to 6 inclusive for 
Week 1 of the treatment, and the mean of Days 8 to 13 inclusive for Week 2. 
 
The average daily pain scores collected on the three days prior to dosing in each 
period constituted the subject‟s period baseline.  The baselines which were fitted into 
the statistical model were derived from these period baselines as follows.  A subject-
level baseline was calculated individually for each subject as the mean of the two 
period baselines.  In addition to this subject-level baseline, a period-level baseline was 
calculated for each period for each subject.  This was calculated as the period baseline 
minus the average of the two baselines.  The subject-level baseline gives a more 
accurate representation of the subjects „true‟ baseline state, whereas the period-level 
baseline reflects the pain intensity experienced by the subject prior to the start of that 
specific period.  Both of these baselines were included in the statistical model. 
 
A mixed effects model for repeated measures (MMRM) analysis was performed 
fitting treatment, period, week, country, diagnostic category, subject-level baseline, 
period-level baseline, treatment by week and period-level baseline by week as fixed 
effects and subject as a random effect.  Point estimates, confidence intervals and p-
values were calculated for the difference between dilmapimod (7.5mg BID; 15mg per 
day) and placebo for each week of treatment.  A responder analysis was conducted on 
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the numbers of subjects with a 30% and 50% reduction in their average daily pain 
score in week 2 compared to baseline. 
 
Analysis for the secondary endpoints 
Current Pain Intensity:  
The Current Pain Intensity (CPI) was recorded on an 11-point NRS scale reporting 
how much pain subjects currently had at the time of their weekly attendance at the 
clinical units (days 1, 7 and 14).   Similar analysis techniques as per the primary 
analysis were performed. 
 
Quantitative Sensory Threshold:  
Baselines for QST data in both the affected and control areas were recorded pre-dose 
on Day 1 of each treatment period, and post-dose assessments were recorded on Day 
14.  A mixed model analysis of variance (ANOVA) was performed on each of the 
sensory tests in both sites, except for cold pain.  An ANOVA model was unable to be 
fitted for the cold pain threshold, as the assumptions of normality were violated, so a 
non-parametric McNemar‟s test was performed.  
 
Area and Intensity of Static and Dynamic Allodynia: 
Area and intensity of static and dynamic allodynia were collected pre-dose on Day 1 
and post-dose on Day 14.  Only subjects with baseline scores greater than 0 cm
2 
for 
period 1 were included in the statistical analysis.  This was determined independently 
for static and dynamic allodynia.  The variability observed between the area and 
intensity scores was large.  Non-parametric McNemar‟s test was performed on both 
the area of static and dynamic allodynia.  This was due to the modelling assumptions 
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for an ANOVA being violated.  As a sensitivity analysis, an ANOVA model was run 
for both sets of data, including and excluding patients who were statistical outliers.  
The exclusion of statistical outliers satisfied modelling assumptions surrounding an 
ANOVA, however there was no clinical reason for the exclusion of these patients.  A 
separate mixed model ANOVA was performed for intensity of both static and 
dynamic allodynia.  The fixed terms in the ANOVA were period, treatment, baseline 
and diagnostic category.  The averages of the two baselines as well as the adjusted 
baseline were fitted, as per the primary analysis.  Subject was fitted as a random 
effect. 
 
Global Impression of Change and Rescue Medication:  
Data for Days 7 and 14 of patient‟s and physician‟s global impression of change, as 
well as the use of rescue medication, were listed and summarised. 
 
Sample size estimation 
The sample size of 40 patients was based on feasibility.  However, based on a 
between-patient standard deviation of 1.85 for change from baseline in pain scores 
observed in a previous study A1A20004 (GSK study identifier A1A20004: a placebo-
controlled parallel group study in patients with peripheral neuropathic pain; 
unpublished) and a sample size of 40 patients, a minimum difference of 1.3 for 
dilmapimod relative to placebo could be detected with at least 80% power, using a 
type 1 error rate of 5%.  A difference of 1.3 units on the 11-point NRS was considered 
to be the „minimally important‟ clinically meaningful difference in the context of an 
exploratory efficacy study, and is broadly consistent with the chronic pain literature 
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and provisional benchmarks identified by the Initiative on Methods, and Pain 
Assessment in Clinical Trials (IMMPACT) (Dworkin et al. 2008). 
 
6.3.3 Results 
 
6.3.3.1 Results on patients recruited from Hammersmith Hospital 
 
During the study period, 50 patients were pre-screened for the trial.  Twenty eight 
patients who consented for the trial were screened.  Nine patients were recruited in the 
trial while nineteen patients failed the screening visit.  One patient recruited into the 
trial withdrew following randomisation before receiving the first dose of medication.  
Two patients withdrew during the first period due to uncontrolled pain.  Six patients 
completed the trial (Table 6.1).   
 
Table 6.1 Patient demographics- Hammersmith Hospital 
Patient 
no. 
Age 
(years) 
Sex Diagnosis Duration of 
symptoms 
1 34 F Cutaneous neuroma over groin. 6 years 
2 45 F Femoral nerve injury following hip surgery. 4.5 years 
3 33 M Sciatic nerve injury following a fracture. 12 years 
4 37 M Neuroma of superficial radial nerve.  20 months 
5 55 F Neuroma right foot, common peroneal 
nerve compression over neck of fibula. 
7 years 
6 28 M Radial nerve injury- post traumatic. 9 months 
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During the treatment phase two out of six patients recruited from Hammersmith 
Hospital had a reduction in pain score and two patients had a reduction in the area of 
allodynia.  Biopsy samples from the hypersensitive skin were available in two of these 
patients; the key patients are illustrated below. 
 
Case series (Table 6.1) 
Patient 1 
A 34 year old female developed a neuroma over her right groin following a Caesarean 
section resulting in an area of pain and hypersensitivity over the groin, with an 
average daily pain score of 7 during baseline.  Thermal perception and pain thresholds 
were elevated over area of the scar.  She was administered placebo during the first 
phase and 7.5mg of dilmapimod during the second phase.  Average daily pain score 
was 6.9 during the placebo phase, while on the active drug the average of the daily 
pain scores decreased to 3.6.  The reduction was more marked during the second week 
of treatment where the average of the daily pain scores was only 0.4 (Figure 6.3).  
Four weeks following discontinuation of treatment the average daily pain score 
returned to 7.  Seven months prior to enrolment in the trial she had an unsuccessful 
attempt to treat her symptoms with surgical excision of the neuroma and part of the 
overlying skin.   
 
 
201 
-3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
2
4
6
8
10
Placebo
Dilmapimod 7.5mg/ day
Days
N
R
S
 
Figure 6.3 Patient 1: Average daily pain score (NRS, 0= no pain, 10= most 
severe pain) 
 
Patient 2 
A 45 year old white Caucasian female sustained an injury to the femoral nerve 
following a hip replacement surgery 54 months previously.  This resulted in a painful 
area over the anterior aspect of the thigh which was hypersensitive to touch.  Tendon 
transfer procedures were performed to regain knee extension.  She was treated with 
analgesics including NSAIDs, Quinine and Amitriptyline which were not effective.  
On examination there was an area of allodynia and pin prick hyperalgesia over the 
anterolateral aspect of the thigh extending to the knee.  Thermal perception and pain 
thresholds were elevated over this area.  This patient was prescribed placebo in the 
first phase and dilmapimod, 15mg per day during the second phase of the trial.  The 
baseline average pain score of 7, reduced to an average of 5.6 following 
administration of SB681323 (Figure 6.4).  Significantly, by the end of the second 
week of treatment with SB681323, this patient showed a reduction in area of skin with 
allodynia and hyperalgesia, from 257 cm
2
 to 24 cm
2
 (Figure 6.5).  This area started 
increasing 5 days after the last dose along with a worsening of pain score, returning to 
a pre-treatment level by 4 weeks.  A skin biopsy was obtained from the hypersensitive 
area on the last day of the clinical trial.  Immunostaining results are described later.   
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Figure 6.4 Patient 2: Average daily pain score (NRS, 0= no pain, 10= most 
severe pain) 
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Figure 6.5 Patient 2- Area of pin prick hyperalgesia  
 
Tissue methods and results 
Tissue taken from the hypersensitive area from patients 1 and 2 were processed and 
immunostained with antibodies to PGP9.5, TRPV1 and NGF as described earlier.   
In patient 1 tissues were snap frozen and not immersion fixed, thus precluding 
immunostaining for the structural nerve marker (PGP 9.5).  
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Figure 6.6 Intra-epidermal nerve fibres (arrowed) and NGF in skin.  Skin biopsies 
from patient 1 (top panels) immunostained with antibodies to TRPV1 (a) and NGF (d) 
and patient 2 (middle panels) immunostained with antibodies to TRPV1 (b) and PGP 
9.5 (e).  Control skin biopsy (bottom panels) immunostained with TRPV1(c) and NGF 
(f).  Scale bars = 50µm (a, b, d, e, f), 25µm (c). 
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Sub- and intra-epidermal nerve fibres immunoreactive for the nociceptive nerve 
marker TRPV1 appeared to be increased in skin from the hypersensitive area of both 
patients compared to control skin (Figure 6.6 a, b, c).  Counts of TRPV1-
immunoreactive intra-epidermal nerve fibres (IENF) per mm length of section 
supported this observation (IENF/mm; patient 1, 16.0; patient 2, 7.6; control 5.7 ± 
1.4).  Epidermal innervation using the structural nerve marker (PGP9.5) in patient 2 
also appeared to be high (Fig 6.6 e; IENF/mm patient 2 was 12.6; control 6.5 ± 1.4; 
counts for patient 1 were unavailable).  In addition, immunoreactivity for NGF was 
detected in supra-basal keratinocytes, several layers above the basal layer to which 
NGF is restricted in normal skin (Figure 6.6 d, f).   
 
6.3.3.2 Overall results 
 
Of the patients enrolled into the study, fifty were randomised and 43 patients 
completed the study.  Overall, 46 patients received at least one dose of placebo, three 
patients received at least one dose of dilmapimod 7.5 mg/day and 44 received at least 
one dose of dilmapimod 15 mg/day.  One patient was enrolled into the study but never 
received a single dose of study medication.  Patient demographics and aetiology of 
neuropathic pain are detailed in Table 6.2.   
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Table 6.2 Patient demographics and aetiology of neuropathic pain.  
Demographics 
Age in Years, Mean (range)  55.1 (22-78)  
Sex, n (%) 
Female: 24 (48) 
Male: 26 (52) 
BMI, Mean (range) 27.3 (19.1-33.2) 
Race, n (%) 
White –  White/Caucasian/European Heritage 49 (98) 
White –  Mixed race 1 (2) 
Classification of neuropathic pain at baseline, n (%) 
Carpal tunnel syndrome
1 
5 (10) 
Nerve trauma
2
 13 (26) 
Radiculopathy
3
 32 (64) 
1
 n = 5 (Australia),   
2
.n = 3 (Australia), n = 10 (UK),   
3
 n = 9 (Australia), n = 20 
(Russia), n = 3 (UK) 
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Details of patient enrolment and completion are in figure 6.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Patient enrolment and progress through the trial. 
Patients enrolled (n=51) 
Excluded (n=1) 
 Not meeting baseline inclusion 
criteria (n=1) 
 Declined to participate (n=0) 
 Other reasons (n=0) 
 Analysed for efficacy (n=45) 
 Excluded from analysis due to withdrawal 
before collection of Day 4 pain score (n=2) 
o Adverse event (n=1) 
o Protocol deviation (n=1) 
 
  
 Lost to follow-up (n=0) 
 Discontinued intervention (n=4) 
o Protocol deviation (n=1) 
o Adverse events (n=2) 
o Withdrew consent (n=1) 
 Lost to follow-up (n= 0) 
 Discontinued intervention (n=3) 
o Adverse events (n=2) 
o Withdrew consent (n=1) 
 Analysed (n=46) 
 Excluded from analysis  (n=0) 
Analysis 
Follow-Up 
Randomized (n= 50) 
 
 
Enrollment 
Planned treatments by period 
Treatment Period 1 Period 2 
Placebo (n) 24 26 
Dilmapimod 7.5mg/day (n) 1 2 
Dilmapimod 15mg/day (n) 25 22 
 
Actual treatments received by period 
Treatment Period 1 Period 2 
Placebo (n) 24 22 
Dilmapimod 7.5mg/day (n) 1 2 
Dilmapimod 15mg/day (n) 25 19 
 
Allocated to dilmapimod (n=50) 
 Received allocated intervention (n=47) 
 Did not receive allocated intervention (n=3) 
o Withdrawn in period 1 during 
placebo treatment (n=3) and did 
not receive dilmapimod in period 2 
Allocated to placebo (n=50) 
 Received allocated intervention (n=46) 
 Did not receive allocated intervention (n=4) 
o Withdrawn in period 1 during 
dilmapimod treatment (n=4) and 
did not receive placebo in period 2 
 
Allocation 
207 
6.3.3.2.1 Average daily pain score:  
Daily pain intensities (PI-NRS) for subjects in the ITT population are shown in Figure 
6.8.  This plot does not take into account the period in which the subjects received 
each of the treatment regimens; however, a clear separation can be seen between the 
daily pain responses for active drug and placebo during the second week of dosing, 
with a reduction in pain intensity being associated with dilmapimod (15mg daily) 
treatment.  No significant difference was observed between the baseline pain 
intensities (average of period 1 and 2) for placebo and dilmapimod (15mg daily).   
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Figure 6.8 Pain intensity score over time (ITT population) 
 
A summary of the primary statistical analysis of the average daily PI-NRS score for 
Weeks 1 and 2, calculated as the average of Days 2 to 6 and Days 8 to 13, 
respectively, is shown in Table 6.3. 
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Table 6.3 Summary of Repeated Measures Analysis for Average Daily Pain 
Intensity Numeric Rating Scale (PI-NRS) Score (Adjusted for Baseline, 
Baseline*Week).   
 
Average daily pain intensity (ITT population) 
Visit 
Adjusted mean Adjusted 
mean 
difference 
(Dilmapimod 
– Placebo) 
95% 
CI                                                 
(lower, 
upper) 
p-
value 
Within-
patient 
SD 
Dilmapimod 
(15 mg/day) 
Placebo 
Overall 4.32 4.86 -0.54 
(-0.97,  
-0.11) 
0.0151 1.04 
Week 1 4.57  4.85  -0.28 
(-0.74, 
0.18) 
0.2244 0.97 
Week 2 4.07  4.87  -0.80 
(-1.33,  
-0.28) 
0.0034 1.10 
[Pain scores are the average for Week 1 (Days 2-6) and Week 2 (Days 8-13)] 
 
The average daily PI-NRS for Weeks 1 and 2 was statistically analysed in all patients 
who received dilmapimod [irrespective of dose, 7.5mg or 15mg daily] and compared 
to placebo.  On average, there was a significant reduction in the average daily PI-NRS 
of 1.01 [95% CI (0.46, 1.57); p = 0.0005] on dilmapimod compared to placebo at 
Week 2.  The overall adjusted mean difference showed a reduction of 0.67 [95% C.I. 
(0.24, 1.09); p = 0.0027].  
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A significant treatment by period interaction was found (p = 0.0445) in the primary 
analysis.  
 
The response to dilmapimod and placebo for each of the treatment periods is 
presented in Table 6.4.  The observed response with dilmapimod was more marked in 
period 2 (-1.69/10) after subjects had received placebo in period 1, whereas the 
response with dilmapimod was not as marked in period 1 (-1.03/10). The average 
daily pain scores across both periods for subjects on placebo remained stable. 
 
Table 6.4 Average daily pain intensity.   
Average Daily Pain Intensity (PI-NRS; ITT population) by Period 
 Mean  SD Period 1 Period 2 
Placebo Baseline 6.0 (1.20) 6.2 (1.56) 
Week 2 5.0 (1.94) 5.7 (1.60) 
Change from baseline (W2) -1.1 (1.22) -0.54 (0.91) 
SB681323 
(15mg/day) 
Baseline 5.9 (1.09) 5.4 (1.49) 
Week 2 4.8 (1.67) 3.7 (2.08) 
Change from baseline (W2) -1.03 (1.59) -1.69 (1.64) 
The pain intensity for week 2 was calculated as the mean of the average daily pain 
scores for days 8-13 
 
6.3.3.2.2 Responder Analysis 
The overall proportion of patients with a 50% response rate at Week 2 was 
significantly higher on dilmapimod 15 mg/day (11/41, 27% of patients) than on 
placebo (4/45, 9% of patients; McNemar‟s test, p = 0.011; Exact test, p = 0.021).  The 
210 
proportion of patients showing a 30% response rate was also higher on dilmapimod 
15 mg/day (15/41, 37% of patients) than on placebo (9/45, 20% of patients).  
 
6.3.3.2.3 Current daily pain intensity 
On Day 14, there was a statistically significant reduction in daily CPI of 0.64 [95% 
C.I. (0.05, 1.23); p = 0.033] for dilmapimod 15mg/day compared to placebo.  There 
was an overall reduction of 0.62 [95% C.I. (0.14, 1.10] in favour of dilmapimod.  All 
estimates were statistically significant at the 5% level. 
 
6.3.3.2.4 Quantitative sensory threshold 
The summary of the ANOVA for QST in the affected area is shown in Table 6.5  A 
statistically significant effect for dilmapimod 15mg/day was obtained on warmth 
detection threshold; there was a 1.20°C increase in warmth detection threshold in the 
affected area [95% CI (0.06, 2.35); p = 0.0395] compared to placebo.  An effect on 
warmth detection was not observed in the control area [dilmapimod – placebo = -
0.3°C, 95% CI (-1.04, 0.44); p = 0.4172].  The results from the McNemar‟s test for 
non-normally distributed QST data showed no significant differences between the 
dilmapimod and placebo treatment arms for the cold detection threshold at affected 
and control sites. 
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Table 6.5 Quantitative Sensory Testing, summary of analyses (Adjusted for 
Baseline, and Diagnostic Category) (n = 41) 
 
Quantitative Sensory Testing – Thermal Thresholds (oC) – Affected Area 
Test 
Adjusted mean 
Estimate 
 
95% CI 
(lower, 
upper) 
p-
value 
Within-
patient SD 
Dilmapimod  
(15 mg/day)  
Placebo 
Cold 
pain  
13.56 14.28 -0.72 
(-3.09, 
1.65) 
0.5420 5.45 
Heat 
pain  
46.32 46.03 0.29 
(-0.51, 
1.10) 
0.4665 1.78 
Warmth 
detection  
40.49 39.29 1.20 
(0.06, 
2.35) 
0.0395 2.50 
Quantitative Sensory Testing – Thermal Thresholds (oC) – Control Area 
Test 
Adjusted mean 
Estimate 
95% CI  
(lower, 
upper) 
p-
value 
Within-
patient SD 
Dilmapimod 
(15 mg/day) 
Placebo 
Cold 
pain  
16.40 15.79 0.61 
(-2.00, 
3.32) 
0.6355 5.42 
Heat 
pain  
44.47 45.23 -0.76 
(-1.65, 
0.13) 
0.0912 1.96 
Warmth 
detection  
37.57 37.87 -0.30 
(-1.04, 
0.44) 
0.4172 1.62 
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6.3.3.2.5 Area and intensity of static and dynamic allodynia 
No significant differences were found between dilmapimod 15 mg/day and placebo 
for area of allodynia (n = 41).  On average, there was a reduction in the pain intensity 
of static allodynia of [dilmapimod – placebo = -1.09, 95% C.I. (-2.89, 0.71)], and a 
reduction in the pain intensity of dynamic allodynia of [dilmapimod – placebo = -1.71 
95% C.I. (-4.89, 1.46)], with dilmapimod 15 mg/day compared to placebo; the results 
were not statistically significant. 
 
6.3.3.2.6 Global Impression of Change and Rescue Medication 
Overall, the patient‟s global impression of change showed that for 25/41 (61%) of 
subjects, their condition had improved following treatment with dilmapimod 15 
mg/day, whereas only 20/45 (44%) patients on placebo improved.  The physician‟s 
global impression of change showed that condition had improved for 24/41 (59%) 
subjects treated with dilmapimod 15 mg/day, in comparison to only 17/45 (38%) of 
patients on placebo. 
 
The proportions of patients who used rescue medication were: no patients on 
dilmapimod 7.5 mg daily, 2/46 patients on placebo (4.3%) and 3/43 patients on 
dilmapimod 15 mg daily (7.0%)  
 
6.3.3.2.7 Safety 
The safety analysis was based on the „All Patients‟ population which comprised all 
patients who were randomised and received at least one dose of study medication 
(Table 6.6).   
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Table 6.6 Summary of most common adverse events ( 2 subjects in any 
treatment group) 
 
 
Placebo 
(n = 46) 
Dilmapimod  
7.5 mg/day 
(n = 3) 
Dilmapimod  
15 mg/day 
(n = 44) 
Any AE, n (%) 23 (50) 2 (67) 20 (45) 
Most Common AEs ( 2 
subjects in any treatment 
group): 
 Headache 
 Nasopharyngitis 
 Pharyngolaryngeal pain 
 Nausea 
 Diarrhoea 
 
 
8 (17) 
3 (7) 
2 (4) 
2 (4) 
2 (4) 
 
 
1 (33) 
0 
1 (33) 
0 
0 
 
 
9 (30) 
0 
1 (2) 
2 (5) 
1 (2) 
 
Overall, dilmapimod was considered to be well tolerated.  Two patients on placebo 
and two patients on dilmapimod 15 mg/day were withdrawn from the study due to 
AEs. One patient treated with dilmapimod 15 mg/day was withdrawn due to nausea, 
abdominal pain and weakness, which were not thought by the investigator to be 
related to the study drug, but to a suspected gastrointestinal infection.  The other 
patient treated with dilmapimod was withdrawn due to herpes zoster rash and itchy 
eyes, neither thought by the investigator to be related to study medication.  One 
patient on placebo was withdrawn due to facial oedema, another due to increased 
proteinuria.  These were not considered to be drug related but due to a pre-existing 
renal condition, which was later confirmed by a nephrologist.  Severe AEs reported 
during treatment with placebo were headache, diarrhoea, nausea, vomiting, bronchitis, 
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arthralgia, back pain, pain in the extremity and dysmenorrhoea, each reported in one 
subject.  The only severe AE reported on dilmapimod 15 mg/day was toothache. 
There were no clinically relevant abnormalities in laboratory data, vital signs or 
electrocardiogram data.  
 
6.3.4 Discussion  
 
The data reported here are consistent with a therapeutic benefit of dilmapimod (SB-
681323) in patients with chronic pain associated with nerve injury or compression.  In 
our study centre two out of the six patients who completed the trial had a reduction in 
average daily pain score while on dilmapimod.  Overall dilmapimod treatment was 
associated with a reduced average daily pain intensity of 0.8 measured using the PI-
NRS following 2 weeks of treatment compared to placebo in patient populations with 
moderate pain intensity despite receiving standard treatments for neuropathic pain.  
Dilmapimod was well tolerated with no clinically relevant safety findings.  Although 
statistically significant, the clinical significance of the observed effect size remains 
uncertain in the context of the present exploratory cross-over trial where the study 
population was heterogeneous with respect to the pain aetiology.  The evaluation of 
clinically significant effects for the purpose of comparing established neuropathic 
pain treatments has generally been undertaken across several large parallel group 
studies [see reviews by (Dworkin et al. 2008; Finnerup et al. 2010)].  In the absence of 
meaningful values for number-needed-to-treat (NNT) or to-harm (NNH), and taking 
into account differences in trial design and patient populations, it is difficult to 
accurately benchmark either the analgesic effects, or the risk-benefit ratio, of 
dilmapimod against other neuropathic pain treatments at this early stage of 
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development.  Nevertheless, the primary outcome of our study was consistent with a 
similar pattern of response that was seen across secondary endpoints including 
response rates, current pain intensity and global impression of change.  Collectively, 
these data would lend support to the likely relevance of p38 MAPK activation in 
neuropathic pain signalling and as a potential target for further exploratory clinical 
trials and drug development. 
 
An important question is whether the observed efficacy outcomes can actually be 
explained in terms of inhibition of p38 MAPK activation at the systemic 
concentrations of dilmapimod likely to have been achieved with the dose levels used 
in the present study.  The pharmacodynamic-pharmacokinetic (PK/PD) relationship 
has been studied previously both in healthy volunteer studies and more recently in 
patients with COPD (Singh et al. 2010), where inhibition of p38 MAPK activation has 
been evaluated by measuring sorbitol-induced pHSP-27 expression ex vivo [a 
surrogate measure of p38 pathway activation (Alford et al. 2007))].  In healthy 
volunteers (GSK study SB681323/001; unpublished data), administration of single 
dilmapimod doses over the range 2-25mg was associated with a significantly greater 
mean percentage inhibition of pHSP-27 at 30 minutes post-dose when compared to 
placebo, an approximate half-maximal effect being observed with 2.5mg and a 
maximal effect (around 90% inhibition) being observed at the 20 and 25mg dose 
level. For all dose groups, maximal inhibition was observed between 30 and 60 
minutes post-dose.  In COPD patients (Singh et al. 2010), single oral doses of 
dilmapimod (7.5mg and 25mg), but not prednisolone, reduced the weighted mean 
pHSP-27 (0-6hrs) by 58% compared to placebo.  In the same study, LPS-induced 
TNF- production, assessed in whole blood ex vivo, was significantly reduced 
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compared with placebo by dilmapimod 25mg (40%) or 7.5mg (33.4%).  Based on 
these data, the exposures likely to have been achieved with the doses used in this 
present investigation would be entirely consistent with a rapid and sustained inhibition 
of p38 MAPK activation throughout the dosing period. 
 
Several aspects of the study design also merit consideration.  Treatment duration in 
this study was for 14 days.  We cannot exclude the possibility that a greater signal of 
efficacy might have been achieved with a longer duration of dosing.  However, it is 
noteworthy that significant effects of gabapentin when compared to placebo have 
been seen as earlier as 1-2 weeks after the start of a dose-titration regimen in 
neuropathic pain patients (Serpell 2002).  Similar early-onset of efficacy has been 
seen with pregablalin in neuropathic pain patients (Freynhagen et al. 2005), and for 
duloxetine in diabetic peripheral neuropathic pain (Kajdasz et al. 2007).  There was, 
therefore, no intrinsic reason to believe that the refractoriness of our neuropathic pain 
population was such that the patients would not be responsive to an appropriate 
therapeutic intervention over a 2-week period.  In addition, for dilmapimod 
specifically, it was also recognised that suppression of p38 pathway activation, as 
described above, along with inhibition of TNF-alpha production in humans, occurs 
within a time-frame of minutes to hours following single dose administration [see e.g. 
(Singh et al. 2010)].  An attenuation of the systemic inflammatory response (hsCRP) 
has also been seen as soon as 3 days following initiation of dosing with dilmapimod 
(7.5 mg per day) (Sarov-Blat et al. 2010).  Furthermore, a previous investigation with 
the novel p38 MAPK inhibitor SCIO-469 suggests that this mechanism can provide 
rapid onset of analgesia in the setting of acute postoperative pain (Tong et al. 2004).  
Finally, it was also appreciated in the context of this two-way cross-over trial that a 
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period of dosing for longer than 2 weeks may have placed an additional burden on the 
enrolled patients as well as on the rate of recruitment. 
 
A further consideration relates to the reason for using a cross-over design to test the 
analgesic efficacy of dilmapimod; this was primarily to enable a shorter recruitment 
period with the requirement for fewer patients.  The design is also considered to be 
eminently suited to the evaluation of stable chronic diseases.  Although a robust signal 
of analgesic efficacy in neuropathic pain clinical trials has generally been 
demonstrated with a parallel group design and larger numbers of patients [see, for 
example, (Serpell 2002; Freynhagen et al. 2005; Kajdasz et al. 2007)], the intention 
here was to undertake an exploratory investigation to establish whether a signal could 
be generated addressing a novel mechanism that might justify further clinical trials 
with the appropriate compound.  However, certain key limitations of a cross-over 
study design are also well established.  In the present study, based on the known 
elimination profile of dilmapimod and its metabolites in relation to the washout 
period, the likelihood of any carry-over effect from one dosing period to the next was 
considered to be negligible.  The baseline values for pain intensity (NRS) across the 
two periods were comparable, which is consistent with the absence of a carry-over 
effect as well as stability of the neuropathic pain condition.  There was, however, a 
significant period-by-treatment interaction.  The placebo effect was slightly greater in 
period 1 (-1.1/10) than in period 2 (-0.54/10), while the effect size for dilmapimod 
treatment was greater in the second dosing period than in the first [-1.03 (period 1) 
and -1.69 (period 2)].  It is acknowledged therefore that the response seen with 
dilmapimod may have been driven, at least in part, by the differences seen in period 2.  
As such, our recommendation is that the observed analgesic benefit of dilmapimod on 
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pain intensity would require further corroboration in adequately-powered parallel 
group studies.  Interestingly, a period effect has also been observed previously in a 
cross-over trial of gabapentin in traumatic nerve injury patients (Gordh et al. 2008); in 
this study, using the 100mm VAS, the placebo effect was seen to be greater during 
period 1 (6.9/100) than during period 2 (0.5/100); the effects of gabapentin were 
similar for the two treatment periods. 
 
In general, the QST changes measured in the affected area were consistent with the 
proposed mechanisms, but the treatment difference only reached significance for one 
endpoint (warmth detection threshold).  No such trends were observed in the control 
area.  In the present exploratory cross-over study, neuropathic pain appears to have 
responded to a novel active p38 MAPK inhibitor dilmapimod when compared to 
placebo.   
 
 
6.4 SUMMARY 
 
p38 MAPK mediates nerve growth factor (NGF)-dependent up regulation of  TRPV1 
expression in dorsal root ganglia (DRG), leading to heat hyperalgesia (Ji et al. 2002; 
Obata et al. 2004a; Obata et al. 2004b).  Several lines of evidence suggest a role for 
p38 MAPK in controlling the level of neuronal excitability, both in the periphery and 
in the CNS, under conditions of neuropathic pain (Ji 2004).   
 
A similar mechanism has recently been described for TRPA1-mediated cold allodynia 
(Obata et al. 2005).  In support, TRPV1 and TRPA1 are increased in human avulsion 
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injured DRG neurons (Smith et al. 2002; Anand et al. 2008). In the CNS, activation of 
p38 in spinal microglia has been described in animal models of neuropathic pain 
associated with nerve injury, and considered important in controlling neuronal 
excitability (Ji and Woolf 2001; Jin et al. 2003; Tsuda et al. 2004; Tsuda et al. 2005; 
Terayama et al. 2008).  Inhibitors of p38 MAPK have shown efficacy and safety in 
previous clinical trials in inflammatory disorders (Parasrampuria et al. 2003; Tong et 
al. 2004; Cohen et al. 2009a; Damjanov et al. 2009).  Our study showed a significant 
reduction in pain score in patients with neuropathic pain following administration of a 
p38 MAPK.  Two patients out of the six studied at our centre revealed a marked 
reduction in the area of allodynia and hyperalgesia.   
 
This study supports the role of p38MAPK as a marker for neuropathic pain, and p38 
MAPK as a potential drug target. 
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Chapter 7 Discussion and Conclusions 
 
 
7.1 DISCUSSION 
 
Alerting the individual to harm is the primary purpose of nociceptors, but this may be 
diverted by changes in the nociceptive pathway leading to chronic pain and sensory 
disturbances including hyperalgesia.   
 
Methods have been devised in animal models to study inflammatory pain in joints 
(Neugebauer et al. 2007) which include injection of chemicals, Freund‟s adjuvant and 
urate to induce inflammation, and neuropathic pain has been studied in animal models 
such as the chronic nerve constriction model (Bennett and Xie 1988).  These models 
result in behavioural changes, but they cannot be solely used to predict the effects of 
analgesics in humans, as there are genetic and neurochemical differences.  
Translational research needs human models to test safety and efficacy of analgesics.  
Studies of experimentally-induced pain are advantageous because the causative 
factors can be controlled, and the changes investigated systematically in homogenous 
human volunteers (Hardy et al. 1940; Mogil et al. 2006).  The main requirements of 
such models are the reversibility, reproducibility, accuracy, sensitivity and 
measurability of chronic pain which reflects clinical pathology.   
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7.2 NOVEL RESULTS 
 
Our studies and of other centres, have provided new insights into the pathophysiology 
underlying human volunteer models of pain, and neuro-inflammatory conditions.   
 
Capsaicin application activates TRPV1 channel leading to pain and hyperalgesia, 
while with chronic application causes degeneration of nerves (Simone et al. 1998).  
Application of other TRP agonists can activate their corresponding channels.  Using 
the known action of such compounds we developed new human models of pain.  
These were studied by recording contact heat evoked potentials as a reliable non-
invasive biomarker of nociception.  In 14 healthy human volunteers, topical 
application of capsaicin for 15 minutes resulted in a significant reduction of heat pain 
threshold but with no changes in the warm perception thresholds, suggesting an action 
purely on nociceptive fibres.  Pain score increased significantly at higher 
concentrations of capsaicin, while the amplitude of evoked potential showed a trend 
towards a decrease as in neuropathic conditions.  The heat hyperalgesia caused by 
capsaicin also resembled those seen in neuropathic states in some patients.  The 
decrease in amplitude of evoked potential is possibly due to asynchronous firing of 
nociceptive fibres, or damage/desensitisation of nerve fibres.  Application of topical 
capsaicin in human volunteers also revealed a significantly increased pain score and 
increased brain activation with functional MRI.   
 
The topical capsaicin models were developed further by chronic application over a 
period of 72 hours.  Regeneration of cutaneous nerve fibres was studied using the pan-
neuronal marker PGP9.5, heat capsaicin receptor TRPV1, and the biomarker of 
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regenerating nerve fibres, GAP43.  Chronic application of capsaicin over the leg in 12 
healthy volunteers resulted in a marked acute reduction of intra-epidermal nerve 
fibres.  This produced a reversible model of degenerative neuropathy.  Regeneration 
of these nerves was studied by performing skin biopsies at intervals up to 54 days and 
recording laser evoked potentials (LEPs).  Skin biopsies were immunostained for 
PGP9.5, TRPV1 and GAP43.  Evoked potentials showed rapid recovery by day 12 
and could be used as a non-invasive marker of regeneration.  While the recovery of 
PGP9.5 and TRPV1 staining fibres lagged, GAP43 sub-epidermal fibre recovery 
paralleled LEPs.  Bases on this finding we propose that GAP43 and LEPs are related 
and reliable markers of regenerating nociceptive fibres for longitudinal studies. 
 
In clinical conditions, skin biopsy and CHEPS showed changes in patients with 
congenital insensitivity to pain.  All patients had normal touch sensation, but absent 
CHEPS evoked potentials.  On immunostaining with PGP9.5 and TRPV1, the 
majority had absence of intraepidermal nerve fibres.  Biomarkers using CHEPS and 
skin biopsy can complement the genetic tests available for diagnosis in congenital 
insensitivity to pain. 
 
Expanding the role of novel biomarkers in the study of clinical pain syndromes, in 
complex regional pain syndrome (CRPS) skin biopsy revealed abnormal morphology 
and staining patterns of intraepidermal fibres to PGP9.5 and TRPV1.  In addition 
there was abnormal staining to nerve growth factor, beyond the basal layer of 
epidermis, indicating a potential ongoing inflammatory process with upregulation of 
NGF.   
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Osteoarthritis a degenerative condition is associated with pain, which does not always 
correlate with radiographic changes.  Hence reliable objective methods of measuring 
pain are to plan and compare therapy.  In patients with hand osteoarthritis who 
underwent fMRI scans while moving the painful and non painful joint, there was 
increased activation of the somatosensory cortex on moving the painful joint.  This 
study offers the potential to use fMRI as a novel tool of assessment of pain in 
osteoarthritis.  Larger studies need to be conducted to validate these findings. 
 
These methods of evaluating changes in nociceptors and their functions could help 
elucidate the pathology in patients presenting with symptoms suggestive of small fibre 
neuropathy.  Using skin biopsy and immunostaining with the markers PGP9.5, 
TRPV1 and GAP43, and by recording CHEPS, we were able to sub-classify 51 
patients with symptoms of small fibre neuropathy into those with preserved or 
increased PGP9.5 IENF, who also had preserved TRPV1 IENF, but increased GAP43 
subepidermal fibre density; those with decreased PGP9.5 IENF who also had 
decreased TRPV1 IENF and GAP43 subepidermal fibre density.  Both groups of 
patients had reduced amplitude of CHEPS evoked potentials, confirming a 
neuropathy.  Based on these findings we postulate that the former patients can have 
pathology nerve roots or conduction block more proximally with secondary 
inflammation.  CHEPS combined with skin biopsy markers such as GAP43 offer 
novel methods of distinguishing between these two patient groups, and from patients 
with inflammatory pain, as the latter have normal or increased CHEPS evoked 
potentials. 
. 
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Biomarkers of pain can also be used in formulating targeted therapy, and as 
mechanistic measures in clinical trials.  p38 mitogen activated protein kinase (MAPK) 
has been show to mediate nerve growth factor mediated up regulation of TRPV1 
leading to pain and hypersensitivity following nerve injury.  Based on human tissue 
biomarker and preclinical studies, a randomised double blind control placebo 
controlled cross-over study was conducted with dilmapimod, a p38MAPK inhibitor.  
The study showed a significant reduction in pain scores while on treatment with the 
active drug with no significant side-effects.  Identification of biomarkers can thus help 
in the diagnosis of pain disorders, and also represent novel targets for treatment. 
 
 
7.3 FUTURE DIRECTIONS 
 
Research for novel pain treatment requires clinically relevant  models of efficacy and 
toxicity (Mogil 2009).  Human pain models that replicate clinical pathologies need to 
be developed (Arendt-Nielsen and Sumikura 2002).  We have studied topical 
application of TRP agonists in a systematic manner with novel techniques such as 
CHEPS.  Future research needs to focus on use of drugs which block specific 
receptors, including TRP channels, both in our novel models and patients, to validate 
the models and develop new analgesics. 
 
fMRI offers great opportunity to study processing of pain.  Our studies in volunteer 
pain models and in osteoarthritis pain of the joint of the hand, have demonstrated the 
potential usefulness of fMRI in assessing clinical pain treatments.  Future studies 
validating these studies are recommended.   
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Central pain monitoring and processing of pain have been studied using CHEPS and 
LEPs.  These techniques enable study of the entire pain pathway.  In combination 
with fMRI they offer the opportunity to study pain with both good temporal and 
spatial resolution.  Translation research with compounds targeting the transmission or 
processing of pain in clinical conditions need to be studied using these methods. 
 
With the development of therapies to help nerve regeneration, sensitive biomarkers 
are needed to identify early signs of regeneration.  We have shown LEPs and skin 
biopsy markers with GAP43 useful to detect early signs of recovery.   
 
A major aim of devising objective methods of nociception is to reliably demonstrate 
efficacy of analgesics in humans.  The identification of biomarkers associated with 
altered pain perception paves way for further studies to develop compounds to 
modulate them and alleviate pain.  Our trial used one such compound, dilmapimod, 
p38 MAPK inhibitor.  Novel objective methods using biomarkers will enable 
demonstrate efficacy of such novel compounds. 
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7.4 SUMMARY 
 
1. Novel human volunteer models have bee developed to assess nociception and 
pain, using TRP agonists. 
2. Using cerebral pain evoked potentials (LEPs) in relation to GAP43 in skin 
biopsies we have been able to identify a non-invasive biomarker of nerve 
degeneration which can detect early signs of nerve regeneration in longitudinal 
studies. 
3. Functional MRI has shown promise in assessing pain in experimental and 
clinical models. 
4. Skin biopsy and staining with biomarkers PGP9.5, TRPV1 and GAP43 have 
enabled identification of subtypes of patients with painful conditions, new targets for 
pain relief. 
5. A clinical trial targeting the biomarker p38MAP kinase, which is involved in 
the development of inflammatory pain via up-regulation of TRPV1, was shown to be 
safe with promising results.  
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